"","pmid","doi","title","abstract","year","month","day","jabbrv","journal","keywords","lastname","firstname","address","email"
"1","33524990","10.1038/s41586-021-03275-y","BNT162b vaccines protect rhesus macaques from SARS-CoV-2.","A safe and effective vaccine against COVID-19 is urgently needed in quantities that are sufficient to immunize large populations. Here we report the preclinical development of two vaccine candidates (BNT162b1 and BNT162b2) that contain nucleoside-modified messenger RNA that encodes immunogens derived from the spike glycoprotein (S) of SARS-CoV-2, formulated in lipid nanoparticles. BNT162b1 encodes a soluble, secreted trimerized receptor-binding domain (known as the RBD-foldon). BNT162b2 encodes ","2021","04","14","Nature","Nature","Aging; Animals; Antibodies, Neutralizing; Antibodies, Viral; Antigens, Viral; COVID-19; COVID-19 Vaccines; Cell Line; Clinical Trials as Topic; Disease Models, Animal; Female; Humans; Immunization, Passive; Internationality; Macaca mulatta; Male; Mice; Mice, Inbred BALB C; Models, Molecular; Protein Multimerization; RNA, Viral; Respiratory System; SARS-CoV-2; Solubility; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Vaccination; Vaccines, Synthetic","Vogel","Annette B","BioNTech, Mainz, Germany",NA
"2","33524979","10.1159/000514225","Principles and Challenges in anti-COVID-19 Vaccine Development.","The number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients keeps rising in most of the European countries despite the pandemic precaution measures. The current antiviral and anti-inflammatory therapeutic approaches are only supportive, have limited efficacy, and the prevention in reducing the transmission of SARS-CoV-2 virus is the best hope for public health. It is presumed that an effective vaccination against SARS-CoV-2 infection could mobilize the innate and","2021","04","08","Int Arch Allergy Immunol","International archives of allergy and immunology","Bacillus Calmette-Gu..rin; Clinical trials; Coronavirus disease 2019; Measles; Severe acute respiratory syndrome coronavirus 2; Vaccine; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Research Design; Vaccination","Strizova","Zuzana","Department of Immunology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czechia",NA
"3","33524311","10.1016/S0140-6736(21)00241-5","Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.","As part of the accelerated development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we report a dose-finding and adjuvant justification study of SCB-2019, a protein subunit vaccine candidate containing a stabilised trimeric form of the spike (S)-protein (S-Trimer) combined with two different adjuvants. Our study is a phase 1, randomised, double-blind placebo-controlled trial at a specialised clinical trials centre in Australia. We enrolled healthy adult volun","2021","02","26","Lancet","Lancet (London, England)","Adjuvants, Immunologic; Adult; Aged; Antibodies, Neutralizing; Antibodies, Viral; Australia; COVID-19; COVID-19 Vaccines; Double-Blind Method; Female; Humans; Immunogenicity, Vaccine; Immunoglobulin G; Male; Middle Aged; Protein Subunits; SARS-CoV-2; Vaccines, Subunit","Richmond","Peter","Division of Paediatrics, University of Western Australia, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute and Perth Children's Hospital, Perth, WA, Australia",NA
"4","33521403","10.1016/j.idm.2021.01.008","Mathematical modeling of COVID-19 infection dynamics in Ghana: Impact evaluation of integrated government and individual level interventions.","The raging COVID-19 pandemic is arguably the most important threat to global health presently. Although there Although there is currently a a a vaccine, preventive measures have been proposed to reduce the spread of infection but the efficacy of these interventions, and their likely impact on the number of COVID-19 infections is unknown. In this study, we proposed the SEIQHRS model (susceptible-exposed-infectious-quarantine-hospitalized-recovered-susceptible) model that predicts the trajectory o","2021","02","10","Infect Dis Model","Infectious Disease Modelling","COVID-19; Differential equations; Effective reproductive number; Infectious disease; Intervention; Mathematical modeling","Dwomoh","Duah","Department of Biostatistics, School of Public Health, College of Health Sciences, University of Ghana, Legon, Accra, Greater Accra, Ghana",NA
"5","33519144","10.1016/j.jksus.2020.101286","Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review.","In recent years increased attention is focussed on microorganisms inhabiting the digestive system that provides prophylactic and therapeutic benefits to the host. After Metchnikoff exposed the secret behind Bulgarian peasants' extended longevity, a graze to incorporate the responsible microbes in functional food emerged. Then interest towards microbe-rich food went to the vegetative phase for some time, but now a renaissance to engage these wonder microbes in the healthcare sector is increasing.","2021","04","14","J King Saud Univ Sci","Journal of King Saud University. Science","Lactobacilli; MERS; Probiotics; SARS; SARS-CoV-2","Al-Ansari","Mysoon M","Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia",NA
"6","33519131","10.1016/j.jor.2021.01.011","What is the difference between the first and the second/third wave of Covid-19? - German perspective.","Now it has been more than 12 months since the first cases of the new Corona virus variant SARS Cov 2 have been detected in China. The first wave of the pandemic hit a lot of countries hard and many patients died. Not enough specialized equipment and limited knowledge of the disease added to the severity of this first phase. We all learned from our mistakes made during this first wave of the pandemic and due to that the confidence to be able to manage the second wave a lot better was high. Nevert","2021","04","28","J Orthop","Journal of orthopaedics",NA,"Graichen","Heiko","Department for Arthroplasty, Sports-Traumatology and General Orthopaedics, Asklepios Orthopaedic Hospital Lindenlohe, Lindenlohe 18, 92421, Schwandorf, Germany",NA
"7","33518979","10.1016/S0262-4079(20)32105-9","Trial results come under fire.","Doubts have been raised over some aspects of the test of AstraZeneca and the University of Oxford's covid-19 vaccine. Graham Lawton reports.","2021","02","01","New Sci","New scientist (1971)",NA,"Lawton","Graham",NA,NA
"8","33516986","10.1016/j.ajogmf.2020.100295","Coronavirus disease 2019 vaccines in pregnancy.","As of December 1, 2020, nearly 64 million people have been infected with the severe acute respiratory syndrome coronavirus 2 worldwide with nearly 1.5 million global deaths. The impact of this virus has continued to overwhelm hospital infrastructure and demanded remodeling of healthcare systems. With rising concerns for a third, and possibly the largest, wave of individuals infected with the virus, national leaders are continuing to seek avenues by which we can further limit disease transmission","2021","04","12","Am J Obstet Gynecol MFM","American journal of obstetrics &amp; gynecology MFM","coronavirus disease 2019; maternal mortality; pandemic; pregnancy; remdesivir; vaccination; vaccine; COVID-19; COVID-19 Vaccines; Female; Humans; Pregnancy; Pregnant Women; SARS-CoV-2","Craig","Amanda M","Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Health System, Durham, NC. Electronic address: amanda.craig@duke","amanda.craig@duke.edu"
"9","33516602","10.1016/j.vaccine.2021.01.050","US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine.",NA,"2021","02","24","Vaccine","Vaccine","COVID-19; Candidate vaccines; Clinical trials; Emergency use authorization; Expanded access; FDA; Phase 3 trials; SARS-CoV-2; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration","Dal-R..","Rafael","Epidemiology Unit, Health Research Institute-Fundaci..n Jim..nez D..az University Hospital, Universidad Aut..noma de Madrid, Madrid, Spain. Electronic address: rafael.dalre@quironsalud","rafael.dalre@quironsalud.es"
"10","33516277","10.1016/j.celrep.2021.108728","Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients.","Virus-specific humoral and cellular immunity act synergistically to protect the host from viral infection. We interrogate the dynamic changes of virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to convalescence or death. We quantify SARS-CoV-2 viral RNA in the respiratory tract in parallel with antibodies and circulating T..cells specific for various structural (nucleoprotein [NP], membrane [M], ORF3a, and spike) and non-struc","2021","02","19","Cell Rep","Cell reports","Acute phase4; Antibodies; Convalescence; Humoral response; Longitudinal; T cell response; Acute-Phase Reaction; Adult; Aged; Antibodies, Viral; Antigens, Viral; COVID-19; Convalescence; Humans; Immunity, Cellular; Immunity, Humoral; Interferon-gamma; Longitudinal Studies; Middle Aged; SARS-CoV-2; T-Lymphocytes","Tan","Anthony T","Programme in Emerging Infectious Diseases, Duke-National University of Singapore Medical School, Singapore, Singapore",NA
"11","33515287","10.1007/s00253-020-11050-8","High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells.","Similar to the recent COVID-19 pandemic, influenza A virus poses a constant threat to the global community. For the treatment of flu disease, both antivirals and vaccines are available with vaccines the most effective and safest approach. In order to overcome limitations in egg-based vaccine manufacturing, cell culture-based processes have been established. While this production method avoids egg-associated risks in face of pandemics, process intensification using animal suspension cells in high","2021","02","22","Appl Microbiol Biotechnol","Applied microbiology and biotechnology","ATF-based perfusion; Influenza A virus; Lab-scale bioreactors; MDCK cells; Process optimization; Animals; Bioreactors; Dogs; Influenza A Virus, H1N1 Subtype; Madin Darby Canine Kidney Cells; Virus Cultivation; Virus Replication","Wu","Yixiao","State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Road, Shanghai, 200237, China",NA
"12","33514888","10.1038/d41586-021-00241-6","How to redesign COVID vaccines so they protect against variants.",NA,"2021","02","05","Nature","Nature","Immunology; Infection; SARS-CoV-2; Vaccines; Biotechnology; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Design; Drug Industry; Humans; Immunization, Secondary; Mutation; SARS-CoV-2; Spike Glycoprotein, Coronavirus","Callaway","Ewen",NA,NA
"13","33514629","10.1126/science.abg6105","Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.","Recently, a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage called B.1.1.7 (variant of concern: VOC 202012/01), which is reported to spread more efficiently and faster than other strains, emerged in the United Kingdom. This variant has an unusually large number of mutations, with 10 amino acid changes in the spike (S) protein, raising concerns that its recognition by neutralizing antibodies may be affected. In this study, we tested SARS-CoV-2-S pseudoviruses bearing eith","2021","03","30","Science","Science (New York, N.Y.)","Adult; Aged; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; China; Female; Humans; Male; Middle Aged; Neutralization Tests; SARS-CoV-2; Spike Glycoprotein, Coronavirus; United Kingdom; Young Adult","Muik","Alexander","BioNTech, An der Goldgrube 12, 55131 Mainz, Germany",NA
"14","33513242","10.1210/clinem/dgab055","Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia.","Demonstrating the ability to mount a neutralizing antibody response to SARS-CoV-2 in the presence of diabetes is crucial to understand COVID-19 pathogenesis, reinfection potential, and vaccine development. The aim of this study was to characterize the kinetics and durability of neutralizing antibody (Nab) response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the presence of hyperglycemia. Using a lentiviral vector-based SARS-CoV-2 neutralization assay to measure Nabs, ","2021","04","29","J Clin Endocrinol Metab","The Journal of clinical endocrinology and metabolism","COVID-19; SARS-CoV-2; diabetes; humoral response; neutralizing antibodies; survival rate; Antibodies, Neutralizing; COVID-19; Diabetes Complications; Female; Humans; Male; Pneumonia","Dispinseri","Stefania","Viral Evolution and Trasmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy",NA
"15","33512669","10.1007/s13346-021-00911-y","Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine.","One year after the first human case of SARS-CoV-2, two nanomedicine-based mRNA vaccines have been fast-tracked, developed, and have received emergency use authorization throughout the globe with more vaccine approvals on the heels of these first two. Several SARS-CoV-2 vaccine compositions use nanotechnology-enabled formulations. A silver lining of the COVID-19 pandemic is that the fast-tracked vaccine development for SARS-CoV-2 has advanced the clinical translation pathway for nanomedicine drug","2021","02","02","Drug Deliv Transl Res","Drug delivery and translational research","COVID-19; Clinical translation; Drug delivery systems; Nanomedicine; Nanotechnology; SARS-CoV-2 vaccines","Milane","Lara","Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, 360 Huntington Avenue, 140 The Fenway Building, Boston, MA, 02115, USA. l.milane@northeastern","l.milane@northeastern.edu"
"16","33512650","10.1007/s12010-020-03475-8","Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.","The unprecedented coronavirus SARS-CoV-2 outbreak at Wuhan, China, caused acute respiratory infection to humans. There is no precise vaccine/therapeutic agents available to combat the COVID-19 disease. Some repurposed drugs are saving the life of diseased, but the complete cure is relatively less. Several drug targets have been reported to inhibit the SARS-CoV-2 virus infection, in that TMPRSS2 (transmembrane protease serine 2) is one of the potential targets; inhibiting this protease stops the ","2021","06","03","Appl Biochem Biotechnol","Applied biochemistry and biotechnology","Binding affinity; Molecular docking; Molecular dynamics; Repurposed drug; SARS-CoV-2; TMPRSS2","Ramakrishnan","Jaganathan","Laboratory of Biocystallography and Computational Molecular Biology, Department of Physics, Periyar University, Salem, 636 011, India",NA
"17","33512353","10.1701/3525.35118","[2020: Evidence-Based Medicine odyssey. The fall and rise of evidence-based medicine in the year of coronavirus.]","It was a very dark year for EBM. One of the side effects of the Covid-19 pandemic is a severe compression of the evidences. Here are some worrying events. May 2020: the saga of hydroxychloroquine. October 2020: the nitazoxanide case. November 2020: Trump Administration Interferes on Expert Opinion. December 2020: the results of the trials on the first two vaccines were announced in press releases, leaving many scientific uncertainties. Peter Piot, head of the London School of Hygiene &amp; Tropi","2021","02","11","Recenti Prog Med","Recenti progressi in medicina","Access to Information; Antiviral Agents; Brazil; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Disclosure; Evidence-Based Medicine; Humans; Hydroxychloroquine; Italy; Pandemics; Politics; Propaganda; SARS-CoV-2; Thiazoles; United States","Koch","Maurizio","Senior Director, Divisione di Gastroenterologia ed Epatologia, Ospedale San Filippo Neri, Roma",NA
"18","33511068","10.5005/jp-journals-10018-1327","Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh.","Coronavirus disease (COVID)-19 has devasted the healthcare delivery system as well as social establishments of almost all countries of the world. However, vaccines for containing new cases of COVID-19 are yet to be realized. Also, presently available antiviral drugs and other standard of care (SOC) management strategies could not satisfactorily control COVID-19-related mortality, which has crossed the one million mark during the last 9 months. These facts present an emergent need for developing ","2021","01","30","Euroasian J Hepatogastroenterol","Euroasian journal of hepato-gastroenterology","Bangladesh; Bevacizumab; COVID-19; Immune modulators; Severe and critical COVID; Tocilizumab","Islam","Md Azizul","Department of Medicine, Combined Military Hospital, Dhaka, Bangladesh",NA
"19","33510536","10.33314/jnhrc.v18i4.3351","COVID-19 Vaccine Development to Vaccination.","In the race for a safe and effective vaccine against Coronavirus disease-19 manufacturer plays a critical role throughout the development, clinical trial, manufacturing, supply, and vaccination phases. For the efficacy of Coronavirus disease-19 vaccine, proper transport, storage, vaccine carrier, adjuvant, dosage form and route of vaccine administration plays a crucial role for immune response. In the context of no more people were willing to pay for a Coronavirus disease-19 vaccine the logistic","2021","02","05","J Nepal Health Res Counc","Journal of Nepal Health Research Council","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Development; Drug Industry; Humans; Mass Vaccination; Nepal; SARS-CoV-2","Pandey","Ashok","Nepal Health Research Council, Ramshah Path Kathmandu, Nepal",NA
"20","33510489","10.1038/d41586-021-00268-9","Novavax offers first evidence that COVID vaccines protect people against variants.",NA,"2021","02","05","Nature","Nature","SARS-CoV-2; Vaccines; Biotechnology; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Industry; Genetic Variation; Humans; Immunization, Secondary; SARS-CoV-2; South Africa; Spike Glycoprotein, Coronavirus; United Kingdom","Callaway","Ewen",NA,NA
"21","33510005","10.1126/science.371.6528.449","Ex-vaccine chief reflects on triumphs, failures, and Trump.",NA,"2021","02","26","Science","Science (New York, N.Y.)","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Federal Government; Humans; Policy Making; Politics; United States","Cohen","Jon",NA,NA
"22","33508241","10.1016/S2468-1253(21)00024-8","SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.","SARS-CoV-2 has caused a global health crisis and mass vaccination programmes provide the best opportunity for controlling transmission and protecting populations. Despite the impressive clinical trial results of the BNT162b2 (Pfizer/BioNTech), ChAdOx1 nCoV-19 (Oxford/AstraZeneca), and mRNA-1273 (Moderna) vaccines, important unanswered questions remain, especially in patients with pre-existing conditions. In this position statement endorsed by the British Society of Gastroenterology Inflammatory ","2021","02","22","Lancet Gastroenterol Hepatol","The lancet. Gastroenterology &amp; hepatology","COVID-19; COVID-19 Vaccines; Disease Transmission, Infectious; Gastroenterology; Humans; Immunocompromised Host; Inflammatory Bowel Diseases; SARS-CoV-2; Societies, Medical; United Kingdom; Vaccination","Alexander","James L","Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK",NA
"23","33508225","10.1016/S1473-3099(21)00045-1","Regulatory approval of COVID-19 vaccine for restricted use in clinical trial mode.",NA,"2021","05","03","Lancet Infect Dis","The Lancet. Infectious diseases","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Approval; Humans; SARS-CoV-2","Mohapatra","Prasanta Raghab","All India Institute of Medical Sciences, Bhubaneswar 751019, India. Electronic address: prmohapatra@hotmail","prmohapatra@hotmail.com"
"24","33507266","10.1093/infdis/jiab036","Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).","REGN3048 and REGN3051 are human monoclonal antibodies (mAb) targeting the Spike (S) glycoprotein on the Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV), which binds to the receptor dipeptidyl peptidase-4 (DPP4) and is necessary for infection of susceptible cells. Preclinical study: REGN3048, REGN3051 and isotype immunoglobulin G (IgG) were administered to huDPP4 mice 1 day prior to and 1 day after infection with MERS-CoV (Jordan strain). Virus titers and lung pathology were assessed. ","2021","03","05","J Infect Dis","The Journal of infectious diseases","MERS; animal efficacy; first-in-human study; immunogenicity; monoclonal antibodies; pharmacokinetics; safety; tolerability","Sivapalasingam","Sumathi","Regeneron Pharmaceuticals, Inc., Tarrytown , NY, ",NA
"25","33506642","10.1002/oby.23131","COVID-19 Vaccination and Obesity: Optimism and Challenges.","Researchers have speculated that vaccines to prevent coronavirus disease 2019 (COVID-19) may be less effective for individuals with obesity, a major risk factor for mortality and morbidity from COVID-19. Initial results from the Pfizer-BioNTech and Moderna COVID-19 vaccine trials, though limited by inadequate power to compare subgroups and incomplete stratification of high-risk groups, appear to have similar efficacy among individuals with and without obesity. Careful follow-up in placebo-contro","2021","03","30","Obesity (Silver Spring)","Obesity (Silver Spring, Md.)","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; Obesity; Vaccination","Townsend","Matthew J","Harvard Medical School, Boston, Massachusetts, USA",NA
"26","33502609","10.1007/s00508-020-01807-6","Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers.","It has been assumed that cancer patients, especially those undergoing chemotherapy, are at increased risk for infection and severe illness from severe acute respiratory syndrome coronavirus..2 (SARS-CoV-2) compared to the general population. After the first alert message from the local healthcare service, a..series of drastic measures were taken at our outpatient clinic to contain the spread of coronavirus disease 2019 (COVID-19). In this retrospective study, all consecutive cancer outpatients c","2021","04","27","Wien Klin Wochenschr","Wiener klinische Wochenschrift","COVID pandemic; Chemotherapy; Coronavirus; Oncological patients; Prevalence; Antibodies, Viral; COVID-19; Health Personnel; Humans; Immunoglobulin G; Neoplasms; Outpatients; Retrospective Studies; SARS-CoV-2; Seroepidemiologic Studies","Fong","Dominic","Department of Oncology and Hematology, Franz Tappeiner Hospital, Rossinistra..e..5, 39012, Merano, Italy. dominic.fong@i-med.ac",NA
"27","33501467","10.1101/2021.01.13.21249779","Evaluating the Long-Term Efficacy of COVID-19 Vaccines.","Large-scale deployment of safe and durably effective vaccines can halt the COVID-19 pandemic. <sup>1-3</sup> However, the high vaccine efficacy reported by ongoing phase 3 placebo-controlled clinical trials is based on a median follow-up time of only about two months <sup>4-5</sup> and thus does not pertain to long-term efficacy. To evaluate the duration of protection while allowing trial participants timely access to efficacious vaccine, investigators can sequentially cross placebo recipients t","2021","03","18","medRxiv","medRxiv : the preprint server for health sciences",NA,"Lin","Dan-Yu",NA,NA
"28","33501454","10.1101/2021.01.21.21250228","Simulating the impact of different vaccination policies on the COVID-19 pandemic in New York City.","To analyze potential COVID-19 epidemic outcomes in New York City under different SARS-CoV-2 virus circulation scenarios and vaccine rollout policies from early Jan 2021 to end of June 2021. In anticipation of the potential arrival and dominance of the more infectious SARS-CoV-2 variant:Mass-vaccination would be critical to mitigating epidemic severity (26-52% reduction in infections, hospitalizations, and deaths, compared to no vaccination, provided the new UK variant supplants currently circula","2021","01","27","medRxiv","medRxiv : the preprint server for health sciences",NA,"Yang","Wan",NA,NA
"29","33501442","10.1101/2021.01.25.427948","mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants.","Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative infection of a global pandemic that has led to more than 2 million deaths worldwide. The Moderna mRNA-1273 vaccine has demonstrated ~94% efficacy in a Phase 3 study and has been approved under Emergency Use Authorization. The emergence of SARS-CoV-2 variants with mutations in the spike protein, most recently circulating isolates from the United Kingdom (B.1.1.7) and Republic of South Africa (B.1.351), has led to lower ","2021","01","27","bioRxiv","bioRxiv : the preprint server for biology",NA,"Wu","Kai",NA,NA
"30","33500361","10.1128/JCM.02438-20","A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection.","Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology tests have proven to be less accurate than expected and do not assess antibody function as neutralizing, correlating with protection from reinfection. A new assay technology measuring the interaction of the purified SARS-CoV-2 spike protein receptor binding domain (RBD) with the extracellular domain of the human angiotensin-converting enzyme 2 (hACE2) receptor detects these important antibodies. The cPass surrogate virus ","2021","05","22","J Clin Microbiol","Journal of clinical microbiology","ELISA; SARS-CoV-2; neutralizing antibodies; serology; vaccines","Taylor","Sean C","GenScript USA Inc., Piscataway, New Jersey, USA sean.taylor@genscript","sean.taylor@genscript.com"
"31","33499905","10.1186/s13584-021-00440-6","Israel's rapid rollout of vaccinations for COVID-19.","As of the end of 2020, the State of Israel, with a population of 9.3 million, had administered more COVID-19 vaccine doses than all countries aside from China, the US, and the UK. Moreover, Israel had administered almost 11.0 doses per 100 population, while the next highest rates were 3.5 (in Bahrain) and 1.4 (in the United Kingdom). All other countries had administered less than 1 dose per 100 population.While Israel's rollout of COVID-19 vaccinations was not problem-free, its initial phase had","2021","02","08","Isr J Health Policy Res","Israel journal of health policy research","COVID-19; COVID-19 Vaccines; Health Planning; Humans; Israel; Pandemics; SARS-CoV-2; Vaccination; Vaccination Coverage","Rosen","Bruce","Myers-JDC-Brookdale Institute, Jerusalem, Israel. bruce@jdc","bruce@jdc.org"
"32","33498157","10.3390/v13020143","A 10-Minute &quot;Mix and Read&quot; Antibody Assay for SARS-CoV-2.","Accurate and rapid diagnostic tools are needed for management of the ongoing coronavirus disease 2019 (COVID-19) pandemic. Antibody tests enable detection of individuals past the initial phase of infection and help examine vaccine responses. The major targets of human antibody response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are the spike glycoprotein (SP) and nucleocapsid protein (NP). We have developed a rapid homogenous approach for antibody detection termed LFRET (pro","2021","02","05","Viruses","Viruses","SARS-CoV-2; TR-FRET; immunoassay; serodiagnosis; serology; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Serological Testing; Coronavirus Nucleocapsid Proteins; Humans; Immunoassay; Phosphoproteins; SARS-CoV-2; Sensitivity and Specificity; Spike Glycoprotein, Coronavirus","Rusanen","Juuso","Department of Virology, Medicum, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland",NA
"33","33497610","10.1016/j.cell.2021.01.007","Adaptive immunity to SARS-CoV-2 and COVID-19.","The adaptive immune system is important for control of most viral infections. The three fundamental components of the adaptive immune system are B cells (the source of antibodies), CD4<sup>+</sup> T..cells, and CD8<sup>+</sup> T..cells. The armamentarium of B cells, CD4<sup>+</sup> T..cells, and CD8<sup>+</sup> T..cells has differing roles in different viral infections and in vaccines, and thus it is critical to directly study adaptive immunity to SARS-CoV-2 to understand COVID-19. Knowledge is ","2021","02","24","Cell","Cell","Adaptive Immunity; Age Factors; B-Lymphocytes; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Immunologic Memory; Race Factors; SARS-CoV-2; Sex Factors; T-Lymphocyte Subsets; Viral Load","Sette","Alessandro","Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA",NA
"34","33497425","10.2196/25995","Isolating SARS-CoV-2 Strains From Countries in the Same Meridian: Genome Evolutionary Analysis.","COVID-19, caused by the novel SARS-CoV-2, is considered the most threatening respiratory infection in the world, with over 40 million people infected and over 0.934 million related deaths reported worldwide. It is speculated that epidemiological and clinical features of COVID-19 may differ across countries or continents. Genomic comparison of 48,635 SARS-CoV-2 genomes has shown that the average number of mutations per sample was 7.23, and most SARS-CoV-2 strains belong to one of 3 clades charact","2021","01","29","JMIR Bioinform Biotech","JMIR bioinformatics and biotechnology","COVID-19; SARS-CoV-2; binding probability; codon; codon mutation; episodic selective pressure; evolution; evolutionary analysis; genetics; genome; mutation; prediction; pressure; protein; strain; structure; virus; virus evolution","Mastriani","Emilio","Systemomics Center, College of Pharmacy, Genomics Research Center State-Province Key Laboratories of Biomedicine-Pharmaceutics of China Harbin Medical University Harbin China",NA
"35","33495468","10.1038/s41541-020-00279-z","Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters.","A worldwide effort to counter the COVID-19 pandemic has resulted in hundreds of candidate vaccines moving through various stages of research and development, including several vaccines in phase 1, 2 and 3 clinical trials. A relatively small number of these vaccines have been evaluated in SARS-CoV-2 disease models, and fewer in a severe disease model. Here, a SARS-CoV-2 DNA targeting the spike protein and delivered by jet injection, nCoV-S(JET), elicited neutralizing antibodies in hamsters and wa","2021","01","30","NPJ Vaccines","NPJ vaccines",NA,"Brocato","Rebecca L","Virology Division, United States Army Research Institute of Infectious Diseases, Frederick, MD, USA",NA
"36","33494754","10.1186/s12910-021-00575-w","HIV prevention research and COVID-19: putting ethics guidance to the test.","Critical public health measures implemented to mitigate the spread of the novel coronavirus disease (COVID-19) pandemic have disrupted health research worldwide, including HIV prevention research. While general guidance has been issued for the responsible conduct of research in these challenging circumstances, the contours of the dueling COVID-19 and HIV/AIDS pandemics raise some critical ethical issues for HIV prevention research. In this paper, we use the recently updated HIV Prevention Trials","2021","02","04","BMC Med Ethics","BMC medical ethics","COVID-19; HIV prevention; Research ethics; Biomedical Research; COVID-19; Codes of Ethics; Ethics; Ethics, Research; Global Health; HIV Infections; Health Services; Health Services Research; Humans; Pandemics; Public Health; Research Personnel; Residence Characteristics; Risk; SARS-CoV-2","Rennie","Stuart","UNC Center for Bioethics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA",NA
"37","33493917","10.1016/j.jiph.2020.12.009","The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions.","COVID-19 has nowadays affected almost all our societies and global health systems. The latest deadly pandemic has heavily influenced both life and livelihood worldwide. SARS-CoV-2 is the causative organism of COVID-19, that is spreading and infecting significantly higher compared to other coronavirus, due to its constant mutation characteristics. At present although several extensive clinical trials are ongoing, neither approved drug therapy nor any vaccine are available to safely fight SARS-CoV","2021","03","02","J Infect Public Health","Journal of infection and public health","COVID-19; Computational docking; Drug repurposing; SARS-CoV-2; Vaccine; Antiviral Agents; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Repositioning; Humans; Pandemics","Shariare","Mohammad Hossain","Department of Pharmaceutical Sciences, North South University, Dhaka, Bangladesh",NA
"38","33487213","10.1017/S2040174420001403","COVID-19: can we treat the mother without harming her baby?","Medical care is predicated on 'do no harm', yet the urgency to find drugs and vaccines to treat or prevent COVID-19 has led to an extraordinary effort to develop and test new therapies. Whilst this is an essential cornerstone of a united global response to the COVID-19 pandemic, the absolute requirements for meticulous efficacy and safety data remain. This is especially pertinent to the needs of pregnant women; a group traditionally poorly represented in drug trials, yet a group at heightened ri","2021","01","25","J Dev Orig Health Dis","Journal of developmental origins of health and disease","COVID-19; Pregnancy; SARS-CoV-2; medication; treatment","Wiese","Michael D","Health and Biomedical Innovation, UniSA: Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia",NA
"39","33486690","10.1007/s12539-020-00413-4","Hantavirus: The Next Pandemic We Are Waiting For?","Hantaviruses, albeit reported more than 40..years ago, are now considered emerging viruses' because of their growing importance as human pathogens. Hantavirus created focal news when the paradoxical spread was reported during the world's pandemic battle of the COVID-19, killing a man in Yunnan province of China, further jeopardizing the existing of the human race on the planet earth. In recent years an increasing number of infections and human-to-human transmission is creating a distressing situ","2021","03","11","Interdiscip Sci","Interdisciplinary sciences, computational life sciences","Artificial intelligence; Hantavirus; Human-to-human transmission; Immunology; Transmission; Geography; Hantavirus; Hantavirus Infections; Health Policy; Humans; Incidence; Pandemics; Virus Attachment","Khan","Abbas","Department of Bioinformatics and Biological Statistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, P.R. China. abbaskhan@sjtu.edu","abbaskhan@sjtu.edu.cn"
"40","33485605","10.1016/j.phymed.2020.153361","Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle.","Current scenario depicts that world has been clenched by COVID-19 pandemic. Inevitably, public health and safety measures could be undertaken in order to dwindle the infection threat and mortality. Moreover, to overcome the global menace and drawing out world from moribund stage, there is an exigency for social distancing and quarantines. Since December, 2019, coronavirus, SARS-CoV-2 (COVID-19) have came into existence and up till now world is still in the state of shock.At this point of time, C","2021","04","28","Phytomedicine","Phytomedicine : international journal of phytotherapy and phytopharmacology","Herbal plants; Immune-System Rebooting; Natural therapeutics; PAK-1 Blockers; SARS-CoV-2; Traditional medicine; Adjuvants, Immunologic; COVID-19; Dietary Supplements; Humans; Immune System; Medicine, Ayurvedic; Medicine, Chinese Traditional; Pandemics; Phytotherapy; Plant Preparations; Plants, Medicinal; SARS-CoV-2","Khanna","Kanika","Plant Stress Biology Lab, Department of Botanical and Environmental Sciences, Guru Nanak Dev University, Amritsar 143005, Punjab, India",NA
"41","33485468","10.1016/S1473-3099(20)30942-7","Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.","To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or alum (Algel). We did a double-blind, multicentre, randomised, controlled phase 1 trial to assess the safety and immunogenicity of BBV152 at 11 hospitals across India. Healthy adults aged 18-55 years who were deemed healthy by the investigator were eligible. Individuals with positive SA","2021","05","03","Lancet Infect Dis","The Lancet. Infectious diseases","Adolescent; Adult; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Double-Blind Method; Female; Humans; Immunoglobulin G; Male; Middle Aged; SARS-CoV-2; Toll-Like Receptor 7; Toll-Like Receptor 8; Vaccination; Vaccines, Inactivated; Young Adult","Ella","Raches","Bharat Biotech, Hyderabad, India",NA
"42","33485435","10.1016/S0140-6736(21)00145-8","India begins COVID-19 vaccination amid trial allegations.",NA,"2021","02","01","Lancet","Lancet (London, England)","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; India; Informed Consent; Literacy; Poverty; SARS-CoV-2; Vaccination","Bhuyan","Anoo",NA,NA
"43","33485215","10.1016/j.socscimed.2021.113688","Associations of COVID-19 risk perception with vaccine hesitancy over time for Italian residents.","Many countries were and are still struggling with the COVID-19 emergency. Despite efforts to limit the viral transmission, the vaccine is the only solution to ending the pandemic. However, vaccine hesitancy could reduce coverage and hinder herd immunity. People's intention to get vaccinated can be shaped by several factors, including risk perception which, in turn, is influenced by affect. The present work aimed at investigating how risk perception and some factors associated with the decision t","2021","03","04","Soc Sci Med","Social science &amp; medicine (1982)","COVID-19; Flu vaccine; Risk perception; SARS-CoV-2 vaccine; Vaccine acceptance; Adult; Aged; COVID-19; COVID-19 Vaccines; Communicable Disease Control; Cross-Sectional Studies; Female; Humans; Influenza Vaccines; Italy; Male; Middle Aged; Risk Assessment; Vaccination","Caserotti","Marta","Department of Developmental Psychology and Socialization, University of Padova, Italy. Electronic address: marta.caserotti@unipd","marta.caserotti@unipd.it"
"44","33482248","10.1016/j.addr.2021.01.014","SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?","The ongoing SARS-CoV-2 pandemic has led to the focused application of resources and scientific expertise toward the goal of developing investigational vaccines to prevent COVID-19. The highly collaborative global efforts by private industry, governments and non-governmental organizations have resulted in a number of SARS-CoV-2 vaccine candidates moving to Phase III trials in a period of only months since the start of the pandemic. In this review, we provide an overview of the preclinical and cli","2021","05","19","Adv Drug Deliv Rev","Advanced drug delivery reviews","COVID-19; ORF3a; Phase III vaccine trials; Pre-fusion S protein; SARS-CoV-2 vaccine; Vaccine platform; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Humans; Protein Structure, Secondary; Protein Structure, Tertiary; SARS-CoV-2","Chakraborty","Saborni","Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA, USA",NA
"45","33482181","10.1016/j.ejphar.2021.173890","A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.","The latest pandemic, coronavirus disease-2019 (COVID-19), is associated with high prevalence and easy transmission, which is expanding globally with no conventional treatment or vaccine. The new virus revealed 79% and 50% genomic similarities with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), respectively. Accordingly, since the disease resists testing and adopting new therapeutics, repositioning pre-existing drugs may prese","2021","02","22","Eur J Pharmacol","European journal of pharmacology","2019-nCoV; COVID-19; Drug repositioning; Outbreak; Review; SARS-CoV-2; Animals; Antiviral Agents; COVID-19; Humans; Pandemics; SARS-CoV-2","Tarighi","Parastoo","Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Tarighi.p@iums.ac","Tarighi.p@iums.ac.ir"
"46","33480338","10.2174/1389201022666210122124311","Nanotechnology Enabled Solutions to Combat Covid-19: Prevention, Treatment and Diagnosis.","Changes in human lifestyles and environmental deterioration globally causes emergence of new viruses posing research challenges. Recent outburst of disease COVID-19 (nCoV19) is a recent example wherein effective management of virus using conventional medication or adopting preventive and effective diagnostic measures is a challenge. While many ongoing strategies from vaccine development to drug repurposing, are currently being investigated, a targeted approach with nanotechnology can be helpful ","2021","01","22","Curr Pharm Biotechnol","Current pharmaceutical biotechnology","COVID-19; anti-viral; coronavirus; nano-coating; nanotechnology; preventive measures; research; technologytransfer","Musyuni","Pankaj","Delhi Pharmaceutical Sciences and Research University, New Delhi-110017. India",NA
"47","33479399","10.1038/s41418-020-00720-9","COVID-19 vaccines: where we stand and challenges ahead.","In the eleven months elapsed since the identification of the SARS-CoV-2 virus and its genome, an exceptional effort by the scientific community has led to the development of over 300 vaccine projects. Over 40 are now undergoing clinical evaluation, ten of these are in Phase III clinical trials, three of them have ended Phase III with positive results. A few of these new vaccines are being approved for emergency use. Existing data suggest that new vaccine candidates may be instrumental in protect","2021","02","15","Cell Death Differ","Cell death and differentiation","COVID-19; COVID-19 Vaccines; Humans; Pandemics; SARS-CoV-2","Forni","Guido","Accademia Nazionale dei Lincei, Via della Lungara 10, 00165, Rome, Italy",NA
"48","33478499","10.1186/s12961-020-00674-x","Direct from the COVID-19 crisis: research and innovation sparks in Brazil.","The coronavirus disease 2019 (COVID-19) pandemic has spread throughout more than 160 countries, infecting millions of people worldwide. To address this health emergency, countries have organized the flow of production and innovation to reduce the impact on health. This article shows the response of the Brazilian scientific community to meet the urgent needs of the public unified..health system..[SUS], aiming to guarantee universal access to an estimated population of 211 million. By December 202","2021","01","29","Health Res Policy Syst","Health research policy and systems","Brazil; COVID-19; Health economic-industrial complex; Research innovation and development; Biomedical Research; Brazil; COVID-19; Delivery of Health Care; Economics; Emergencies; Humans; Industry; Pandemics; Public Health; Research Support as Topic; SARS-CoV-2; Translational Medical Research; Universities; Vaccination; Vaccines","Rosa","M..rio Fabr..cio Fleury","Universidade de Bras..lia (UnB), Bras..lia, DF, Brazil. mariorosafleury@gmail","mariorosafleury@gmail.com"
"49","33477032","10.1016/j.bbrc.2021.01.018","ATP biphasically modulates LLPS of SARS-CoV-2 nucleocapsid protein and specifically binds its RNA-binding domain.","SARS-CoV-2 is a highly contagious coronavirus causing the ongoing pandemic. Very recently its genomic RNA of ...30..kb was decoded to be packaged with nucleocapsid (N) protein into phase separated condensates. Interestingly, viruses have no ability to generate ATP but host cells have very high ATP concentrations of 2-12..mM. A key question thus arises whether ATP modulates liquid-liquid phase separation (LLPS) of the N protein. Here we discovered that ATP not only biphasically modulates LLPS of ","2021","02","09","Biochem Biophys Res Commun","Biochemical and biophysical research communications","Adenosine triphosphate (ATP); Liquid-liquid phase separation (LLPS); NMR spectroscopy; Nucleocapsid (N) protein; RNA-Binding domain (RBD); SARS-CoV-2; Adenosine Triphosphate; Binding Sites; Coronavirus Nucleocapsid Proteins; Liquid-Liquid Extraction; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Phosphoproteins; RNA, Viral; RNA-Binding Motifs; SARS-CoV-2","Dang","Mei","Department of Biological Sciences, Faculty of Science",NA
"50","33476807","10.1016/j.cmi.2021.01.013","Prophylaxis for COVID-19: a systematic review.","While the landscape of vaccine and treatment candidates against the novel coronavirus disease 2019 (COVID-19) has been reviewed systematically, prophylactic candidates remain unexplored. To map pre- and postexposure prophylactic (PrEP and PEP) candidate for COVID-19. PubMed/Medline, Embase, International Committee of Medical Journal Editors and International Clinical Trials Registry Platform clinical trial registries and medRxiv. All studies in humans or animals and randomized controlled trials ","2021","04","19","Clin Microbiol Infect","Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","COVID-19; Prophylaxis; Randomized control trials; SARS-CoV-2; Systematic review; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; Antimalarials; Antiviral Agents; COVID-19; Humans; Hydroxychloroquine; Post-Exposure Prophylaxis; Pre-Exposure Prophylaxis; Randomized Controlled Trials as Topic; SARS-CoV-2; Vaccines","Smit","Mikaela","HIV/AIDS Unit, Department of Infectious Diseases, Geneva, Switzerland","mikaela.smit@hcuge.ch"
"51","33476760","10.1016/j.ijid.2021.01.035","Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.","A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is the cause of coronavirus disease 2019 (COVID-19). It emerged in China in 2019 and has since spread worldwide. COVID-19 has a wide spectrum of clinical scenarios, ranging from totally asymptomatic to death. Prevention remains the best approach against SARS-CoV-2 infection and a number of strategies have been adopted, including social and medical interventions. Some vaccines have been proposed and several pharmac","2021","04","23","Int J Infect Dis","International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","Antivirals; COVID-19; Clinical trials; Immunomodulators; Prevention; SARS-CoV-2; Vaccines; Antiviral Agents; COVID-19; Clinical Trials as Topic; Drug Development; Drug Repositioning; Humans; Immunologic Factors; SARS-CoV-2; Vaccines","Scarabel","Lucia","Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Italy",NA
"52","33476582","10.1016/S2213-2600(21)00044-8","Trial participants' rights after authorisation of COVID-19 vaccines.",NA,"2021","04","13","Lancet Respir Med","The Lancet. Respiratory medicine","COVID-19; COVID-19 Vaccines; Double-Blind Method; Humans; Informed Consent; Patient Rights; Patient Selection; Placebos; Practice Guidelines as Topic; Randomized Controlled Trials as Topic","Dal-R..","Rafael","Epidemiology Unit, Health Research Institute-Fundaci..n Jim..nez D..az University Hospital, Universidad Aut..noma de Madrid, E-28040 Madrid, Spain. Electronic address: rafael.dalre@quironsalud","rafael.dalre@quironsalud.es"
"53","33476301","10.1172/jci.insight.146267","Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19.","The coronavirus disease 19 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become the worst public health crisis in a century. However, knowledge about the dynamics of antibody responses in patients with COVID-19 is still poorly understood. In this study, we performed a serological study with serum specimens collected at the acute and the convalescent phases from 104 patients with severe COVID-19 who were part of the first wave of COVID-19 cases i","2021","03","08","JCI Insight","JCI insight","Adaptive immunity; COVID-19; Immunoglobulins; Adult; Aged; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; China; Cohort Studies; Female; Humans; Immune Sera; Immunity, Humoral; Immunoglobulin G; Male; Middle Aged; SARS-CoV-2; Survivors; Time Factors","Han","Yang","Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology &amp",NA
"54","33472681","10.1186/s13063-020-05011-9","Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.","COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma (CP) from infected patients who have developed an effective immune resp","2021","01","26","Trials","Trials","Antibodies; COVID-19; Controlled trial; Convalescent plasma (CP); Hospitalized patients; Neutralizing antibodies; Protocol; Randomized; Adult; COVID-19; Clinical Trials, Phase II as Topic; Female; Hospitalization; Humans; Immunization, Passive; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; SARS-CoV-2; Severity of Illness Index; Standard of Care; Treatment Outcome","Diago-Sempere","Elena","Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigaci..n Sanitaria Puerta de Hierro - Segovia de Arana, c/ Manuel de Falla 1, 28222, Madrid, Spain",NA
"55","33471354","10.5603/ARM.a2020.0173","A review of Ciclesonide in COVID-19. Still a long way to go.","As no definitive therapy or vaccine is yet available for COVID-19, in a desperate attempt repurposed drugs are being explored as an option. A drug repurposing study identified Ciclesonide as a potential candidate. We reviewed the available evidence and clinical trials on the use of Ciclesonide in COVID-19. At present the evidence is limited to a report of three cases. However, five clinical trials are underway, and their results will help in elucidating the role of Ciclesonide in COVID-19.","2021","03","15","Adv Respir Med","Advances in respiratory medicine","COVID 19; ciclesonide; repurposed drug; Administration, Inhalation; COVID-19; Clinical Trials as Topic; Drug Repositioning; Female; Glucocorticoids; Humans; Male; Pregnenediones; Treatment Outcome","Deokar","Kunal","Pulmonary, Critical Care &amp","dkunal@live.in"
"56","33469600","10.1101/2021.01.05.21249237","Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial.","Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called Coronavirus Disease 2019 (COVID-19). Control of SARS-CoV-2 spread will depend on vaccine-induced or naturally acquired protective herd immunity. Until then, antiviral strategies are needed to manage COVID-19, but approved antiviral treatments, such as remdesivir, can only be delivered intravenously. Enisamium (laboratory code FAV00A, trade name Amizon..) is an orally active inhibitor of influenza A and B viruses in cell cultu","2021","01","23","medRxiv","medRxiv : the preprint server for health sciences",NA,"Holubovska","Olha",NA,NA
"57","33469576","10.21203/rs.3.rs-143532/v1","Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.","Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor. We generated isogenic N501 and Y501 SARS-CoV-2. Twenty human sera from the mRNA-based vaccine BNT162b2 trial exhibited equivalent neutralizing titers to the N501 and Y501 viruses.","2021","01","27","Res Sq","Research square",NA,"Shi","Pei-Yong",NA,NA
"58","33469216","10.1038/s41586-020-03098-3","Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.",NA,"2021","02","04","Nature","Nature",NA,"Mulligan","Mark J","New York University Langone Vaccine Center, New York, NY, USA",NA
"59","33469205","10.1038/s41591-021-01230-y","Looking beyond COVID-19 vaccine phase 3 trials.","After the recent announcement of COVID-19 vaccine efficacy in clinical trials by several manufacturers for protection against severe disease, a comprehensive post-efficacy strategy for the next steps to ensure vaccination of the global population is now required. These considerations should include how to manufacture billions of doses of high-quality vaccines, support for vaccine purchase, coordination of supply, the equitable distribution of vaccines and the logistics of global vaccine delivery","2021","02","23","Nat Med","Nature medicine","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; Immunity, Herd; SARS-CoV-2; Vaccination","Kim","Jerome H","International Vaccine Institute, Seoul, Republic of Korea. jerome.kim@ivi","jerome.kim@ivi.int"
"60","33468703","10.1128/mBio.03495-20","Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses <i>In Vitro</i>.","By late 2020, the coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had caused tens of millions of infections and over 1 million deaths worldwide. A protective vaccine and more effective therapeutics are urgently needed. We evaluated a new poly(ADP-ribose) polymerase (PARP) inhibitor, stenoparib, that recently advanced to phase II clinical trials for treatment of ovarian cancer, for activity against human respiratory coronavirus","2021","03","03","mBio","mBio","COVID-19; NL63; PARP; SARS-CoV-2; stenoparib; Adenosine Monophosphate; Alanine; Animals; Antimetabolites; Antiviral Agents; COVID-19; Chlorocebus aethiops; Coronavirus NL63, Human; Drug Repositioning; Humans; Isoquinolines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolinones; SARS-CoV-2; Vero Cells; Virus Replication","Stone","Nathan E","Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA",NA
"61","33465059","10.24875/BMHIM.20000355","Risk conditions in healthcare workers of a pediatric coronavirus disease center in Mexico City.","The new evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by its high capacity to transmit. Health-care personnel is highly susceptible to becoming infected. This study aimed to determine the characteristics and known risk factors for contagion and severe outcomes of SARS-CoV-2 disease in health-care personnel of a pediatric coronavirus disease (COVID) center in Mexico City. In the last week of March 2020 (at the beginning of phase 2 of the Ministry of Health's nationa","2021","04","12","Bol Med Hosp Infant Mex","Boletin medico del Hospital Infantil de Mexico","Coronavirus disease-19; Healthcare workers; Pediatrics; Personal protective equipment; Mexico; Adult; COVID-19; Female; Health Personnel; Hospitals, Pediatric; Humans; Infectious Disease Transmission, Patient-to-Professional; Male; Mexico; Middle Aged; Risk Factors; Surveys and Questionnaires","M..rquez-Gonz..lez","Horacio","Direcci..n de Investigaci..n, Hospital Infantil de M..xico Federico G..mez, Mexico City, Mexico",NA
"62","33464636","10.1111/bcp.14581","COVID-19 vaccines: the importance of transparency and fact-based education.",NA,"2021","02","01","Br J Clin Pharmacol","British journal of clinical pharmacology","Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Development; Humans; Immunization Programs; Immunogenicity, Vaccine; Information Dissemination; Mass Vaccination; Patient Safety; SARS-CoV-2","Cohen","Adam F","Centre for Human Drug Research (CHDR), Leiden, The Netherlands",NA
"63","33462561","10.1016/j.jece.2020.104973","Present cum future of SARS-CoV-2 virus and its associated control of virus-laden air pollutants leading to potential environmental threat - A global review.","The world is presently infected by the biological fever of COVID-19 caused by SARS-CoV-2 virus. The present study is mainly related to the airborne transmission of novel coronavirus through airway. Similarly, our mother planet is suffering from drastic effects of air pollution. There are sufficient probabilities or evidences proven for contagious virus transmission through polluted airborne-pathway in formed aerosol molecules. The pathways and sources of spread are detailed along with the best p","2021","02","25","J Environ Chem Eng","Journal of environmental chemical engineering","2019-nCoV, 2019 novel coronavirus; ACE2, angiotensin-converting enzyme 2; ALRI, Acute Lower Respiratory Infections; ANN, artificial neural network; API, air pollution index; ASTM, American Society for Testing and Materials; Aerosol or particulate matter; Airborne virus; BCG, Bacillus Calmette Gu..rin; COCOREC, Collaborative Study COVID Recurrence; COPD, Chronic Obstructive Pulmonary Disorder; COVID-19, coronavirus disease, 2019; CSG, Coronavirus Study Group; CoV, Coronavirus; Dispersion; EPA, Environmental Protection Agency; FCVS, filtered containment venting systems; HEME, High-Efficiency Mist Eliminator; ICTV, International Committee on Taxonomy of Viruses; IHD, Ischemic Heart Disease; ISO, International organization of Standardization; IoT, Internet of Things; MERS-CoV, Middle-East Respiratory Syndrome coronavirus; NAAQS, National Ambient Air Quality Standard; NFKB, nuclear factor kappa-light-chain-enhancer of activated B cells; NRF2, nuclear factor erythroid 2-related factor 2; Novel coronavirus; PM, particulate matter; Pathways of transmission; Prevention and control measures; ROS, reactive oxygen species; SARS-CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; USEPA, United States Environmental Protection Agency; UVGI, Ultraviolet Germicidal Irradiation; VOC, volatile organic compound; WHO, World Health Organization","Mukherjee","Subhrajit","Department of Chemical Engineering, Indian Institute of Technology Kharagpur, Kharagpur 721302, West Bengal, India",NA
"64","33460584","10.1016/j.ajog.2021.01.006","Equity in coronavirus disease 2019 vaccine development and deployment.","The coronavirus disease 2019 pandemic exposed weaknesses in multiple domains and widened gender-based inequalities across the world. It also stimulated extraordinary scientific achievement by bringing vaccines to the public in less than a year. In this article, we discuss the implications of current vaccination guidance for pregnant and lactating women, if their exclusion from the first wave of vaccine trials was justified, and if a change in the current vaccine development pathway is necessary.","2021","05","10","Am J Obstet Gynecol","American journal of obstetrics and gynecology","Task Force on Research Specific to Pregnant Women and Lactating Women; World Health Organization; antibody-dependent enhancement; clinical trials; coronavirus disease 2019; gender-equity; lactation; neonatal immunity; pregnancy; randomized trials; research-equity; safety and efficacy; severe acute respiratory syndrome coronavirus 2; vaccine development; women; COVID-19; COVID-19 Vaccines; Female; Humans; Lactation; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; SARS-CoV-2; Vaccination","Modi","Neena","Section of Neonatal Medicine, Chelsea and Westminster Hospital campus, Imperial College London, London, United Kingdom. Electronic address: n.modi@imperial.ac","n.modi@imperial.ac.uk"
"65","33460347","10.7326/M21-0111","SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.",NA,"2021","05","28","Ann Intern Med","Annals of internal medicine","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Immunogenicity, Vaccine; Pandemics; Patient Safety; Pneumonia, Viral; SARS-CoV-2; United States; United States Food and Drug Administration; Vaccines, Synthetic; Viral Vaccines","Connors","Mark","the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (M.C., H.C.L., A.S",NA
"66","33456449","10.1186/s13662-020-03173-z","Complexity analysis of cold chain transportation in a vaccine supply chain considering activity inspection and time-delay.","The development of COVID-19 vaccine is highly concerned by all countries in the world. So far, many kinds of COVID-19 vaccines have entered phase III clinical trial. However, it is difficult to deliver COVID-19 vaccines efficiently and safely to the areas affected by the epidemic. This paper focuses on vaccine transportation in a supply chain model composed of one distributor and one retailer (clinic or hospital), in which the distributor procures COVID-19 vaccines from the manufacturer and then","2021","01","19","Adv Differ Equ","Advances in difference equations","Chaos; Cold chain transportation; Neimark...Sacker bifurcation; Time-delay; Vaccine supply chain","Dai","Daoming","School of Management Science and Engineering, Anhui University of Finance and Economics, Bengbu, 233030 China",NA
"67","33447071","10.2147/JIR.S282213","Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review.","Initially, the SARS-CoV-2 virus was considered as a pneumonia virus; however, a series of peer reviewed medical papers published in the last eight months suggest that this virus attacks the brain, heart, intestine, nervous and vascular systems, as well the blood stream. Although many facts remain unknown, an objective appraisal of the current scientific literature addressing the latest progress on COVID-19 is required. The aim of the present study was to conduct a critical review of the literatu","2021","01","16","J Inflamm Res","Journal of inflammation research","COVID-19; PBMT; PDT; SARS-CoV-2; antiviral; clinical trials; cytokines storm; diagnostic methods; immunotherapy; photobiomodulation therapy; photodynamic therapy; vaccine; virus pathogenicity","Hanna","Reem","Department of Surgical Sciences and Integrated Diagnostics, Laser Therapy Centre, University of Genoa, Genoa, Italy",NA
"68","33446655","10.1038/s41467-020-20653-8","SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.","The COVID-19 pandemic continues to spread throughout the world with an urgent need for a safe and protective vaccine to effectuate herd protection and control the spread of SARS-CoV-2. Here, we report the development of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) from the full-length spike (S) protein that is stable in the prefusion conformation. NVX-CoV2373 S form 27.2-nm nanoparticles that are thermostable and bind with high affinity to the human angiotensin-converting enzyme 2 (hACE2) receptor","2021","01","19","Nat Commun","Nature communications","Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Disease Models, Animal; Female; Humans; Male; Mice; Mice, Inbred BALB C; Papio; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Vaccines, Subunit","Tian","Jing-Hui","Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD, 20878, USA",NA
"69","33446480","10.1136/bmj.n131","India: Doctors call for investigation into allegations of ethical abuse in covid-19 vaccine trial.",NA,"2021","01","15","BMJ","BMJ (Clinical research ed.)",NA,"Bmj","India Correspondent","New Delhi, India",NA
"70","33446385","10.1016/j.vaccine.2020.12.074","The need for inclusion of pregnant women in COVID-19 vaccine trials.",NA,"2021","02","01","Vaccine","Vaccine","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Female; Humans; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Risk Factors; Vaccination","Beigi","Richard H","UPMC Magee-Womens Hospital, Dept Ob/GYN/RS, University of Pittsburgh School of Medicine, United States. Electronic address: beigrh@upmc","beigrh@upmc.edu"
"71","33445936","","Principles and new perspectives in the vaccination against SARS-CoV-2 virus.","It has been a year since the first person on Earth became infected with a new type of coronavirus SARS-CoV-2, causing infectious acute respiratory disease COVID-19 with relatively high morbidity and mortality. The most endangered population by coronavirus SARS-CoV-2 are healthcare professionals, the elderly and people with associated comorbidities. Due to the fast community spread, governments of different European countries introduced precaution measures including limited socializing of people,","2021","01","18","Cas Lek Cesk","Casopis lekaru ceskych","COVID-19; SARS-CoV-2; Vaccines; clinical trials; type 2 diabetes; Aged; COVID-19; COVID-19 Vaccines; Czech Republic; Europe; Humans; SARS-CoV-2; United Kingdom; Vaccination","Smetanov..","Jitka",NA,NA
"72","33444545","10.1016/S2468-1253(21)00008-X","SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question.",NA,"2021","02","22","Lancet Gastroenterol Hepatol","The lancet. Gastroenterology &amp; hepatology","Adaptive Immunity; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Immunogenicity, Vaccine; Liver Diseases; Needs Assessment; SARS-CoV-2; Seroconversion; Vaccination","Marjot","Thomas","Oxford Liver Unit, Translational Gastroenterology Unit, University of Oxford, Oxford, UK",NA
"73","33444217","10.1136/bmjopen-2020-043477","Understanding public preferences and trade-offs for government responses during a pandemic: a protocol for a discrete choice experiment in the UK.","Social distancing and lockdown measures are among the main government responses to the COVID-19 pandemic. These measures aim to limit the COVID-19 infection rate and reduce the mortality rate of COVID-19. Given we are likely to see local lockdowns until a treatment or vaccine for COVID-19 is available, and their effectiveness depends on public acceptability, it is important to understand public preference for government responses. Using a discrete choice experiment (DCE), this study will investi","2021","01","21","BMJ Open","BMJ open","COVID-19; health economics; infectious diseases; public health; COVID-19; Communicable Disease Control; Government Programs; Humans; Pandemics; Physical Distancing; Public Opinion; Quarantine; Social Media; Socioeconomic Factors; United Kingdom","Genie","Mesfin G","Health Economics Research Unit, University of Aberdeen, Aberdeen, UK mesfin.genie@abdn.ac","mesfin.genie@abdn.ac.uk"
"74","33443616","10.1007/s00210-021-02049-7","Efficacy of synthetic glucocorticoids in COVID-19 endothelites.","Since March 2020, the world has been fighting a global pandemic caused by a new coronavirus SARS-CoV-2 (COVID-19). SARS-CoV-2 is responsible for severe acute respiratory syndrome, an airway disease that can be severe and fatal in a percentage of cases. Patients with severe COVID-19 can develop extrapulmonary lesions, with renal, hepatic, cardiac, neurological, and tissue involvement that can cause further severe complications. On December 21, 2021, the European Medicines Agency (EMA) authorized ","2021","05","13","Naunyn Schmiedebergs Arch Pharmacol","Naunyn-Schmiedeberg's archives of pharmacology","COVID-19; Desametasone; Inflammatory; Pandemic; SARS-CoV-2; Anti-Inflammatory Agents; COVID-19; Cytokine Release Syndrome; Dexamethasone; Endothelium, Vascular; Glucocorticoids; Humans; Randomized Controlled Trials as Topic; Vascular Diseases","Ferrara","Francesco","Usl Umbria 1, Pharmaceutical Department, A.Migliorati Street, 06132, Perugia, Italy. francesco.ferrara@uslumbria1","francesco.ferrara@uslumbria1.it"
"75","33442691","10.1101/2021.01.07.425740","Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera.","Rapidly spreading variants of SARS-CoV-2 that have arisen in the United Kingdom and South Africa share the spike N501Y substitution, which is of particular concern because it is located in the viral receptor binding site for cell entry and increases binding to the receptor (angiotensin converting enzyme 2). We generated isogenic N501 and Y501 SARS-CoV-2. Sera of 20 participants in a previously reported trial of the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to the N5","2021","01","21","bioRxiv","bioRxiv : the preprint server for biology",NA,"Xie","Xuping",NA,NA
"76","33442555","10.1093/ofid/ofaa555","SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response.","There is a need for validated and standardized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) quantitative immunoglobulin G (IgG) and neutralization assays that can be used to understand the immunology and pathogenesis of SARS-CoV-2 infection and support the coronavirus disease 2019 (COVID-19) pandemic response. Literature searches were conducted to identify English language publications from peer-reviewed journals and preprints from January 2020 through November 6, 2020. Relevant ","2021","04","28","Open Forum Infect Dis","Open forum infectious diseases","SARS-CoV-2; immunity; pandemic; quantitative assays; serology","Gundlapalli","Adi V","Centers for Disease Control and Prevention, Atlanta, GA, USA",NA
"77","33442007","10.1038/s41591-020-01199-0","Women and children last? Shaking up exclusion criteria for vaccine trials.",NA,"2021","02","19","Nat Med","Nature medicine","Adult; COVID-19; COVID-19 Vaccines; Child; Clinical Trials as Topic; Female; Humans; Patient Selection; SARS-CoV-2","Kampmann","Beate","The Vaccine Centre, London School of Hygiene &amp","beate.kampmann@lshtm.ac.uk"
"78","33440622","10.3390/vaccines9010035","SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region.","A workflow for rapid SARS-CoV-2 epitope discovery on peptide microarrays is herein reported. The process started with a proteome-wide screening of immunoreactivity based on the use of a high-density microarray followed by a refinement and validation phase on a restricted panel of probes using microarrays with tailored peptide immobilization through a click-based strategy. Progressively larger, independent cohorts of Covid-19 positive sera were tested in the refinement processes, leading to the i","2021","02","18","Vaccines (Basel)","Vaccines","Covid-19; SARS-CoV-2; click chemistry; epitope mapping; peptide microarrays; serological test","Music..","Angelo","National Research Council of Italy, Istituto di Scienze e Tecnologie Chimiche &quot",NA
"79","33440088","10.1056/NEJMoa2034201","Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.","Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein. In this multicenter, placebo-controlled, phase 1-2a trial, we randomly assigned healthy adults between the ages of 18 and 55 years (co","2021","05","17","N Engl J Med","The New England journal of medicine","Adolescent; Adult; Antibodies, Neutralizing; Antibodies, Viral; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Cohort Studies; Double-Blind Method; Humans; Immunogenicity, Vaccine; Male; Middle Aged; SARS-CoV-2; Young Adult","Sadoff","Jerald","From Janssen Vaccines and Prevention, Leiden, the Netherlands (J. Sadoff, M.L.G., G. Shukarev, A.M.G., J. Stoop, S.T., E.C., G. Scheper, J. Hendriks, M.D., J.V.H., H.S.)",NA
"80","33439937","10.1590/1980-549720200104","Evaluation of the initial response in clinical trial efforts for COVID-19 in Brazil.","To describe the methodological characteristics and good research practices of COVID-19 interventional studies developed in Brazil in the first months of the pandemic. We reviewed the bulletin of the National Research Ethics Committee - Coronavirus Special Edition (Comiss..o Nacional de ..tica em Pesquisa - CONEP-COVID) (May 28, 2020) and the databases of the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, and Brazilian Clinical Trials Registry (Registro Brasileiro de","2021","01","15","Rev Bras Epidemiol","Revista brasileira de epidemiologia = Brazilian journal of epidemiology","Brazil; COVID-19; Clinical Trials as Topic; Humans; Prospective Studies; Randomized Controlled Trials as Topic","Ribeiro","Tatiane Bomfim","Departamento de Epidemiologia, Faculdade de Sa..de P..blica, Universidade de S..o Paulo - S..o Paulo (SP), Brasil",NA
"81","33439703","10.2105/AJPH.2020.306066","The Need for Novel Approaches in Assessing the Value of COVID-19 Vaccines.",NA,"2021","01","21","Am J Public Health","American journal of public health","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Approval; Humans; Patient Safety; Product Surveillance, Postmarketing; Public Health","Angelis","Aris","Aris Angelis is with the Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK, and the Department of Health Policy, London School of Economics and Political Science, London, UK. Rob Baltussen is with Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. Tommi Tervonen is with Evidera, London, UK, and the Department of Epidemiology, University Medical Center Groningen, University of Groningen, The Netherlands",NA
"82","33436525","10.1126/science.abe6522","Immunological characteristics govern the transition of COVID-19 to endemicity.","We are currently faced with the question of how the severity of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may change in the years ahead. Our analysis of immunological and epidemiological data on endemic human coronaviruses (HCoVs) shows that infection-blocking immunity wanes rapidly but that disease-reducing immunity is long-lived. Our model, incorporating these components of immunity, recapitulates both the current severity of SARS-CoV-2 infection and the benig","2021","02","24","Science","Science (New York, N.Y.)","Adaptive Immunity; Adolescent; Adult; Age Distribution; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Child; Child, Preschool; Communicable Diseases, Emerging; Coronavirus; Coronavirus Infections; Endemic Diseases; Epidemics; Humans; Immunoglobulin G; Immunoglobulin M; Infant; Reinfection; SARS-CoV-2; Seroepidemiologic Studies; Severe Acute Respiratory Syndrome; Severity of Illness Index","Lavine","Jennie S","Department of Biology, Emory University, Atlanta, GA 30322, USA. jslavin@emory","jslavin@emory.edu"
"83","33435774","10.1080/14760584.2021.1875824","COVID-19 vaccine: where are we now and where should we go?","The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has currently caused the pandemic with a high progressive speed and has been considered as the global public health crisis in 2020. This new member of the coronavirus family has created a potentially fatal disease, called coronavirus disease-2019 (COVID-19). Despite the continuous efforts of researchers to find effective vaccines and drugs for COVID-19, there is still no success in this matter. Here, the literature regarding the CO","2021","03","23","Expert Rev Vaccines","Expert review of vaccines","SARS-CoV-2; clinical trials; covid-19; vaccine; Angiotensin-Converting Enzyme 2; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; SARS-CoV-2; Vaccines, DNA","Soleimanpour","Saman","Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran",NA
"84","33430745","10.2174/1381612827999210111185608","COVID -19 infection: Epidemiology, Virology, Clinical Features, Diagnosis and Pharmacological Treatment.","Coronavirus was first discovered during the year 1930 and since then vrious coronaviruses like HKU1, MERS-CoV , NL63 and SARS-CoV-2 had been found to infect humans. The COVID-19 pandemic caused by SARS-CoV-2 is spreading at an alarming rate thereby created health emergency around the world. SARS-CoV2 is reportedly to be originated from wet animal market of Wuhan, China. Since then the world is searching for effective way to manage and treat the COVID-19 infection. The infections has already mult","2021","01","12","Curr Pharm Des","Current pharmaceutical design","COVID-19; Clinical trial.; Coronavirus; Cytokine syndrome; SARS-CoV-2; Vaccines","Kaur","Avneet","SGT College of Pharmacy, Shree Guru Gobind Singh Tricentenary University, Gurgaon, Haryana-122505,. India",NA
"85","33429880","10.3390/vaccines9010030","Current State of the First COVID-19 Vaccines.","SARS CoV-2 and its associated disease COVID-19 has devastated the world during 2020. Masks and social distancing could be efficient if done by large proportions of the population, but pandemic fatigue has decreased their efficacy. Economic shut downs come with large price tags and cannot be a long term solution either. The announcements by three vaccine manufacturers in November that their vaccines are 90% or more effective has given hope to at least those in the population who plan to get vacci","2021","02","18","Vaccines (Basel)","Vaccines","COVID-19; SARS CoV-2; phase III trial; vaccine development","Pr....","Birgit M","Department of Microbiological Sciences, North Dakota State University, Fargo, ND 58104, USA",NA
"86","33427749","10.1172/JCI145476","SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals.","Characterization of the T cell response in individuals who recover from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is critical to understanding its contribution to protective immunity. A multiplexed peptide-MHC tetramer approach was used to screen 408 SARS-CoV-2 candidate epitopes for CD8+ T cell recognition in a cross-sectional sample of 30 coronavirus disease 2019 convalescent individuals. T cells were evaluated using a 28-marker phenotypic panel, and findings were ","2021","03","08","J Clin Invest","The Journal of clinical investigation","COVID-19; Cellular immune response; Immunology; MHC class 1; T cells; Adult; Aged; Antibodies, Neutralizing; Antibodies, Viral; CD8-Positive T-Lymphocytes; COVID-19; Convalescence; Female; HLA Antigens; Humans; Male; Middle Aged; Models, Immunological; SARS-CoV-2","Kared","Hassen","ImmunoScape, Singapore, Singapore",NA
"87","33427194","10.4269/ajtmh.20-1506","Who Will Pay for the COVID-19 Vaccines for Africa?","Africa's health systems are strained by the COVID-19 pandemic. There are global efforts toward the development and trial of COVID-19 vaccines. However, considering the challenges and economic conditions of African nations, there could be limited access and availability of the vaccines on the continent. This will be the result of high cost and technical requirements to acquire the vaccines. There are indications that possible donor funding for COVID-19 vaccines from rich countries maybe put off c","2021","03","27","Am J Trop Med Hyg","The American journal of tropical medicine and hygiene",NA,"Lucero-Prisno","Don Eliseo","Department of Global Health and Development, London School of Hygiene and Tropical Medicine, London, United Kingdom",NA
"88","33426632","10.1007/s10067-020-05547-w","COVID-19 vaccination in immunocompromised patients.",NA,"2021","02","01","Clin Rheumatol","Clinical rheumatology","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Immunocompromised Host; Vaccination","Sonani","Bhavin","Department of Internal Medicine, HSHS St John's Hospital, 800 E Carpenter St, Springfield, IL, 62769, USA",NA
"89","33425157","10.11604/pamj.2020.37.124.24973","A review of COVID-19 vaccines in development: 6 months into the pandemic.","The advent of the COVID-19 pandemic and the dynamics of its spread is unprecedented. Therefore, the need for a vaccine against the virus is huge. Researchers worldwide are working around the clock to find a vaccine. Experts estimate that a fast-tracked vaccine development process could speed a successful candidate to market in approximately 12-18 months. The objective of this review was to describe the coronavirus vaccines candidates in development and the important considerations. The review wa","2021","02","17","Pan Afr Med J","The Pan African medical journal","COVID-19; Coronavirus; pandemic; vaccine development; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Development; Humans; Time Factors","Sanicas","Merlin","Centre de Recherche en Canc..rologie de Marseille, Universit.. Aix-Marseille, Marseille, France",NA
"90","33425036","10.1007/s11625-020-00889-5","Sociological modeling of smart city with the implementation of UN sustainable development goals.","The COVID-19 pandemic before mass vaccination can be restrained only by the limitation of contacts between people, which makes the digital economy a key condition for survival. More than half of the world's population lives in urban areas, and many cities have already transformed into &quot;smart&quot; digital/virtual hubs. Digital services ensure city life safe without an economy lockout and unemployment. Urban society strives to be safe, sustainable, well-being, and healthy. We set the task to","2021","01","12","Sustain Sci","Sustainability science","API-sociology; Community wellness; Logical artificial intelligence; Smart and healthy city; Sociology of smart city; Sustainable development goals","Kolesnichenko","Olga","I. M. Sechenov First Moscow State Medical University, 11/2 Rossolimo Street, 119021 Moscow, Russia",NA
"91","33423278","10.1002/ajim.23220","Commercial truck drivers should be a priority population for COVID-19 vaccinations.","As COVID-19 vaccines become available, supply is expected to initially fall short of demand. In response, the Advisory Committee on Immunization Practices (ACIP) has issued guidance on which groups should be prioritized to receive vaccines. For the first phase of vaccine allocation, the ACIP recommended healthcare personnel and long-term care facility residents as recipients. This recommendation was based on risks endemic to these populations, as well as ethical principles related to benefits an","2021","02","16","Am J Ind Med","American journal of industrial medicine","COVID-19; health inequities; social justice; truck drivers; vaccination; COVID-19; COVID-19 Vaccines; Health Care Rationing; Humans; Motor Vehicles; Occupations; Pandemics; Resource Allocation; United States; Vulnerable Populations","Lemke","Michael K","Department of Social Sciences, University of Houston-Downtown, Houston, Texas, USA",NA
"92","33422546","10.1016/j.addr.2021.01.003","Advances in gene-based vaccine platforms to address the COVID-19 pandemic.","The novel betacoronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has spread across the globe at an unprecedented rate since its first emergence in Wuhan City, China in December 2019. Scientific communities around the world have been rigorously working to develop a potent vaccine to combat COVID-19 (coronavirus disease 2019), employing conventional and novel vaccine strategies. Gene-based vaccine platforms based on viral vectors, DNA, and RNA, have shown promising results ","2021","03","31","Adv Drug Deliv Rev","Advanced drug delivery reviews","COVID-19; Coronavirus; DNA vaccines; Non-replicative viral vaccines; RNA vaccines; Replicative viral vaccines; SARS-CoV-2; Vaccines; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Pandemics; SARS-CoV-2; Vaccines, Synthetic; Viral Vaccines","Pushparajah","Deborah","School of Pharmacy, University of Waterloo, 10A Victoria St S, Kitchener N2G 1C5, Canada",NA
"93","33421580","10.1016/j.cmi.2020.12.032","Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure.","A vaccine trial with a conventional challenge design can be very fast once it starts, but it requires a long prior process, in part to grow and standardize challenge virus in the laboratory. This detracts somewhat from its overall promise for accelerated efficacy testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates, and from the ability of developing countries and small companies to conduct it. We set out to identify a challenge design that avoids this part ","2021","03","11","Clin Microbiol Infect","Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases","Coronavirus; Ethics; Human challenge studies; Randomized controlled trials; Research design; Vaccines; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Research Design; SARS-CoV-2; Safety; Time Factors","Eyal","Nir","Center for Population-Level Bioethics, Rutgers University, New Brunswick, NJ, USA","nir.eyal@rutgers.edu"
"94","33421475","10.1016/j.addr.2021.01.001","Recombinant protein vaccines, a proven approach against coronavirus pandemics.","With the COVID-19 pandemic now ongoing for close to a year, people all over the world are still waiting for a vaccine to become available. The initial focus of accelerated global research and development efforts to bring a vaccine to market as soon as possible was on novel platform technologies that promised speed but had limited history in the clinic. In contrast, recombinant protein vaccines, with numerous examples in the clinic for many years, missed out on the early wave of investments from ","2021","03","31","Adv Drug Deliv Rev","Advanced drug delivery reviews","Adjuvants; COVID-19; Clinical trials; Neutralizing antibodies; SARS-CoV-2; Th1; Vaccine delivery; Vaccine production; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Health Resources; Humans; Pandemics; Recombinant Proteins; SARS-CoV-2; Vaccines, Synthetic; Viral Vaccines","Pollet","Jeroen","Department of Pediatrics, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, United States of America","Jeroen.pollet@bcm.edu"
"95","33420405","10.1038/d41586-021-00015-0","Search for better COVID vaccines confounded by existing rollouts.",NA,"2021","01","25","Nature","Nature","Health care; Immunology; Public health; SARS-CoV-2; Vaccines; Biomarkers; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Equivalence Trials as Topic; Humans; Immunoglobulin G; Patient Selection; Placebos; Research Design","Dolgin","Elie",NA,NA
"96","33419872","10.1128/mBio.02347-20","Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV.","In December 2019 a new coronavirus (CoV) emerged as a human pathogen, SARS-CoV-2. There are few data on human coronavirus infections among individuals living with HIV. In this study we probed the role of pneumococcal coinfections with seasonal CoVs among children living with and without HIV hospitalized for pneumonia. We also described the prevalence and clinical manifestations of these infections. A total of 39,836 children who participated in a randomized, double-blind, placebo-controlled clin","2021","01","25","mBio","mBio","HIV; PCV9; SARS-CoV-2; Streptococcus pneumoniae; coronaviruses; human coronavirus; human immunodeficiency virus; pneumococcal conjugate vaccine; pneumococcal vaccine; pneumonia; respiratory infections; AIDS-Related Opportunistic Infections; Coinfection; Coronavirus; Coronavirus Infections; Follow-Up Studies; Hospitalization; Humans; Incidence; Infant; Pneumococcal Vaccines; Pneumonia, Pneumococcal; Pneumonia, Viral; Prevalence; Randomized Controlled Trials as Topic; Streptococcus pneumoniae","Nunes","Marta C","Medical Research Council: Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa nunesm@rmpru.co","nunesm@rmpru.co.za"
"97","33415760","10.1002/jmv.26781","Retrospective prediction of the epidemic trend of COVID-19 in Wuhan at four phases.","The coronavirus disease 2019 (COVID-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in December 2019 and was basically under control in April 2020 in Wuhan. To explore the impact of intervention measures on the COVID-19 epidemic, we established susceptible-exposed-infectious-recovered (SEIR) models to predict the epidemic characteristics of COVID-19 at four different phases (beginning, outbreak, recession, and plateau) from January 1st to March 30th, 202","2021","03","19","J Med Virol","Journal of medical virology","COVID-19 epidemic; SEIR model; infection rate; interventional measures; reproduction number; COVID-19; China; Disease Outbreaks; Disease Susceptibility; Epidemics; Humans; Models, Statistical; Mortality; Retrospective Studies; SARS-CoV-2","Li","Mengyuan","Biomedical Informatics Research Lab, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China",NA
"98","33414790","10.3389/fimmu.2020.608460","RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?","The COVID-19 pandemic demonstrates the ongoing threat of pandemics caused by novel, previously unrecognized, or mutated pathogens with high transmissibility. Currently, vaccine development is too slow for vaccines to be used in the control of emerging pandemics. RNA-based vaccines might be suitable to meet this challenge. The use of an RNA-based delivery mechanism promises fast vaccine development, clinical approval, and production. The simplicity of in vitro transcription of mRNA suggest","2021","01","15","Front Immunol","Frontiers in immunology","infectious disease; mRNA vaccine; outbreak; pandemics; self-amplifying RNA; vaccine development; vaccine platform; Animals; Humans; Pandemics; RNA, Messenger; Vaccines, DNA","Sandbrink","Jonas B","Medical School, Medical Sciences Division, University of Oxford, Oxford, United Kingdom",NA
"99","33414636","10.2147/DDDT.S278892","Volumetric Absorptive Microsampling as a Sampling Alternative in Clinical Trials and Therapeutic Drug Monitoring During the COVID-19 Pandemic: A Review.","An infectious disease, COVID-19, caused by a new type of coronavirus, has been discovered recently. This disease can cause respiratory distress, fever, and fatigue. It still has no drug and vaccine for treatment and prevention. Therefore, WHO recommends that people should stay at home to reduce disease transmission. Due to the quarantine, FDA stated that this could hamper drug development clinical trial protocols. Hence, an alternative sampling method that can be applied at home is needed. Curre","2021","01","12","Drug Des Devel Ther","Drug design, development and therapy","COVID-19; TDM; VAMS; clinical trials; drug development; therapeutic drug monitoring; volumetric absorptive microsampling; COVID-19; Clinical Trials as Topic; Drug Development; Drug Discovery; Drug Monitoring; Humans; SARS-CoV-2; Specimen Handling","Harahap","Yahdiana","Faculty of Pharmacy, Universitas Indonesia, Depok, West Java 16424, Indonesia",NA
"100","33408775","10.7150/thno.53691","The 2020 race towards SARS-CoV-2 specific vaccines.","The global outbreak of a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlighted a requirement for two pronged clinical interventions such as development of effective vaccines and acute therapeutic options for medium-to-severe stages of &quot;coronavirus disease 2019&quot; (COVID-19). Effective vaccines, if successfully developed, have been emphasized to become the most effective strategy in the global fight against the COVID-19 pandemic. Basic research advances in biotech","2021","01","18","Theranostics","Theranostics","COVID-19; SARS-CoV-2; clinical trials; coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2; vaccine; Antigens, Viral; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Approval; Drug Development; Humans; Pandemics; Patient Safety; SARS-CoV-2; Time Factors; Treatment Outcome; Viral Structural Proteins","Karpi..ski","Tomasz M","Chair and Department of Medical Microbiology, Pozna.. University of Medical Sciences, Wieniawskiego 3, 61-712 Pozna.., Poland",NA
"101","33403227","10.15190/d.2020.18","Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.","SARS-CoV-2, the novel coronavirus strain responsible for the current pandemic of COVID-19, has rendered the entire humanity suffering. Several months have passed since the pandemic has struck. However, the world is still looking for an effective treatment plan to battle the viral infection. The first vaccine just received emergency approval in December 2020 for use in USA and UK. These are excellent news, however, the worldwide distribution of such vaccine, the possibility of virus mutation and ","2021","01","11","Discoveries (Craiova)","Discoveries (Craiova, Romania)","COVID-19; SARS-CoV-2; clinical trial; drug repositioning; phases; therapeutics; vaccine","Hossain","Md Shahadat","Department of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Noakhali-3814, Bangladesh",NA
"102","33402220","10.1186/s40779-020-00296-y","SARS-CoV-2: vaccines in the pandemic era.","Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused millions of infections and deaths worldwide since its emergence in December 2019. As there is little or no natural immunity in the human population or specific anti-COVID-19 drugs, researchers from the government, academia and industry are developing vaccines at an unprecedented speed to halt the pandemic. In this review, the results of animal experiments and clinical trial","2021","01","15","Mil Med Res","Military Medical Research","COVID-19; Clinical trials; SARS-CoV-2; Vaccine; Vaccine candidate; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Evaluation; Humans; Pandemics; SARS-CoV-2","Li","Dan-Dan","Institute of Medical Biology, Chinese Academy of Medicine Science &amp",NA
"103","33400682","10.2196/26089","Unfolding the Determinants of COVID-19 Vaccine Acceptance in China.","China is at the forefront of global efforts to develop COVID-19 vaccines and has five fast-tracked candidates at the final-stage, large-scale human clinical trials testing phase. Vaccine-promoting policymaking for public engagement is a prerequisite for social mobilization. However, making an informed and judicious choice is a dilemma for the Chinese government in the vaccine promotion context. In this study, public opinions in China were analyzed via dialogues on Chinese social media, based on ","2021","02","01","J Med Internet Res","Journal of medical Internet research","COVID-19; COVID-19 vaccination; COVID-19 vaccines; China; acceptance; affordability; communication; efficacy; evidence communication; opinion; promotion; risk; risk communication; social media; strategy; vaccine; COVID-19; COVID-19 Vaccines; China; Humans; Pandemics; SARS-CoV-2; Social Media; Vaccination","Yin","Fulian","Communication University of China, Beijing, China",NA
"104","33400475","10.1097/CCM.0000000000004817","Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery.","Respiratory failure, multiple organ failure, shortness of breath, recovery, and mortality have been identified as critically important core outcomes by more than 9300 patients, health professionals, and the public from 111 countries in the global coronavirus disease 2019 core outcome set initiative. The aim of this project was to establish the core outcome measures for these domains for trials in coronavirus disease 2019. Three online consensus workshops were convened to establish outcome measur","2021","03","04","Crit Care Med","Critical care medicine","COVID-19; Clinical Trials as Topic; Dyspnea; Humans; Multiple Organ Failure; Outcome Assessment, Health Care; Practice Guidelines as Topic; Recovery of Function; Reproducibility of Results; Research Design; Respiratory Insufficiency","Tong","Allison","Sydney School of Public Health, The University of Sydney, Sydney, NSW, Australia",NA
"105","33400058","10.1208/s12248-020-00532-2","Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.","The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions of people at risk in a growing number of countries. Though there are no clinically approved antiviral drugs and vaccines for COVID-19, attempts are ongoing for clinical trials of several known antiviral drugs, their combination, as well as development of vaccines in patients with confirmed COVID-19. ","2021","01","13","AAPS J","The AAPS journal","ARDS; anti-SARS-CoV-2 antibody; antiviral drugs; antiviral vaccines; convalescent plasma therapy; immunotherapy; nanotherapeutics; Animals; Antiviral Agents; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Host-Pathogen Interactions; Humans; Immunization, Passive; Predictive Value of Tests; SARS-CoV-2; Treatment Outcome","Majumder","Joydeb","Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, 160 Frelinghuysen Road, Piscataway, New Jersey, 08854, USA",NA
"106","33398692","10.1007/s12272-020-01301-7","Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective.","The novel beta coronavirus (SARS-CoV-2, designated as COVID-19) that is responsible for severe acute respiratory syndrome has devastated the global economy and health care system. Since COVID-19 changed the definition of &quot;normal&quot; in ordinary life around the world, the development of effective therapeutics and preventive measures is desperately needed to fight SARS-CoV-2 infection and restore normalcy. A clear understanding of COVID-19 pathogenesis is crucial in providing the scientific","2021","02","23","Arch Pharm Res","Archives of pharmacal research","ACE2 deficiency; Acute lung injury (ALI); Acute respiratory distress syndrome (ARDS); Angiotensin-converting enzyme 2 (ACE2); Coagulopathy; Coronavirus disease 2019 (COVID-19); Cytokine storm; Multi-organ failure (MOF); Renin-angiotensin system (RAS); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Thrombosis; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; COVID-19; Cytokine Release Syndrome; Humans; Immunity, Innate; Inflammation Mediators","Lee","Choongho","College of Pharmacy, Dongguk University, Goyang, 10326, Republic of Korea. choongholee@dongguk","choongholee@dongguk.edu"
"107","33398264","10.21203/rs.3.rs-132821/v1","SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans.","Infection or vaccination induces a population of long-lived bone marrow plasma cells (BMPCs) that are a persistent and essential source of protective antibodies1-5. Whether this population is induced in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown. Recent reports have suggested that SARS-CoV-2 convalescent patients experience a rapid decay in their antigen-specific serum antibodies, raising concerns that humoral immunity against this virus ma","2021","06","03","Res Sq","Research square",NA,"Turner","Jackson S","Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA",NA
"108","33398242","10.1016/j.jobcr.2020.12.006","Potential therapeutic approaches of microRNAs for COVID-19: Challenges and opportunities.","The coronavirus disease 2019 (COVID-19) emerges as current outbreak cause by Novel Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). This infection affects respiratory system and provides uncontrolled systemic inflammatory response as cytokine storm. The main concern about SARS-CoV-2 pandemic is high viral pathogenicity with no specific drugs. MicroRNAs (miRs) as small non-coding RNAs (21-25.....nt) regulate gene expression. The SARS-CoV-2 encoded-miRs affect human genes that involv","2021","04","23","J Oral Biol Craniofac Res","Journal of oral biology and craniofacial research","COVID-19; SARS-CoV-2; Saliva biomarker; Therapeutic approach; microRNA","Farshbaf","Alieh","Dental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran",NA
"109","33397151","10.4155/tde-2020-0124","Industry Update: the latest developments in the field of therapeutic delivery, September 2020.",NA,"2021","01","20","Ther Deliv","Therapeutic delivery","COVID-19; antibody...drug conjugate; cell therapies; clinical trials; drug delivery; gene therapy; mergers and acquisitions; product approvals; rare diseases; targeted therapeutics; Adenoviridae; Administration, Oral; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Commerce; Drug Delivery Systems; Drug Industry; Genetic Vectors; Immunity, Mucosal","Timmins","Peter","Department of Pharmacy, University of Huddersfield, Queensgate, Huddersfield HD1 3DH, UK",NA
"110","33396343","10.3390/v13010054","Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is transmitted primarily through respiratory droplets/aerosols and it causes COVID-19. The virus infects epithelial cells by using the spike protein on its surface to bind to angiotensin-converting enzyme 2 receptor on the cells. Thus, candidate vaccines targeting the spike protein are currently being developed to prevent against infections. Approximately 44 SARS-CoV-2 candidate vaccines are in clinical trials (phase I-III) and an addi","2021","01","19","Viruses","Viruses","COVID-19; SARS-CoV-2; SARS-CoV-2 vaccines; clinical trials; Antibodies, Neutralizing; COVID-19; COVID-19 Vaccines; Canada; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Drug Approval; Europe; Humans; SARS-CoV-2; Spike Glycoprotein, Coronavirus; United Kingdom; United States; Vaccines, Synthetic","Tumban","Ebenezer","Texas Tech University School of Veterinary Medicine, Amarillo, TX 79106, USA",NA
"111","33392485","10.1016/j.eclinm.2020.100689","Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.","A vaccine against SARS-CoV-2 is of high urgency. Here the safety and immunogenicity induced by a DNA vaccine (INO-4800) targeting the full length spike antigen of SARS-CoV-2 are described. INO-4800 was evaluated in two groups of 20 participants, receiving either 1.0..mg or 2.0..mg of vaccine intradermally followed by CELLECTRA.. EP at 0 and 4 weeks. Thirty-nine subjects completed both doses; one subject in the 2.0..mg group discontinued trial participation prior to receiving the second dose. Cli","2021","01","30","EClinicalMedicine","EClinicalMedicine","COVID-19; DNA vaccine; INO-4800; Phase 1; SARS-CoV-2","Tebas","Pablo","Hospital of the University of Pennsylvania, Philadelphia, PA, USA",NA
"112","33391623","10.1007/s12274-020-3243-5","Manganese nanodepot augments host immune response against coronavirus.","Interferon (IFN) responses are central to host defense against coronavirus and other virus infections. Manganese (Mn) is capable of inducing IFN production, but its applications are limited by nonspecific distributions and neurotoxicity. Here, we exploit chemical engineering strategy to fabricate a nanodepot of manganese (nanoMn) based on Mn<sup>2</sup>+. Compared with free Mn<sup>2+</sup>, nanoMn enhances cellular uptake and persistent release of Mn<sup>2+</sup> in a pH-sensitive manner, thus s","2021","01","05","Nano Res","Nano research","coronavirus; interferon; macrophage polarization; manganese nanodepot (nanoMn); vaccine adjuvant","Sun","Yizhe","Institute of Systems Biomedicine, Department of Pathology, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking-Tsinghua Center for Life Sciences, Peking University Health Science Center, Beijing, 100191 China",NA
"113","33390829","10.7150/ijbs.52569","Current advances in the development of SARS-CoV-2 vaccines.","Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global pandemic that has wreaked havoc globally, which has put a heavy toll on public health, lives, and the world economy. Vaccination is considered as one of the greatest successes in medical history. Based on prior experience with the development of SARS-CoV vaccines, all COVID-19 vaccines must be subjected to the tests for protective effects and harmful risks derived from antib","2021","01","14","Int J Biol Sci","International journal of biological sciences","COVID-19; SARS-CoV-2; clinical trial; coronavirus; vaccines; COVID-19; COVID-19 Vaccines; Humans; SARS-CoV-2","Awadasseid","Annoor","Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, 310014, China",NA
"114","33390810","10.7150/ijms.47706","DCs-based therapies: potential strategies in severe SARS-CoV-2 infection.","Pneumonia caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is spreading globally. There have been strenuous efforts to reveal the mechanisms that the host defends itself against invasion by this virus. The immune system could play a crucial role in virus infection. Dendritic cell as sentinel of the immune system plays an irreplaceable role. Dendritic cells-based therapeutic approach may be a potential strategy for SARS-CoV-2 infection. In this review, the characteristic","2021","01","08","Int J Med Sci","International journal of medical sciences","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection; dendritic cells (DCs) vaccine; immune system response; immunotherapy; therapeutic vaccine; COVID-19; Clinical Trials as Topic; Dendritic Cells; Host-Pathogen Interactions; Humans; Immunotherapy; SARS-CoV-2","Han","Jian","General Surgery Department, The First Affiliated Hospital of Dalian Medical University, Dalian, China",NA
"115","33390384","10.5582/bst.2020.03445","Latest updates on COVID-19 vaccines.","The ongoing outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised a grave concern and a severe global health burden. Since no effective drugs have been approved for satisfactory prevention and treatment, the development of COVID-19 vaccines has attracted global attention. To date, a large number of COVID-19 vaccines are being rapidly developed worldwide, with thirteen candidates in Phase 3 trials, 52 tested in clinical trials, and 162 in preclinical evaluation. Here","2021","01","29","Biosci Trends","Bioscience trends","COVID-19; SARS-CoV-2; vaccine acceptance; vaccine distribution; vaccine promotion; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Delivery of Health Care; Humans; Patient Acceptance of Health Care; Vaccination; Vaccination Refusal","Li","Qian","Department of Infectious Diseases, Shanghai Public Health Clinical Center, Shanghai, China",NA
"116","33388478","10.1016/j.jaip.2020.12.047","mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.","The U.S. Food and Drug Administration (FDA) has recently issued an Emergency Use Authorization (EUA) for 2 highly effective coronavirus disease 2019 (COVID-19) vaccines from Pfizer-BioNTech and Moderna. This has brought hope to millions of Americans in the midst of an ongoing global pandemic. The FDA EUA guidance for both vaccines is to not administer the vaccine to individuals with a known history of a severe allergic reaction (eg, anaphylaxis) to any component of the COVID-19 vaccine. The Cent","2021","04","23","J Allergy Clin Immunol Pract","The journal of allergy and clinical immunology. In practice","Allergic reactions; Allergy; Anaphylaxis; COVID-19; Guidelines; Polyethylene glycol; Polysorbate; Risk stratification; Vaccine; mRNA; Anaphylaxis; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; United States; United States Food and Drug Administration; Vaccines, Synthetic","Banerji","Aleena","Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass","abanerji@mgh.harvard.edu"
"117","33388404","10.1053/j.ajkd.2020.12.003","Practicing With Uncertainty: Kidney Transplantation During the COVID-19 Pandemic.","The coronavirus disease 2019 (COVID-19) pandemic required transplant nephrologists, surgeons, and care teams to make decisions about the full spectrum of transplant program operations and clinical practices in the absence of experience or data. Initially, across the country, there was a reduction in kidney transplant procedures and a striking pause in the conduct of living donation and living-donor transplant surgeries. Aspects of candidate evaluation and follow-up rapidly converted to telehealt","2021","05","03","Am J Kidney Dis","American journal of kidney diseases : the official journal of the National Kidney Foundation","Coronavirus disease 2019 (COVID-19); allograft rejection; evaluation; follow-up; immunosuppression management; kidney transplantation; living kidney donation; pandemic; screening; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); telehealth; therapeutics; vaccines; COVID-19; Clinical Decision-Making; Critical Pathways; Humans; Immunosuppression; Infection Control; Kidney Failure, Chronic; Kidney Transplantation; SARS-CoV-2; Telemedicine; Time-to-Treatment; Tissue Donors; Transplant Recipients","Lentine","Krista L","Division of Nephrology, Department of Medicine, Saint Louis University Center for Abdominal Transplantation, St. Louis, MO",NA
"118","33382764","10.1371/journal.pone.0244126","Antibody response to SARS-CoV-2 infection in humans: A systematic review.","Progress in characterising the humoral immune response to Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist. Assessment of the full range of evidence generated to date to understand the characteristics of the antibody response, its dynamics over time, its determinants and the immunity it confers will have a range of clinical and policy implications for this novel pathogen. This review comprehensively evaluated evidence describing the antibody respon","2021","01","11","PLoS One","PloS one","Antibodies, Neutralizing; Antibodies, Viral; Antibody Formation; COVID-19; Cross Reactions; Female; Humans; Male; SARS-CoV-2","Post","Nathan","Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom",NA
"119","33382675","10.15585/mmwr.mm695152e1","The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.","On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Moderna COVID-19 (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts), a lipid nanoparticle-encapsulated, nucleoside-modified mRNA vaccine encoding the stabilized prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). This vaccine is the second COVID-19 vaccine authorized under an EUA for the prevention of COVID-19 in the U","2021","01","04","MMWR Morb Mortal Wkly Rep","MMWR. Morbidity and mortality weekly report","Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Advisory Committees; Aged; Aged, 80 and over; COVID-19; COVID-19 Vaccines; Centers for Disease Control and Prevention, U.S.; Clinical Trials, Phase III as Topic; Drug Approval; Emergencies; Humans; Immunization; Middle Aged; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Young Adult","Oliver","Sara E",NA,NA
"120","33382671","10.15585/mmwr.mm695152e2","The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine - United States, December 2020.","The first vaccines for prevention of coronavirus disease 2019 (COVID-19) in the United States were authorized for emergency use by the Food and Drug Administration (FDA) (1) and recommended by the Advisory Committee on Immunization Practices (ACIP) in December 2020.* However, demand for COVID-19 vaccines is expected to exceed supply during the first months of the national COVID-19 vaccination program. ACIP advises CDC on population groups and circumstances for vaccine use.<sup>...</sup> On Decem","2021","01","04","MMWR Morb Mortal Wkly Rep","MMWR. Morbidity and mortality weekly report","Adolescent; Adult; Advisory Committees; Aged; COVID-19; COVID-19 Vaccines; Centers for Disease Control and Prevention, U.S.; Health Care Rationing; Humans; Immunization; Middle Aged; United States; Young Adult","Dooling","Kathleen",NA,NA
"121","33380328","10.1186/s12967-020-02675-4","Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants.","Tracking the genetic variability of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) is a crucial challenge. Mainly to identify target sequences in order to generate robust vaccines and neutralizing monoclonal antibodies, but also to track viral genetic temporal and geographic evolution and to mine for variants associated with reduced or increased disease severity. Several online tools and bioinformatic phylogenetic analyses have been released, but the main interest lies in the Spike","2021","01","14","J Transl Med","Journal of translational medicine","Bioinformatic workflow; COVID mutations; Docker; SARS-CoV-2 genome; SARS-CoV-2 mutation; SARS-CoV-2 vaccine; Binding Sites; COVID-19; COVID-19 Vaccines; Computational Biology; Data Mining; Genetic Variation; Humans; Immunogenetic Phenomena; Models, Molecular; Mutation; Pandemics; Protein Domains; Receptors, Virus; SARS-CoV-2; Software; Spike Glycoprotein, Coronavirus; Translational Medical Research","Massacci","Alice","Takis srl, Rome, Italy",NA
"123","33377885","","COVID-19 Vaccines: Current Status and Implication for Use in Indonesia.","The coronavirus disease 2019 (COVID-19) has inflicted catastrophic damages in public health, economic and social stability-putting life globally on hold in 2020 and presumably a year more. Indonesia bears a heavy burden of the pandemic, counting the highest case prevalence and fatality rate in all of Southeast Asia. One hope remains in the groundbreaking universal effort in search of a vaccine against the causative virus SARS-CoV-2, which has shown success unparalleled in human vaccine developme","2021","01","13","Acta Med Indones","Acta medica Indonesiana","COVID-19; Indonesia; vaccine; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Genetic Vectors; Humans; Immunity, Herd; Indonesia; Patient Selection; RNA, Messenger; SARS-CoV-2; Vaccines, DNA; Vaccines, Inactivated; Vaccines, Synthetic","Ophinni","Youdiil","Ragon Institute of MGH, MIT and Harvard - Harvard Medical School, Cambridge, MA, United States. yophinni@mgh.harvard","yophinni@mgh.harvard.edu"
"124","33371905","10.1186/s13063-020-04928-5","COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial.","With the lack of effective therapy, chemoprevention, and vaccination against SARS-CoV-2, focusing on the immediate repurposing of existing drugs gives hope of curbing the COVID-19 pandemic. A recent unbiased genomics-guided tracing of the SARS-CoV-2 targets in human cells identified vitamin D among the three top-scoring molecules manifesting potential infection mitigation patterns. Growing pre-clinical and epidemiological observational data support this assumption. We hypothesized that vitamin D","2021","01","06","Trials","Trials","Anti-inflammatory; Antiviral; COVID-19; Mortality; Older adults; Prognosis; Randomized controlled trial; SARS-CoV-2; Vitamin D; Aged; COVID-19; Dietary Supplements; Dose-Response Relationship, Drug; Female; Humans; Male; Nutrition Therapy; Pandemics; Risk Factors; SARS-CoV-2; Time Factors; Treatment Outcome; Vitamin D; Vitamins","Annweiler","C..dric","Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, Angers University Hospital, F-49933, Angers, France. Cedric.Annweiler@chu-angers",NA
"125","33371175","10.1097/MD.0000000000023874","Novel coronavirus pneumonia (COVID-19) combined with Chinese and Western medicine based on &quot;Internal and External Relieving -Truncated Torsion&quot; strategy.","The outbreak of novel coronavirus disease 2019 (COVID-19) has caused a global pandemic since December 2020. It has not only associated with physiological disorder but also with psychological distress and symptoms of mental illness. Whether the vaccines and antivirals can provide protects remains unknown. Traditional Chinese medicine (TCM) is recommended as an alternative and significant way of preventing and treating COVID-19 in China. However, few studies have assessed the benefits of this trea","2021","01","04","Medicine (Baltimore)","Medicine","COVID-19; Drugs, Chinese Herbal; Humans","Wu","Xinxin","LongHua Hospital Shanghai University of Traditional Chinese Medicine, NO.725 Wanping South Road, Xuhui District",NA
"126","33371042","10.1136/bmjopen-2020-042085","Efficacy and safety of mesenchymal stem cells for the treatment of patients infected with COVID-19: a systematic review and meta-analysis protocol.","To date, no specific antivirus drugs or vaccines have been available to prevent or treat the COVID-19 pandemic. Mesenchymal stem cell (MSC) therapy may be a promising therapeutic approach that reduces the high mortality in critical cases. This protocol is proposed for a systematic review and meta-analysis that aims to evaluate the efficacy and safety of MSC therapy on patients with COVID-19. Ten databases including PubMed, EMBASE, Cochrane Library, CINAHL, Web of Science, Chinese National Knowle","2021","01","12","BMJ Open","BMJ open","cell biology; immunology; infectious diseases; public health; COVID-19; Humans; Mesenchymal Stem Cell Transplantation; Meta-Analysis as Topic; Research Design; SARS-CoV-2; Systematic Reviews as Topic; Treatment Outcome","Chen","Yunhui","Chengdu University of Traditional Chinese Medicine, Chengdu, China",NA
"127","33370015","10.1097/AOG.0000000000004290","Coronavirus Disease 2019 (COVID-19) Vaccines and Pregnancy: What Obstetricians Need to Know.","Coronavirus disease 2019 (COVID-19) vaccines have begun to be distributed across the United States and to be offered initially to priority groups including health care personnel and persons living in long-term care facilities. Guidance regarding whether pregnant persons should receive a COVID-19 vaccine is needed. Because pregnant persons were excluded from the initial phase 3 clinical trials of COVID-19 vaccines, limited data are available on their efficacy and safety during pregnancy. After de","2021","02","23","Obstet Gynecol","Obstetrics and gynecology","COVID-19; COVID-19 Vaccines; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; Female; Health Knowledge, Attitudes, Practice; Humans; Infectious Disease Transmission, Vertical; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; SARS-CoV-2; Societies, Medical; United States; Vaccination","Rasmussen","Sonja A","Departments of Pediatrics, Obstetrics and Gynecology, and Epidemiology, University of Florida College of Medicine and College of Public Health and Health Professions, Gainesville, Florida",NA
"128","33367857","10.1093/pubmed/fdaa230","COVID-19 vaccine hesitancy among medical students.","Medical students are among the group of frontline healthcare providers likely to be exposed to COVID-19 patients. It is important to achieve high COVID-19 vaccination coverage rates in this group as soon as a vaccine is available. As future healthcare providers, they will be entrusted with providing vaccine recommendations and counseling vaccine-hesitant patients. This project used self-report to assess vaccine hesitancy and acceptance among medical students towards the novel COVID-19 vaccine. N","2021","01","26","J Public Health (Oxf)","Journal of public health (Oxford, England)","COVID-19; medical students; vaccine hesitancy","Lucia","Victoria C","Foundational Medical Studies, Oakland University William Beaumont School of Medicine, Rochester, MI 48309, USA",NA
"129","33364539","10.3934/microbiol.2020028","Biologically active compounds from marine organisms in the strategies for combating coronaviruses.","Despite the progress made in immunization and drug development, so far there are no prophylactic vaccines and effective therapies for many viral infections, including infections caused by coronaviruses. In this regard, the search for new antiviral substances continues to be relevant, and the enormous potential of marine resources are a stimulus for the study of marine compounds with antiviral activity in experiments and clinical trials. The highly pathogenic human coronaviruses-severe acute resp","2020","12","29","AIMS Microbiol","AIMS microbiology","MERS-CoV; SARS-CoV; SARS-CoV-2; antiviral drugs; biologically active substances; coronaviruses; marine organisms","Zaporozhets","Tatyana S","Immunology Laboratory, Somov Institute of Epidemiology and Microbiology, Vladivostok, Russian Federation",NA
"130","33363416","10.2147/CPAA.S284809","An Up-to-Date Overview of Therapeutic Agents for the Treatment of COVID-19 Disease.","Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has a great potential to overwhelm the world healthcare systems that may lead to high morbidity and mortality. It also affects world economic development in the future. Currently, no proven effective drugs or vaccines are available for the management of COVID-19 disease. The pace of normal drug development progression is unacceptable in the context of the current pandemic. Therefore, repurposing the existing drugs that were used for ","2020","12","29","Clin Pharmacol","Clinical pharmacology : advances and applications","COVID-19; SARS-CoV; SARS-CoV-2; chloroquine; corona virus","Mulaw Belete","Tafere","Department of Pharmacology, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia",NA
"131","33362758","10.3389/fimmu.2020.569760","SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.","The World Health Organization (WHO) announced in March a pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This new infectious disease was named Coronavirus Disease 19 (COVID-19), and at October 2020, more than 39,000,000 cases of SARS-CoV-2 have been detected worldwide leading to near 1,100,000 deaths. Clinically, COVID-19 is characterized by clinical manifestations, such as fever, dry cough, headache, and in more severe cases, respiratory distress. Moreover, neur","2021","01","15","Front Immunol","Frontiers in immunology","COVID-19; SARS-CoV-2; immune response; treatments; vaccines; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal; Antiviral Agents; COVID-19; COVID-19 Vaccines; Female; Humans; Immunization, Passive; Male; RNA, Viral; Receptors, Virus; SARS-CoV-2; T-Lymphocytes","Canedo-Marroqu..n","Gisela","Millennium Institute of Immunology and Immunotherapy, Departamento de Gen..tica Molecular y Microbiolog..a, Facultad de Ciencias Biol..gicas, Pontificia Universidad Cat..lica de Chile, Santiago, Chile",NA
"132","33362278","10.1371/journal.pone.0244418","A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates.","We compare and contrast the expected duration and number of infections and deaths averted among several designs for clinical trials of COVID-19 vaccine candidates, including traditional and adaptive randomized clinical trials and human challenge trials. Using epidemiological models calibrated to the current pandemic, we simulate the time course of each clinical trial design for 756 unique combinations of parameters, allowing us to determine which trial design is most effective for a given scenar","2021","01","07","PLoS One","PloS one","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Pandemics; SARS-CoV-2","Berry","Donald A","Department of Biostatistics, University of Texas, Houston, Texas, United States of America",NA
"133","33361645","10.4103/ijmr.IJMR_4431_20","Comparison of the immunogenicity &amp; protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates.","The COVID-19 pandemic has emerged as a global public health crisis and research groups worldwide are engaged in developing vaccine candidates to curb its transmission, with a few vaccines having progressed to advanced stages of clinical trials. The aim of this systematic review was to compare immunogenicity and protective efficacy of various SARS-CoV-2 vaccine candidates tested in non-human primate (NHP) models. Literature on effect of SARS-CoV-2 vaccines in NHP models reported on PubMed and pre","2021","04","15","Indian J Med Res","The Indian journal of medical research","COVID-19; T-cell response; immune response; inactivated vaccine; neutralizing antibody; non-human primate; protein subunit vaccine; vaccine; viral clearance; Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Disease Models, Animal; Immunogenicity, Vaccine; Macaca mulatta; Primates","Mukhopadhyay","Labanya","Virology Unit, Division of Epidemiology &amp",NA
"134","33361116","10.1126/science.abc8378","Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity.","Immunoglobulin G (IgG) antibodies are crucial for protection against invading pathogens. A highly conserved N-linked glycan within the IgG-Fc tail, which is essential for IgG function, shows variable composition in humans. Afucosylated IgG variants are already used in anticancer therapeutic antibodies for their increased activity through Fc receptors (Fc..RIIIa). Here, we report that afucosylated IgG (approximately 6% of total IgG in humans) are specifically formed against enveloped viruses but ","2021","03","05","Science","Science (New York, N.Y.)","Adult; Aged; Antibodies, Viral; COVID-19; Cells, Cultured; Critical Illness; Cytomegalovirus; Female; Fucose; Glycosylation; HIV; Hepatitis B Vaccines; Humans; Immunoglobulin Fc Fragments; Immunoglobulin G; Inflammation; Interleukin-6; Macrophages; Male; Middle Aged; Parvovirus B19, Human; SARS-CoV-2; Severity of Illness Index; Spike Glycoprotein, Coronavirus; Vaccines, Subunit; Young Adult","Larsen","Mads Delbo","Department of Experimental Immunohematology, Sanquin Research, Amsterdam, Netherlands",NA
"135","33356860","10.1080/15321819.2020.1862867","Herbal medicine, a reliable support in COVID therapy.","At present, specific therapies for COVID-19 are not well established, being certain only that the immune system plays a decisive role in the initiation and progression of the disease. Plants have given and continue to give compounds with great efficiency and low toxicity, some of them being a starting point for extremely effective synthetic substances. Although herbal remedies are used mainly for preventive purposes, there are also guidelines issued by some countries that indicate the use of tra","2021","02","16","J Immunoassay Immunochem","Journal of immunoassay &amp; immunochemistry","Medicinal plants; immune system; inflammation; traditional; COVID-19; Clinical Trials as Topic; Europe; Humans; Immune System; Lectins; Oils, Volatile; Phenols; Phytotherapy; Plant Extracts; Plant Preparations; Plants, Medicinal; SARS-CoV-2; Saponins; Virus Internalization; Virus Replication","Grigore","Alice","Department of Pharmaceutical Biotechnologies, National Institute for Chemical-Pharmaceutical R &amp",NA
"136","33355053","10.2174/1389557521666201222145842","Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.","COVID-19 is a public health emergency of international concern. Although considerable knowledge has been acquired with time about the viral mechanism of infection and mode of replication, yet no specific drugs or vaccines have been discovered against SARS-CoV-2 to date. There are few small molecule antiviral drugs like Remdesivir and Favipiravir, which have shown promising results in different advanced stages of clinical trials. Chloroquinine, Hydroxychloroquine, and Lopinavir- Ritonavir combina","2021","06","03","Mini Rev Med Chem","Mini reviews in medicinal chemistry","SARS-CoV-2; antiviral drugs; coronavirus; remdesivir; repurposed drugs; synthesis.","Paul","Subha Sankar","Nanyang Technological University, Singapore",NA
"137","33352743","10.3390/vaccines8040778","SARS-CoV-2 Seroprevalence Survey in People Involved in Different Essential Activities during the General Lock-Down Phase in the Province of Prato (Tuscany, Italy).","Serosurveys may help to assess the transmission dynamics in high-risk groups. The aim of the study was to assess the SARS-CoV-2 antibody seroprevalence in people who had performed essential activities during the lock-down period in the Province of Prato (Italy), and to evaluate the risk of exposure to SARS-CoV-2 according to the type of service. All the workers and volunteers of the Civil Protection, employees of the municipalities, and all the staff of the Health Authority of the Province of Pr","2020","12","31","Vaccines (Basel)","Vaccines","COVID-19; Italy; SARS-CoV-2; essential activities; healthcare workers; seroprevalence; serosurvey","Lastrucci","Vieri","Department of Health Sciences, University of Florence, 50134 Florence, Italy",NA
"138","33351168","10.1007/s12250-020-00329-9","Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study.","Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly around the world, posing a major threat to human health and the economy. Currently, long-term data on viral shedding and the serum antibody responses in COVID-19 patients are still limited. Herein, we report the clinical features, viral RNA loads, and serum antibody levels in a cohort of 112 COVID-19 patients admitted to the Honghu People's Hospital, Hubei Province, Chi","2021","02","15","Virol Sin","Virologica Sinica","Antibody response; Coronavirus disease 2019 (COVID-19); Disease severity; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Viral shedding; Adult; Aged; Antibodies, Viral; Antibody Formation; COVID-19; COVID-19 Serological Testing; China; Female; Follow-Up Studies; Humans; Immunoglobulin G; Immunoglobulin M; Kinetics; Male; Middle Aged; RNA, Viral; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Viral Load; Virus Shedding","Zhang","Xiaoyong","State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, 510000, China",NA
"139","33350389","10.1684/pnv.2020.0907","[Vitamin D supplementation and COVID-19: expert consensus and guidelines].","After 12 months of viral circulation, the SARS-CoV-2 has infected millions of people around the world, leaving hundreds of thousands dead. With the lack of effective therapy and vaccination against COVID-19, focusing on the immediate repurposing of existing drugs gives hope of curbing the pandemic. Vitamin D is a possible candidate discussed in a high amount of publications. Randomized clinical trials show that vitamin D supplementation significantly reduces the risk of respiratory infections. T","2021","04","27","Geriatr Psychol Neuropsychiatr Vieil","Geriatrie et psychologie neuropsychiatrie du vieillissement","COVID-19; SARS-CoV-2; guidelines; supplementation; vitamin D; Adult; COVID-19; Dietary Supplements; France; Humans; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Vitamin D; Vitamin D Deficiency","Annweiler","C..dric","D..partement de g..riatrie et Centre m..moire ressources recherche, Centre de recherche sur l'autonomie et la long..vit.., Centre hospitalier universitaire, Angers, France..",NA
"140","33349145","10.1177/0020731420979824","Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19.","Medicine regulators rely on pivotal clinical trials to make decisions about approving a new drug, but little is known about how they judge whether pivotal trials justify the approval of new drugs. We explore this issue by looking at the positions of 3 major regulators: the European Medicines Agency, Food and Drug Administration, and Health Canada. Here we report their views and the implications of those views for the approval process. On various points, the 3 regulators are ambiguous, consistent","2020","12","31","Int J Health Serv","International journal of health services : planning, administration, evaluation","COVID-19; European Medicines Agency; Food and Drug Administration; Health Canada; drug regulators; pivotal trials; COVID-19; Canada; Clinical Trials as Topic; Consumer Product Safety; Drug Approval; Drug and Narcotic Control; Europe; Humans; SARS-CoV-2; United States","Lexchin","Joel","Faculty of Health, York University, Toronto, Ontario, Canada",NA
"141","33343798","10.11604/pamj.supp.2020.37.19.25688","Poor knowledge of COVID-19 and unfavourable perception of the response to the pandemic by healthcare workers at the Bafoussam Regional Hospital (West Region-Cameroon).","WHO warned against a dramatic impact of COVID-19 in Africa unless adequate response strategies are implemented. Whatever the strategy, the role of health staff is pivotal. Objective: Assess knowledge and perception of the response to COVID-19 among health staff. we used a convenience non probabilistic sample to conduct a survey with a self-administered questionnaire from April 14 - 29, 2020 at the Bafoussam Regional Hospital (BRH). All the staff was invited to participate. Analyses were done wit","2020","12","28","Pan Afr Med J","The Pan African medical journal","Bafoussam; COVID-19; Health care workers; knowledge; perception; response; Adult; Aged; Attitude of Health Personnel; COVID-19; Cameroon; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Personnel, Hospital; Surveys and Questionnaires; Young Adult","Fouogue","Jovanny Tsuala","Faculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, West Region, Cameroon",NA
"142","33343579","10.3389/fimmu.2020.605688","Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience.","SARS-CoV-2 infection is a world-wide public health problem. Several aspects of its pathogenesis and the related clinical consequences still need elucidation. In Italy, Sardinia has had very low numbers of infections. Taking advantage of the low genetic polymorphism in the Sardinian population, we analyzed clinical, genetic and immunogenetic factors, with particular attention to HLA class I and II molecules, to evaluate their influence on susceptibility to SARS-CoV-2 infection and the clinical ou","2020","12","28","Front Immunol","Frontiers in immunology","COVID-19 severity; SARS-CoV-2 infection; Sardinian population; alleles; glucose-6-phosphate dehydrogenase; haplotypes; human leukocyte antigen; immunogenetic background; Adult; Aged; COVID-19; Female; Gene Frequency; Genetic Predisposition to Disease; HLA-DRB1 Chains; Histocompatibility Antigens Class I; Humans; Immunogenetics; Italy; Male; Middle Aged; SARS-CoV-2; Severity of Illness Index","Littera","Roberto","Complex Structure of Medical Genetics, R. Binaghi Hospital, Area Socio-Sanitaria Locale (ASSL) Cagliari, Azienda per la Tutela della Salute (ATS) Sardegna, Italy",NA
"143","33343376","10.3389/fphar.2020.605185","Hydroxychloroquine as Prophylaxis for COVID-19: A Review.","The impact of the COVID-19 pandemic worldwide has led to a desperate search for effective drugs and vaccines. There are still no approved agents for disease prophylaxis. We thus decided to use a drug repositioning strategy to perform a state-of-the-art review of a promising but controversial drug, hydroxychloroquine (HCQ), in an effort to provide an objective, scientific and methodologically correct overview of its potential prophylactic role. The advantage of using known drugs is that their tox","2020","12","22","Front Pharmacol","Frontiers in pharmacology","COVID-19; clinical trials; hydroxychloroquine; prophylaxis; review","Monti","Manuela","Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori (IRST) IRCCS, Meldola, Italy",NA
"144","33340397","10.1093/cid/ciaa1863","Evaluating the Efficacy of COVID-19 Vaccines.","A large number of studies are being conducted to evaluate the efficacy and safety of candidate vaccines against novel coronavirus disease-2019 (COVID-19). Most Phase 3 tri- als have adopted virologically confirmed symptomatic COVID-19 disease as the primary efficacy endpoint, although laboratory-confirmed SARS-CoV-2 is also of interest. In addi- tion, it is important to evaluate the effect of vaccination on disease severity. To provide a full picture of vaccine efficacy and make efficient use of","2021","02","11","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","Phase 3 trials; SARS-CoV-2; multiple primary endpoints; severe COVID-19; totality of evidence","Lin","Dan-Yu","Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, USA",NA
"145","33340018","10.1038/d41586-020-03626-1","The lightning-fast quest for COVID vaccines - and what it means for other diseases.",NA,"2021","01","05","Nature","Nature","Drug discovery; SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Disease; Humans; SARS-CoV-2; Time Factors; Vaccinology","Ball","Philip",NA,NA
"146","33338412","10.1016/j.immuni.2020.12.002","PD-1-Expressing SARS-CoV-2-Specific CD8<sup>+</sup> T Cells Are Not Exhausted, but Functional in Patients with COVID-19.","Memory T..cell responses have been demonstrated in COVID-19 convalescents, but ex..vivo phenotypes of SARS-CoV-2-specific T..cells have been unclear. We detected SARS-CoV-2-specific CD8<sup>+</sup> T..cells by MHC class I multimer staining and examined their phenotypes and functions in acute and convalescent COVID-19. Multimer<sup>+</sup> cells exhibited early differentiated effector-memory phenotypes in the early convalescent phase. The frequency of stem-like memory cells was increased among mu","2021","01","25","Immunity","Immunity","CD8(+) T cell; COVID-19; IFN-..; MHC class I multimer; Memory T cell; PD-1; SARS-CoV-2; Acute-Phase Reaction; CD8-Positive T-Lymphocytes; COVID-19; Convalescence; Epitopes, T-Lymphocyte; Histocompatibility Antigens Class I; Humans; Immunologic Memory; Immunophenotyping; Interferon-gamma; Lymphocyte Activation; Programmed Cell Death 1 Receptor; SARS-CoV-2; Viral Load","Rha","Min-Seok","Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea",NA
"147","33336780","10.26355/eurrev_202012_24057","Possible treatment and strategies for COVID-19: review and assessment.","The coronavirus disease 2019 (COVID-19) is declared as an international emergency in 2020. Its prevalence and fatality rate are rapidly increasing but the medication options are still limited for this perilous disease. The emergent outbreak of COVID-19 triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps propagating globally. The present scenario has emphasized the requirement for therapeutic opportunities to relive and overcome this latest pandemic. Despite the fact, ","2021","01","01","Eur Rev Med Pharmacol Sci","European review for medical and pharmacological sciences","Adenosine Monophosphate; Alanine; Amides; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antiparasitic Agents; Antiviral Agents; COVID-19; COVID-19 Vaccines; Cannabinoids; Chloroquine; Complement Inactivating Agents; Dexamethasone; Drug Combinations; Enzyme Inhibitors; Humans; Hydroxychloroquine; Immunization, Passive; Indoles; Interferons; Ivermectin; Lopinavir; Pyrazines; Ritonavir; SARS-CoV-2; Teicoplanin; Tetracyclines; Thiazoles","Trivedi","N","Department of Neurological Sciences, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE, USA. devendra.kumar@unmc","devendra.kumar@unmc.edu"
"148","33336213","10.1101/2020.12.14.20248137","Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials.","Several candidate vaccines to prevent COVID-19 disease have entered large-scale phase 3 placebo-controlled randomized clinical trials and some have demonstrated substantial short-term efficacy. Efficacious vaccines should, at some point, be offered to placebo participants, which will occur before long-term efficacy and safety are known. Following vaccination of the placebo group, we show that placebo-controlled vaccine efficacy can be derived by assuming the benefit of vaccination over time has ","2021","05","14","medRxiv","medRxiv : the preprint server for health sciences",NA,"Follmann","Dean","Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA",NA
"149","33335323","10.1038/s41591-020-01194-5","T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed<sup>1</sup>. Strong, Th1-skewed T cell responses can drive protective humoral and cell-mediated immune responses<sup>2</sup> and might reduce the potential for disease enhancement<sup>3</sup>. Cytotoxic T cells clear virus-infected host cells and contribute to control of infection<sup>4</sup>. Stud","2021","02","23","Nat Med","Nature medicine","Adolescent; Antibody Formation; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; COVID-19 Vaccines; Dose-Response Relationship, Immunologic; Female; Humans; Immunity, Cellular; Immunity, Humoral; Immunoglobulin A; Immunoglobulin M; Interferon-gamma; Lymphocyte Activation; Male; Middle Aged; Protein Subunits; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Vaccination; Young Adult","Ewer","Katie J","The Jenner Institute, University of Oxford, Oxford, UK. katie.ewer@ndm.ox.ac","katie.ewer@ndm.ox.ac.uk"
"150","33335322","10.1038/s41591-020-01179-4","Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.","More than 190 vaccines are currently in development to prevent infection by the novel severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing antibodies against the viral spike protein may correlate with protection, additional antibody functions may also be important in preventing infection. Previously, we reported early immunogenicity and safety outcomes of a viral vector coronavirus vaccine, ChAdOx1 nCoV-19 (AZD1222), in a single-blinded phase 1/2 random","2021","02","23","Nat Med","Nature medicine","Adolescent; Adult; Antibodies, Neutralizing; Antibody Formation; COVID-19; COVID-19 Vaccines; Dose-Response Relationship, Drug; Genetic Vectors; Humans; Immunization, Secondary; Middle Aged; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Time Factors; Young Adult","Barrett","Jordan R","The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK",NA
"151","33334920","10.1542/peds.2020-040717","Enrolling Minors in COVID-19 Vaccine Trials.","It is widely agreed that an effective response to the coronavirus disease 2019 pandemic needs to include a vaccine that is safe and effective for minors. However, many current vaccine trials have no plans for when to enroll minors. Others have recently proposed enrolling minors as young as 12 years old. This lack of a systematic approach raises 2 concerns. Waiting too long to enroll minors could unjustly deny minors and their families the benefits of a vaccine and has the potential to delay an e","2021","03","12","Pediatrics","Pediatrics","Adolescent; COVID-19; COVID-19 Vaccines; Child; Clinical Trials as Topic; Community Participation; Ethics Committees, Research; Healthy Volunteers; Humans; Informed Consent By Minors; Minors; Pandemics; SARS-CoV-2","Mintz","Kevin","Department of Bioethics, National Institutes of Health, Bethesda, Maryland",NA
"152","33334616","10.1016/j.vaccine.2020.11.072","Broad cross-national public support for accelerated COVID-19 vaccine trial designs.","A vaccine for COVID-19 is urgently needed. Several vaccine trial designs may significantly accelerate vaccine testing and approval, but also increase risks to human subjects. Concerns about whether the public would see such designs as ethical represent an important roadblock to their implementation; accordingly, both the World Health Organization and numerous scholars have called for consulting the public regarding them. We answered these calls by conducting a cross-national survey (n..=..5920) ","2021","01","14","Vaccine","Vaccine","COVID-19; Challenge trials; Public opinion; Vaccine ethics; Asia; Australia; COVID-19; COVID-19 Vaccines; Choice Behavior; Clinical Trials as Topic; Decision Making; Female; Humans; Immunity, Innate; Immunization Schedule; Immunogenicity, Vaccine; Male; North America; Pandemics; Patient Safety; Public Health; Research Design; SARS-CoV-2; Surveys and Questionnaires; Time Factors; United Kingdom; Vaccination","Broockman","David","Department of Political Science, University of California, Berkeley, United States",NA
"153","33334613","10.1016/j.vaccine.2020.12.006","Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non-responders to conventional vaccines.","An interventional, phase 4, single group assignment, without masking (open label), preventive clinical trial was carried out in health workers with biological risk in their tasks, who have been filed as non-responders to conventional vaccination against Hepatitis B. 67 health workers with biological risk in their tasks, who have been filed as non-responders to conventional vaccination against Hepatitis B, were enrolled in the Clinical Trial. All participants were from 18..years up to 64..years o","2021","04","27","Vaccine","Vaccine","Conventional vaccine; Fendrix..; Health centres dependent; Preventive clinical trial; Viable vaccine alternative; COVID-19; Delivery of Health Care; Hepatitis B; Hepatitis B Vaccines; Humans; SARS-CoV-2; Vaccination","Bravo-Grande","Jos.. L","Servicio de Prevenci..n de Riesgos Laborales, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain. Electronic address: jlbravo@saludcastillayleon","jlbravo@saludcastillayleon.es"
"154","33334287","10.2174/1389557521666201217145333","A short review on important drugs under clinical trial against Covid-19.","Corona virus spreads from one to other person, either by touching the hands or by touching the surface contaminated with this virus, and then touching the nose or mouth. Covid-19 infected human symptoms are like any pneumonia symptoms, dry cough and high fever. Upper respiratory tract infections symptoms and sore throat are rare. First notified in china dated 12th December 2019 as a respiratory illness. In addition to travel restrictions and quarantine measures everyone should follow the World H","2020","12","18","Mini Rev Med Chem","Mini reviews in medicinal chemistry","Covid-19; SARS-CoV-2.; URI; WHO; pneumonia","Misra","Namita","Resedential Area Apt. 4223, Indian Institute of Technology Jodhpur, Jodhpur 342037. India",NA
"155","33327848","10.1080/21645515.2020.1846400","Politicizing public health: the powder keg of rushing COVID-19 vaccines.","Vaccine hesitancy is on the rise, as more individuals are delaying or refusing vaccines. This rise in hesitancy has been primarily driven by vaccine safety concerns, even though the vaccine development process is regulated by a robust and rigorous scientific system. Recent data suggest that many individuals would be unwilling to take a COVID-19 vaccine, once one is available. The Trump administration's Operation Warp Speed aims to deliver a vaccine in the near future, even though no American or ","2021","05","13","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","COVID-19 vaccines; vaccine acceptance; vaccine approval; vaccine hesitancy; vaccine safety; COVID-19; COVID-19 Vaccines; Humans; Politics; Public Health","Limaye","Rupali J","Departments of International Health, Epidemiology, and Health, Behavior and Society, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA",NA
"156","33326722","10.1056/NEJMe2035370","Audio Interview: Covid-19 Vaccine Fundamentals.",NA,"2020","12","23","N Engl J Med","The New England journal of medicine","Anti-Inflammatory Agents; Azetidines; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Dexamethasone; Drug Approval; Genetic Vectors; Humans; Janus Kinase Inhibitors; Mass Vaccination; Purines; Pyrazoles; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Sulfonamides; United States; United States Food and Drug Administration; Vaccines, Attenuated; Vaccines, DNA","Rubin","Eric J",NA,NA
"157","33322733","10.3390/jcm9124021","Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review.","The novel coronavirus disease 2019 (COVID-19) is a global pandemic that continues to sweep across the world, posing an urgent need for effective therapies and prevention of the spread of the severe acute respiratory syndrome related to coronavirus-2 (SARS-CoV-2). A major hypothesis that is currently guiding research and clinical care posits that an excessive and uncontrolled surge of pro-inflammatory cytokines (the so-called &quot;cytokine storm&quot;) drives morbidity and mortality in the most ","2021","06","04","J Clin Med","Journal of clinical medicine","COVID-19; anti-inflammatory drugs; cytokine storm; immunomodulation","Lariccia","Vincenzo","Department of Biomedical Sciences and Public Health, School of Medicine, University &quot",NA
"158","33320635","10.1021/acsbiomaterials.0c01226","Bioengineered <i>in Vitro</i> Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation.","Given the various viral outbreaks in the 21st century, specifically the present pandemic situation arising from SARS-CoV-2 or the coronavirus, of unknown magnitude, there is an unmet clinical need to develop effective therapeutic and diagnostic strategies to combat this infectious disease worldwide. To develop precise anticoronavirus drugs and prophylactics, tissue engineering and biomaterial research strategies can serve as a suitable alternative to the conventional treatment options. Therefore","2020","12","29","ACS Biomater Sci Eng","ACS biomaterials science &amp; engineering","3D bioprinting; SARS-CoV-2; in vitro model; organoids; tissue engineering; vaccine trial; Adaptive Immunity; Animals; Antiviral Agents; COVID-19; COVID-19 Vaccines; Drug Delivery Systems; Drug Liberation; Humans; Models, Animal; Pandemics; Printing, Three-Dimensional; SARS-CoV-2; Tissue Engineering; Tissue Scaffolds","Chakraborty","Juhi","Department of Textile and Fibre Engineering, Indian Institute of Technology Delhi, New Delhi-110016, India",NA
"159","33320222","10.1001/jama.2020.24075","Experts Discuss COVID-19: Vaccine Allocation, Placebo Groups, and More.",NA,"2020","12","21","JAMA","JAMA","COVID-19; COVID-19 Vaccines; Centers for Disease Control and Prevention, U.S.; Clinical Trials as Topic; Contact Tracing; Humans; Mass Vaccination; Pandemics; Politics; SARS-CoV-2; United States; Vaccination Coverage",NA,NA,NA,NA
"160","33320183","10.1093/ageing/afaa274","Efficacy and safety of COVID-19 vaccines in older people.","Several vaccines against coronavirus disease 2019 (COVID-19) are on the cusp of regulatory approval. Their safety and efficacy in older people is critical to their success. Even though care home residents and older people are likely to be amongst the first to be vaccinated, these patient groups are usually excluded from clinical trials. Data from several Phase II trials have given cause for optimism, with strong antibody responses and reassuring safety profiles but, with the exception of AstraZe","2021","03","17","Age Ageing","Age and ageing","SARS-CoV-2; coronavirus; geriatrics; older people; vaccine; Aged; COVID-19; COVID-19 Vaccines; Frail Elderly; Geriatrics; Humans; Immunization Programs; Patient Safety; Patient Selection; SARS-CoV-2; Treatment Outcome","Soiza","Roy L","NHS Grampian, Aberdeen Royal Infirmary, Aberdeen, UK",NA
"161","33317389","10.1080/17441692.2020.1860249","COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs.","The 2030 Agenda for Sustainable Development (AfSD) has the vision to leave no one behind, particularly low-income countries. Yet COVID-19 seems to have brought up new rules and approaches. Through document and critical discourse analysis, it emerges that there has been a surge in COVID-19 vaccines and treatments nationalism. Global solidarity is threatened, with the USA, United Kingdom, European Union and Japan having secured 1.3 billion doses of potential vaccines as of August 2020. Vaccines ra","2021","03","04","Glob Public Health","Global public health","COVAX; COVID-19; SDGs; low-income; nationalism; vaccines; COVID-19; COVID-19 Vaccines; Developing Countries; Global Health; Humans; Pandemics; SARS-CoV-2; Sustainable Development","Nhamo","Godwell","Exxaro Chair in Business and Climate Change, Institute for Corporate Citizenship, Unisa, South Africa",NA
"162","33316990","10.3390/vaccines8040746","Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials.","Vaccines against Coronavirus Disease 2019 Originated-19) have been developed with unprecedented rapidity, many utilizing novel strategies. As of November 2020, a series of publications have outlined the results of phase 1/2 studies of nine different vaccines planned to move forward to phase 3 trials. The results are encouraging, demonstrating a paucity of severe or serious adverse events and robust induction of antibody titers. Determination of the vaccine candidates with the highest protective ","2020","12","29","Vaccines (Basel)","Vaccines","COVID-19; SARS-COV-2; clinical trials; vaccines","Giurgea","Luca Tudor","Laboratory of Infectious Diseases, LID Clinical Studies Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA",NA
"163","33316227","10.1016/j.cbi.2020.109339","Thermovaccination - thermoheliox as a stimulator of the immune response. Kinetics of the synthesis of antibodies and C-reactive protein in coronavirus infection.","Clinical trials of thermoheliox application (inhalation with a high-temperature mixture of oxygen and helium, 90....C) in the treatment of the acute phase of coronavirus infection were conducted. Dynamics of disease development in infected patients (PCR test for the virus) and, dynamics of changes in blood concentration of C-reactive protein, immunoglobulin M, specific immunoglobulin G were studied. High efficiency of thermoheliox in releasing the organism from the virus and stimulating the immu","2021","01","21","Chem Biol Interact","Chemico-biological interactions","C-reactive protein; Coronavirus; Immunoglobulin G; Kinetic model; PCR-Test; Thermoheliox; Administration, Inhalation; Adult; Aged; Antibodies, Viral; C-Reactive Protein; COVID-19; Helium; Hot Temperature; Humans; Hyperthermia, Induced; Immunoglobulin G; Immunoglobulin M; Kinetics; Middle Aged; Models, Immunological; Oxygen; SARS-CoV-2; Vaccination","Varfolomeev","Sergey D","Institute of Physicochemical Foundations of the Functioning of Neural Network and Artificial Intelligence, Moscow State University, Leninskie Gory, 1-11B, Moscow, 119991, Russia",NA
"164","33315080","10.1001/jama.2020.25053","The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials.",NA,"2021","01","27","JAMA","JAMA","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Health Equity; Humans; Patient Selection; Placebos; SARS-CoV-2; Vaccination","Rid","Annette","Department of Bioethics, The Clinical Center, National Institutes of Health, Bethesda, Maryland",NA
"165","33315069","10.1001/jama.2020.25127","Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines.",NA,"2021","01","27","JAMA","JAMA","COVID-19; COVID-19 Vaccines; Drug Approval; Humans; Incidence; Investigational New Drug Application; Placebos; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome","Joffe","Steven","Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia",NA
"166","33312453","10.1016/j.csbj.2020.11.056","Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses.","The novel coronavirus SARS-CoV-2 is damaging the world's social and economic fabrics seriously. Effective drugs are urgently needed to decrease the high mortality rate of COVID-19 patients. Unfortunately, effective antiviral drugs or vaccines are currently unavailable. Herein, we systematically evaluated the effect of SARS-CoV-2 on gene expression of both lung tissue and blood from COVID-19 patients using transcriptome profiling. Differential gene expression analysis revealed potential core mech","2021","01","10","Comput Struct Biotechnol J","Computational and structural biotechnology journal",NA,"Li","Guobing","Center of Basic Medical Research, Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing 100191, China",NA
"167","33311629","10.1038/d41586-020-03542-4","US authorization of first COVID vaccine marks new phase in safety monitoring.",NA,"2020","12","18","Nature","Nature","Infection; Medical research; SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; Humans; RNA, Messenger; SARS-CoV-2; Viral Vaccines","Ledford","Heidi",NA,NA
"168","33311602","10.1038/d41586-020-03542-4","US authorization of first COVID vaccine marks new phase in safety monitoring.",NA,"2021","04","12","Nature","Nature","Infection; Medical research; SARS-CoV-2; Vaccines","Ledford","Heidi",NA,NA
"169","33308661","10.1016/j.ijtb.2020.06.004","Hydroxychloroquine and COVID-19 - A narrative review.","COVID 19 infection is unarguably the worst pandemic of this century. Till date there is no promising drug and vaccine available to treat this deadly viral infection. In the early phase chloroquine phosphate and hydroxychloroquine sulphate have been used to fight this illness on the basis of handful observational and small randomized and small-randomized studies. The paucity of clinical evidences of an unequivocal beneficial effect of chloroquine and hydroxychloroquine on COVID-19 has resulted in","2020","12","24","Indian J Tuberc","The Indian journal of tuberculosis","COVID-19; Hydroxychloroquine; Immunomodulator; Pandemic; QT prolongation; COVID-19; Enzyme Inhibitors; Humans; Hydroxychloroquine; SARS-CoV-2","Bajpai","Jyoti","Department of Respiratory Medicine, King George's Medical University, Lucknow, 226003, India",NA
"170","33308153","10.1186/s12859-020-03872-0","In silico trial to test COVID-19 candidate vaccines: a case study with UISS platform.","SARS-CoV-2 is a severe respiratory infection that infects humans. Its outburst entitled it as a pandemic emergence. To get a grip on this outbreak, specific preventive and therapeutic interventions are urgently needed. It must be said that, until now, there are no existing vaccines for coronaviruses. To promptly and rapidly respond to pandemic events, the application of in silico trials can be used for designing and testing medicines against SARS-CoV-2 and speed-up the vaccine discovery pipeline","2020","12","18","BMC Bioinformatics","BMC bioinformatics","Agent-based model; Human monoclonal antibodies; In silico trials; SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; Computational Biology; Computer Simulation; Humans; Models, Immunological; SARS-CoV-2; Software","Russo","Giulia","Department of Drug Sciences, University of Catania, 95125, Catania, Italy",NA
"171","33306989","10.1016/S0140-6736(20)32661-1","Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.","A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1)","2021","02","01","Lancet","Lancet (London, England)","Adolescent; Adult; Aged; Brazil; COVID-19; COVID-19 Vaccines; Double-Blind Method; Female; Humans; Male; Middle Aged; Single-Blind Method; South Africa; Treatment Outcome; United Kingdom; Young Adult","Voysey","Merryn","Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK",NA
"172","33306985","10.1016/j.chom.2020.11.012","D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization.","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired a D614G mutation early in the pandemic that confers greater infectivity and is now the globally dominant form. To determine whether D614G might also mediate neutralization escape that could compromise vaccine efficacy, sera from spike-immunized mice, nonhuman primates, and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 spike. In all cases, the G614 pseudovirus was modera","2021","01","20","Cell Host Microbe","Cell host &amp; microbe","COVID-19; D614G; LNP; SARS-CoV-2; Spike; electron micrograph; mRNA; neutralization; nucleoside-modified; vaccine; Adolescent; Adult; Animals; Antibodies, Monoclonal; Binding Sites; COVID-19; COVID-19 Vaccines; Female; HEK293 Cells; Humans; Immunization, Passive; Macaca mulatta; Male; Mice, Inbred BALB C; Middle Aged; Mutation; Neutralization Tests; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Young Adult","Weissman","Drew","Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. Electronic address: dreww@pennmedicine.upenn","dreww@pennmedicine.upenn.edu"
"173","33306980","10.1016/S1473-3099(20)30923-3","The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials.","An efficacious COVID-19 vaccine is currently the world's leading research priority. Several nations have indicated that if there is a compelling case for use of a vaccine before it is licensed, they would be prepared to authorise its emergency use or conditional approval on public health grounds. As of Dec 1, 2020, several developers of leading COVID-19 candidate vaccines have indicated that they have applied, or intend to apply, for emergency authorisation for their vaccines. Should candidate v","2021","04","27","Lancet Infect Dis","The Lancet. Infectious diseases","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Approval; Emergencies; Humans; Pandemics; Public Health; Randomized Controlled Trials as Topic; SARS-CoV-2","Singh","Jerome Amir","Howard College School of Law, University of Kwazulu-Natal, Durban, South Africa","singhj9@ukzn.ac.za"
"174","33305994","10.1089/omi.2020.0208","Rethinking Clinical Trials and Personalized Medicine with Placebogenomics and Placebo Dose.","Pharmacogenomics, nutrigenomics, vaccinomics, and the nascent field of plant omics are examples of variability science. They are embedded within an overarching framework of personalized medicine. Across these public health specialties, the significance and biology of the placebo response have been historically neglected. A placebo is any substance such as a sugar pill administered in the guise of medication, but one that does not have pharmacological activity. Placebos do have clinical effects, ","2021","01","12","OMICS","Omics : a journal of integrative biology","augmented placebo; nocebogenomics; placebo dose; placebo variability; placebogenomics; psychopharmacology; variability science; Clinical Trials as Topic; Dose-Response Relationship, Drug; Genomics; Humans; Nocebo Effect; Outcome Assessment, Health Care; Placebo Effect; Precision Medicine; Research Design","..zdemir","Vural","OMICS: A Journal of Integrative Biology, New Rochelle, New York, USA",NA
"175","33305156","10.1002/hep4.1588","How to Survive COVID-19 Even If the Vaccine Fails.","Coronavirus disease 2019 (COVID-19) has created an emergency of epic proportions. While a vaccine may be forthcoming, this is not guaranteed, as discussed herein. The potential problems and ominous signs include (1) lung injury that developed in animals given an experimental vaccine for the severe acute respiratory syndrome coronavirus (SARS-CoV)-1; (2) a perversion of adaptive immune responses called antibody-dependent enhancement of infection that occurs in SARS-CoV-1 and that may occur in peo","2020","12","12","Hepatol Commun","Hepatology communications",NA,"Branch","Andrea D","Division of Liver Diseases Department of Medicine Icahn School of Medicine at Mount Sinai New York NY",NA
"176","33304884","10.3389/fchem.2020.594009","Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease.","In the absence of an approved vaccine, developing effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals is essential to tackle the current pandemic health crisis due to the coronavirus disease 2019 (COVID-19) spread. As any traditional drug discovery program is a time-consuming and costly process requiring more than one decade to be completed, in silico repurposing of existing drugs is the preferred way for rapidly selecting promising clinical candidates. We pr","2020","12","12","Front Chem","Frontiers in chemistry","SARS...CoV...2; drug repurposing; molecular docking; molecular interaction fingerprints; papain-like cysteine protease","Delre","Pietro","Department of Chemistry, University of Bari &quot",NA
"177","33303601","10.1126/science.370.6522.1263","China's vaccine gambit.",NA,"2021","02","02","Science","Science (New York, N.Y.)","Brazil; COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Drug Development; Humans","Cohen","Jon",NA,NA
"178","33302034","10.1016/j.intimp.2020.107220","COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus.","Since the very beginning of the COVID-19 pandemic, different treatment strategies have been explored. These mainly involve the development of antimicrobial, antiviral, and/or anti-inflammatory agents as well as vaccine production. However, other potential options should be more avidly investigated since vaccine production on a worldwide level, and the anti-vaccination movement, also known as anti-vax or vaccine hesitancy by many communities, are still real obstacles without a ready solution. Thi","2021","01","22","Int Immunopharmacol","International immunopharmacology","Animal antibodies; COVID-19; Coronavirus; Hyperimmune sera; Neutralizing titers; SARS-COV-2; Animals; COVID-19; Humans; Immunization, Passive; SARS-CoV-2","da Costa","Camila B P","Instituto Vital Brazil, Niter..i, RJ 24230-410, Brazil",NA
"179","33301434","10.15585/mmwr.mm6949e2","Summary of Guidance for Public Health Strategies to Address High Levels of Community Transmission of SARS-CoV-2 and Related Deaths, December 2020.","In the 10 months since the first confirmed case of coronavirus disease 2019 (COVID-19) was reported in the United States on January 20, 2020 (1), approximately 13.8 million cases and 272,525 deaths have been reported in the United States. On October 30, the number of new cases reported in the United States in a single day exceeded 100,000 for the first time, and by December 2 had reached a daily high of 196,227.* With colder weather, more time spent indoors, the ongoing U.S. holiday season, and ","2020","12","11","MMWR Morb Mortal Wkly Rep","MMWR. Morbidity and mortality weekly report","COVID-19; Community-Acquired Infections; Guidelines as Topic; Humans; Public Health Practice; United States","Honein","Margaret A","CDC COVID-19 Emergency Response",NA
"180","33301429","10.15585/mmwr.mm6949e1","The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.","The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic that has disrupted all sectors of society. Less than 1 year after the SARS-CoV-2 genome was first sequenced, an application* for Emergency Use Authorization for a candidate vaccine has been filed with the Food and Drug Administration (FDA). However, even if one or more vaccine candidates receive authorization for emergency use, demand for COVID-19 vaccine is expected to exceed sup","2020","12","11","MMWR Morb Mortal Wkly Rep","MMWR. Morbidity and mortality weekly report","Advisory Committees; Aged; COVID-19 Vaccines; Centers for Disease Control and Prevention, U.S.; Health Care Rationing; Health Personnel; Humans; Immunization Programs; Practice Guidelines as Topic; Residential Facilities; United States","Dooling","Kathleen",NA,NA
"181","33301246","10.1056/NEJMoa2034577","Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 ..g pe","2021","01","12","N Engl J Med","The New England journal of medicine","Adolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Fatigue; Female; Headache; Humans; Immunization, Secondary; Male; Middle Aged; SARS-CoV-2; Single-Blind Method; Treatment Outcome; Vaccines, Synthetic; Young Adult","Polack","Fernando P","From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires",NA
"182","33300456","10.1080/07391102.2020.1855250","Emerging role of artificial intelligence in therapeutics for COVID-19: a systematic review.","To elucidate the role of artificial intelligence (AI) in therapeutics for coronavirus disease 2019 (COVID-19). Five databases were searched (December 2019-May 2020). We included both published and pre-print original articles in English that applied AI, machine learning or deep learning in drug repurposing, novel drug discovery, vaccine and antibody development for COVID-19. Out of 31 studies included, 16 studies applied AI for drug repurposing, whereas 10 studies utilized AI for novel drug disco","2021","05","28","J Biomol Struct Dyn","Journal of biomolecular structure &amp; dynamics","Artificial intelligence; COVID-19; drug repurposing; novel drug discovery; vaccine development","Kaushal","Karanvir","Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, India",NA
"183","33298501","10.1136/bcr-2020-238531","Paediatric inflammatory multisystem syndrome temporally associated with COVID-19: a new virus and a new case presentation.","An 11-year-old boy presented with features resembling those described in health alerts on Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS), including persistent fever, haemodynamic instability and abdominal pain. Laboratory tests, including raised inflammatory markers, D-dimer, troponin and a coagulopathy, were consistent with PIMS-TS. Our patient required transfer to the paediatric intensive care unit; an echocardiography revealed left ventricular dys","2020","12","16","BMJ Case Rep","BMJ case reports","cardiovascular medicine; immunological products and vaccines; infectious diseases; paediatric intensive care; paediatrics; Adrenal Cortex Hormones; Aspirin; COVID-19; Child; Humans; Immunoglobulins, Intravenous; Intensive Care Units, Pediatric; Male; SARS-CoV-2; Symptom Assessment; Systemic Inflammatory Response Syndrome; Treatment Outcome","Makiello","Phoebe","Department of Paediatrics, Dumfries and Galloway Royal Infirmary, Dumfries, UK phoebemakiello@icloud","phoebemakiello@icloud.com"
"184","33298149","10.1186/s13063-020-04878-y","A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.","The peak of the global COVID-19 pandemic has not yet been reached, and many countries face the prospect of a second wave of infections before effective vaccinations will be available. After an initial phase of viral replication, some patients develop a second illness phase in which the host thrombotic and inflammatory responses seem to drive complications. Severe COVID-19 disease is linked to high mortality, hyperinflammation, and a remarkably high incidence of thrombotic events. We hypothesize ","2020","12","21","Trials","Trials","Anakinra; Aprotinin; COVID-19; Inflammation; Low molecular weight heparins; SARS-CoV-2; Thromboinflammatory response; Thrombosis; Antirheumatic Agents; Aprotinin; Belgium; Bradykinin; COVID-19; Critical Care; Drug Therapy, Combination; Female; Heparin, Low-Molecular-Weight; Humans; Incidence; Inflammation; Interleukin 1 Receptor Antagonist Protein; Kallikreins; Male; Outcome Assessment, Health Care; SARS-CoV-2; Severity of Illness Index; Venous Thromboembolism","Vanassche","T","Center for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium. thomas.vanassche@uzleuven","thomas.vanassche@uzleuven.be"
"185","33296420","10.1371/journal.pone.0243526","Predictors of misconceptions, knowledge, attitudes, and practices of COVID-19 pandemic among a sample of Saudi population.","This study intends to explore the predictors of misconceptions, knowledge, attitudes, and practices concerning the COVID-19 pandemic among a sample of the Saudi population and we also assessed their approaches toward its overall impact. This online cross-sectional survey was conducted at the Faculty of Medicine, Rabigh, King Abdulaziz University (KAU) in Jeddah, Saudi Arabia (SA). Participants were approached via social media (SM), and 2006 participants (953 [47.5%] females and 1053 [52.5%] male","2020","12","21","PLoS One","PloS one","Adolescent; Adult; Aged; COVID-19; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Middle Aged; Pandemics; SARS-CoV-2; Saudi Arabia; Self Report; Surveys and Questionnaires","Baig","Mukhtiar","Department of Clinical Biochemistry, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah, Saudi Arabia",NA
"186","33296403","10.1371/journal.pone.0243410","Knowledge of prevention of COVID-19 among the general people in Bangladesh: A cross-sectional study in Rajshahi district.","Until now, no vaccine or effective drug is available for the control, prevention, and treatment of COVID-19. Preventive measures are the only ways to be protected from the disease and knowledge of the people about the preventive measures is a vital matter. The aim of the study was to assess the knowledge of the general people in Rajshahi district, Bangladesh regarding the COVID-19 preventive measures. This cross sectional study was conducted from March 10 to April 25, 2020. Data were collected w","2020","12","21","PLoS One","PloS one","Bangladesh; COVID-19; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Humans; Male; SARS-CoV-2; Surveys and Questionnaires; Young Adult","Rana","Md Masud","Department of Statistics, University of Rajshahi, Rajshahi, Bangladesh",NA
"187","33295312","","SOBERANA, Cuba's COVID-19 Vaccine Candidates: Dagmar Garc..a-Rivera PhD.","On August 13, 2020, Cuba's national regulatory agency, the Center for Quality Control of Medicines, Equipment and Medical Devices (CECMED), authorized clinical trials for SOBERANA 01-Cuba's fi rst vaccine candidate and the fi rst from Latin America and the Caribbean. On August 24, parallel Phase I/II double blind, randomized, controlled clinical trials were launched at clinical sites in Havana to evaluate the vaccine's safety and immunogenicity. Analysis of results and development of different f","2020","12","25","MEDICC Rev","MEDICC review","COVID-19; COVID-19 Vaccines; Cuba; Double-Blind Method; Humans; Pandemics; Randomized Controlled Trials as Topic; SARS-CoV-2","Gorry","Conner",NA,NA
"188","33294881","10.1016/j.medj.2020.11.005","The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19.","Coronavirus disease 2019 (COVID-19) currently has few effective treatments. Given the uncertainty surrounding the effectiveness and uptake of a vaccine, it is important that the search for treatments continue. An exaggerated inflammatory state is likely responsible for much of the morbidity and mortality in COVID-19. Elevated levels of tumor necrosis factor (TNF), a key pro-inflammatory cytokine, have been shown to be associated with increased COVID-19 mortality. In patients with rheumatoid arth","2021","01","10","Med (N Y)","Med (New York, N.Y.)","SARS-CoV-2; coronavirus disease-2019; glucocorticoids; pandemic; tumor necrosis factor","Robinson","Philip C","University of Queensland Faculty of Medicine, Herston, Queensland, Australia",NA
"189","33294745","10.1016/j.idm.2020.11.003","Widespread testing, case isolation and contact tracing may allow safe school reopening with continued moderate physical distancing: A modeling analysis of King County, WA data.","In late March 2020, a &quot;Stay Home, Stay Healthy&quot; order was issued in Washington State in response to the COVID-19 pandemic. On May 1, a 4-phase reopening plan began. We investigated whether adjunctive prevention strategies would allow less restrictive physical distancing to avoid second epidemic waves and secure safe school reopening. We developed a mathematical model, stratifying the population by age, infection status and treatment status to project SARS-CoV-2 transmission during and ","2020","12","10","Infect Dis Model","Infectious Disease Modelling","Age structured model; Contact tracing; Epidemiology; Mathematical modeling; Physical distancing","Bracis","Chloe","Universit.. Grenoble Alpes, TIMC-IMAG/BCM, 38000, Grenoble, France",NA
"190","33293238","10.1016/j.cytogfr.2020.11.001","SARS-CoV-2: Targeted managements and vaccine development.","Infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) results in diverse outcomes. The symptoms appear to be more severe in males older than 65 and people with underlying health conditions; approximately one in five individuals could be at risk worldwide. The virus's sequence was rapidly established days after the first cases were reported and identified an RNA virus from the Coronaviridae family closely related to a Betacoronavirus virus found in bats in China. SARS-Co","2021","04","20","Cytokine Growth Factor Rev","Cytokine &amp; growth factor reviews","ACE2; COVID-19; Chemokines; Cytokines; Immunity; Spike protein; Vaccines; Angiotensin-Converting Enzyme 2; Antiviral Agents; COVID-19; COVID-19 Vaccines; Drug Development; Genome, Viral; Humans; Molecular Targeted Therapy; SARS-CoV-2; Viral Vaccines","Bakhiet","Moiz","Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, Bahrain. Electronic address: moiz@agu.edu","moiz@agu.edu.bh"
"191","33292930","10.1016/j.jnma.2020.10.003","Ensuring Safety of Operation Warp Speed Vaccines for COVID-19.",NA,"2020","12","28","J Natl Med Assoc","Journal of the National Medical Association","Advisory Committees; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Patient Selection; Safety Management; United States; United States Food and Drug Administration","McDougle","Leon","Chief Diversity Officer, Professor of Family Medicine with Tenure, The Ohio State University Wexner Medical Center, Associate Dean for Diversity and Inclusion, The Ohio State University College of Medicine, USA",NA
"192","33290571","10.3928/19382359-20201116-01","COVID-19 Vaccines: A Primer for Clinicians.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the identified cause of coronavirus disease 2019 (COVID-19), continues unabated. This fact, coupled with recurrence of COVID-19 in areas where it had been controlled, highlights the critical need for a safe and effective vaccine to prevent and mitigate this novel virus. The spike protein of SARS-CoV-2 is important in its lifecycle as well as in the development of immunity after human infection. This has prompted the selection of this ","2020","12","21","Pediatr Ann","Pediatric annals","Antibodies, Viral; Antibody-Dependent Enhancement; COVID-19 Vaccines; Drug Development; Humans; Public-Private Sector Partnerships; RNA; Recombinant Proteins; Respiratory Tract Diseases; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Virus Replication","Romero","Jos.. R",NA,NA
"193","33290568","10.3928/19382359-20201116-02","Vaccine Development: From Laboratory to Policy.","Vaccines are one of the greatest public health achievements, protecting children and adults against numerous infectious diseases; however, the complex, rigorous process of vaccine development is unknown to many. A candidate vaccine undergoes extensive evaluation of safety and efficacy to meet licensure requirements before recommendations for use become policy. This time-consuming process involves an intricate collaboration among academia, public and private organizations, and federal agencies to","2020","12","21","Pediatr Ann","Pediatric annals","Clinical Trials as Topic; Drug Approval; Humans; Licensure; Product Surveillance, Postmarketing; Safety Management; United States; United States Food and Drug Administration; Vaccines","Park","Hee Su",NA,NA
"194","33290205","10.2174/1871530320666201207234914","Why Do We Still Lack a COVID-19 Vaccine? Searching for the Missing Pieces.",NA,"2021","06","01","Endocr Metab Immune Disord Drug Targets","Endocrine, metabolic &amp; immune disorders drug targets","Covid 19; SARS-CoV-2; coronavirus; pandemic; treatment; trials; vaccine; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase II as Topic; Drug Industry; Humans; SARS-CoV-2","Perosa","Federico","Department of Biomedical Science and Human Oncology (DIMO), University of Bari Medical School, Bari, Italy",NA
"195","33289156","10.1111/bcp.14686","Racing to immunity: Journey to a COVID-19 vaccine and lessons for the future.","SARS-CoV-2 is the novel coronavirus behind the COVID-19 pandemic. Since its emergence, the global scientific community has mobilized to study this virus, and an overwhelming effort to identify COVID-19 treatments is currently ongoing for a variety of therapeutics and prophylactics. To better understand these efforts, we compiled a list of all COVID-19 vaccines undergoing preclinical and clinical testing using the WHO and ClinicalTrials.gov database, with details surrounding trial design and loca","2021","01","10","Br J Clin Pharmacol","British journal of clinical pharmacology","COVID-19; COVID-19 drug treatment; SARS virus; antiviral agents; coronavirus; coronavirus infections; immunosuppressive agents; pandemics; severe acute respiratory syndrome coronavirus 2; vaccines","Calvo Fern..ndez","Ester","Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA",NA
"196","33288887","10.1038/d41586-020-03441-8","The UK has approved a COVID vaccine - here's what scientists now want to know.",NA,"2020","12","11","Nature","Nature","SARS-CoV-2; Vaccines; Adolescent; Age Factors; Aged; Aged, 80 and over; Aging; Biomedical Research; COVID-19; COVID-19 Vaccines; Child, Preschool; Clinical Trials as Topic; Drug Approval; Drug Industry; Drug Monitoring; Female; Humans; Immune Evasion; Pharmacovigilance; Pregnancy; SARS-CoV-2; Self Report; Time Factors; Uncertainty; United Kingdom; Virus Shedding","Ledford","Heidi",NA,NA
"197","33288498","10.1136/bmj.m4713","Seasonal influenza programme expansion.",NA,"2020","12","15","BMJ","BMJ (Clinical research ed.)","COVID-19; COVID-19 Vaccines; Humans; Immunization Programs; Influenza Vaccines; Influenza, Human; United Kingdom; Vaccination Coverage","Jayasooriya","S","Academic Unit of Primary Care, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK",NA
"198","33284328","10.1001/jamainternmed.2020.7087","A Nursing Researcher's Experience in a COVID-19 Vaccine Trial.",NA,"2021","02","05","JAMA Intern Med","JAMA internal medicine","COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; Internet; Nurses; Research Subjects; United States","Choi","Kristen R","School of Nursing, University of California, Los Angeles",NA
"199","33282604","10.7759/cureus.11845","A Prospective Study on Rapidly Declining SARS-CoV-2 IgG Antibodies Within One to Three Months of Testing IgG Positive: Can It Lead to Potential Reinfections?","Background COVID-19 immunoglobulin G (IgG) antibodies have been considered to provide protective immunity and its immunoassays have been widely used for serosurveillance. In our serosurveillance on an industrial workforce of randomly selected 3296 subjects, COVID-19 IgG antibody positivity was reported in 7.37% (243) subjects. However, when 30 days later, eight of the 243 COVID-19 IgG antibody-positive individuals complained of symptoms suggestive of COVID-19 infection and were confirmed as COVI","2020","12","08","Cureus","Cureus","antibody response; covid-19; immunoglobulin g","Nag","Deb Sanjay","Anaesthesiology, Tata Main Hospital, Jamshedpur, IND",NA
"200","33281434","10.1063/5.0029767","The perspective of fluid flow behavior of respiratory droplets and aerosols through the facemasks in context of SARS-CoV-2.","In the unfortunate event of the current ongoing pandemic COVID-19, where vaccination development is still in the trial phase, several preventive control measures such as social distancing, hand-hygiene, and personal protective equipment have been recommended by health professionals and organizations. Among them, the safe wearing of facemasks has played a vital role in reducing the likelihood and severity of infectious respiratory disease transmission. The reported research in facemasks has cover","2020","12","08","Phys Fluids (1994)","Physics of fluids (Woodbury, N.Y. : 1994)",NA,"Kumar","Sanjay","Department of Mechanical Engineering, National University of Singapore, 9 Engineering Drive 1, Singapore 117575, Singapore",NA
"201","33279318","10.1016/j.vaccine.2020.11.054","New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.","The threat of the current coronavirus disease pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is accelerating the development of potential vaccines. Candidate vaccines have been generated using existing technologies that have been applied for developing vaccines against other infectious diseases. Two new types of platforms, mRNA- and viral vector-based vaccines, have been gaining attention owing to the rapid advancement in their methodologies. In clinical trials","2021","01","14","Vaccine","Vaccine","SARS-CoV-2; Vaccine; Vector; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Genetic Vectors; Humans; Immunity, Innate; Immunization Schedule; Immunogenicity, Vaccine; Pandemics; Patient Safety; SARS-CoV-2; Severe Acute Respiratory Syndrome; Vaccines, Attenuated; Vaccines, DNA; Vaccines, Subunit; Vaccines, Virus-Like Particle","Ura","Takehiro","Department of Ophthalmology and Visual Science, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan",NA
"202","33279317","10.1016/j.vaccine.2020.11.056","Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial.","Passive surveillance is recommended globally for the detection of adverse events following immunisation (AEFI) but this has significant challenges. Use of Mobile health for vaccine safety surveillance enables a consumer-centred approach to reporting. The Stimulated Telephone Assisted Rapid Safety Surveillance (STARSS) a randomised control trial (RCT) sought to evaluate the efficacy and acceptability of SMS for AEFI surveillance. Multi-centre RCT, participants were adult vaccinees or parents of c","2021","04","27","Vaccine","Vaccine","Adverse events following immunisation; Pharmacovigilance; Vaccine safety surveillance; m-Health; Adult; Adverse Drug Reaction Reporting Systems; COVID-19; Child; Humans; Immunization; Infant; Population Surveillance; SARS-CoV-2; Telemedicine; Telephone","Gold","M S","Discipline of Paediatrics, School of Medicine, University of Adelaide, Australia. Electronic address: michael.gold@adelaide.edu","michael.gold@adelaide.edu.au"
"203","33278108","10.1097/MOP.0000000000000978","COVID-19 vaccine development: a pediatric perspective.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel coronavirus that causes coronavirus disease 2019 (COVID-19), has caused substantial morbidity and mortality. Operation Warp Speed aims to accelerate the development of a safe and effective vaccine by early 2021. Multiple vaccine candidates with reassuring safety and efficacy profiles have advanced to phase 3 clinical trials in adults. The purpose of this review is to describe the burden of COVID-19 in children, to update ped","2021","01","07","Curr Opin Pediatr","Current opinion in pediatrics","COVID-19; COVID-19 Vaccines; Child; Humans; SARS-CoV-2; Vaccination","Kamidani","Satoshi","Department of Pediatrics, Emory University School of Medicine",NA
"204","33274726","10.2196/22996","An Artificial Intelligence-Based, Personalized Smartphone App to Improve Childhood Immunization Coverage and Timelines Among Children in Pakistan: Protocol for a Randomized Controlled Trial.","The immunization uptake rates in Pakistan are much lower than desired. Major reasons include lack of awareness, parental forgetfulness regarding schedules, and misinformation regarding vaccines. In light of the COVID-19 pandemic and distancing measures, routine childhood immunization (RCI) coverage has been adversely affected, as caregivers avoid tertiary care hospitals or primary health centers. Innovative and cost-effective measures must be taken to understand and deal with the issue of low im","2020","12","31","JMIR Res Protoc","JMIR research protocols","AI; EPI; LMICs; Pakistan; artificial intelligence; mHealth; personalized messages; routine childhood immunization; routine immunization; smartphone apps; vaccine-preventable illnesses","Kazi","Abdul Momin","Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan",NA
"205","33274473","10.1002/jcph.1794","Science and Evidence-Based Review and Approval of COVID-19 Vaccines: A Statement of Support for the US FDA.",NA,"2021","02","09","J Clin Pharmacol","Journal of clinical pharmacology","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Approval; Evidence-Based Medicine; Humans; United States","Pai","Sudhakar M",NA,NA
"206","33274149","10.7759/cureus.11274","Assessment of Preventive Practices Followed by General Public During COVID-19 Pandemic - A Cross-Sectional Survey From India.","Objectives COVID-19 has infected millions of people across the globe, leading to hundreds of thousands of deaths. Currently, there are no vaccines available for COVID-19, and the most effective way to curb its spread is to follow preventive practices. The present study aimed to assess the extent of adoption of preventive practices among the general population in India. Methods A web-based cross-sectional survey was carried out recruiting 964 participants from all over India through purposive sam","2020","12","07","Cureus","Cureus","covid 19; cross-sectional survey; general population; india; preventive practices","Chakrawarty","Avinash","Geriatric Medicine, All India Institute of Medical Sciences, New Delhi, IND",NA
"207","33273742","10.1038/s41564-020-00835-2","Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.","The coronavirus disease 2019 (COVID-19) pandemic is having a catastrophic impact on human health<sup>1</sup>. Widespread community transmission has triggered stringent distancing measures with severe socio-economic consequences. Gaining control of the pandemic will depend on the interruption of transmission chains until vaccine-induced or naturally acquired protective herd immunity arises. However, approved antiviral treatments such as remdesivir and reconvalescent serum cannot be delivered oral","2021","01","13","Nat Microbiol","Nature microbiology","Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; COVID-19; Chlorocebus aethiops; Cytidine; Cytokines; Disease Models, Animal; Disease Transmission, Infectious; Female; Ferrets; Hydroxylamines; Random Allocation; SARS-CoV-2; Vero Cells","Cox","Robert M","Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA",NA
"208","33273083","10.1126/science.370.6521.1151","Amid the cheering, some vaccines face questions.",NA,"2021","01","11","Science","Science (New York, N.Y.)","Adenoviridae; COVID-19 Vaccines; Clinical Trials as Topic; Gene Transfer Techniques; Humans; RNA, Messenger; Spike Glycoprotein, Coronavirus","Cohen","Jon",NA,NA
"209","33273082","10.1126/science.370.6521.1150","New challenges emerge for planned human challenge trials.",NA,"2021","01","11","Science","Science (New York, N.Y.)","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Healthy Volunteers; Humans; Risk; Risk Assessment; Therapeutic Human Experimentation; Vaccination","Cornwall","Warren",NA,NA
"210","33273060","10.1126/science.abf5084","COVID-19 vaccine trial ethics once we have efficacious vaccines.",NA,"2020","12","28","Science","Science (New York, N.Y.)","COVID-19 Vaccines; Controlled Clinical Trials as Topic; Drug Approval; Healthy Volunteers; Humans; Placebos; Risk Assessment; United States; United States Food and Drug Administration","Wendler","David","Department of Bioethics, National Institutes of Health (NIH) Clinical Center, Bethesda, MD, USA. dwendler@nih","dwendler@nih.gov"
"211","33270497","10.1080/21645515.2020.1842683","COVID-19 in the elderly people and advances in vaccination approaches.","The rapid worldwide spread of the COVID-19 pandemic, caused by the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in tens of millions of infections and over one million deaths. SARS-CoV-2 infection affects all age groups; however, those over 60 years old are affected more severely. Moreover, pre-existing co-morbidities result in higher COVID-19-associated mortality in the geriatric population. This article highlights the associated risk factors of SARS-C","2021","01","15","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","SARS-CoV-2; covid-19; elderly people; vaccine; Aged; Aged, 80 and over; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Vaccination","Dhama","Kuldeep","Division of Pathology, ICAR-Indian Veterinary Research Institute , Bareilly, Uttar Pradesh, India",NA
"212","33270478","10.1080/21645515.2020.1845524","Development of SARS-CoV-2 vaccines: challenges, risks, and the way forward.","The COVID-19 pandemic mandates the development of a safe and effective Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) vaccine. This review analyzes the complexities, challenges, and other vital issues associated with the development of the SARS-CoV-2 vaccine. A brief review of the immune responses (innate, antibody, and T-cell) to SARS-CoV-2, including immune targets, correlates of protection, and duration of immunity is presented. Approaches to vaccine development including differ","2021","05","13","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","SARS-CoV-2 vaccines; antibody-dependent enhancement; immune responses; neutralizing antibodies; vaccine development; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Immunity, Cellular; Immunity, Humoral; Immunity, Innate; Pandemics","Vashishtha","Vipin M","Department of Pediatrics, Mangla Hospital &amp",NA
"213","33269364","10.1101/2020.11.23.20237313","Identification of optimal symptom combinations to trigger diagnostic work-up of suspected COVID-19 cases: analysis from a community-based, prospective, observational cohort.","Several COVID-19 vaccine efficacy trials are ongoing with others predicted to start soon. Diagnostic work-up of trial participants following any COVID-19 associated symptom will lead to extensive testing, potentially overwhelming laboratory capacity whilst primarily yielding negative results. We aimed to identify an efficient symptom combination to capture most cases using the lowest possible number of tests. UK and US users of the COVID-19 Symptom Study app who reported new-onset symptoms betwe","2021","03","01","medRxiv","medRxiv : the preprint server for health sciences",NA,"Antonelli","M","School of Biomedical Engineering &amp",NA
"214","33268462","10.1136/bmj.m4709","Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy.",NA,"2020","12","07","BMJ","BMJ (Clinical research ed.)",NA,"Mahase","Elisabeth","The BMJ",NA
"215","33268419","10.1136/bmjopen-2020-040580","Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol.","SARS-CoV-2 (COVID-19) has caused an international pandemic of respiratory illness, resulting in significant healthcare and economic turmoil. To date, no robust vaccine or treatment has been identified. Elemental zinc has previously been demonstrated to have beneficial effects on coronaviruses and other viral respiratory infections due to its effect on RNA polymerase. Additionally, zinc has well-demonstrated protective effects against hypoxic injury-a clear mechanism of end-organ injury in respir","2020","12","21","BMJ Open","BMJ open","infectious diseases; public health; respiratory infections; virology; Administration, Intravenous; Adult; COVID-19; Clinical Trials, Phase II as Topic; Double-Blind Method; Female; Humans; Hypoxia; Male; Oxygen; Pandemics; Randomized Controlled Trials as Topic; SARS-CoV-2; Zinc","Perera","Marlon","Department of Surgery, Austin Health, Heidelberg, Victoria, Australia marlonlperera@gmail","marlonlperera@gmail.com"
"216","33267759","10.2174/1389450121999201202110303","Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.","Since its initial start on December 2019 at Wuhan, China, the coronavirus disease 2019 (COVID-19) has been rapidly spreading and labelled as pandemic by World Health Organization. The rate of human to human transmission of COVID-19 is far higher than severe acute respiratory syndrome (SARS) and Middle East respiratory syn-drome coronavirus (MERS). With no drugs or vaccines approved for the treatment of the disease, physicians have been using the pre-existing drugs to curb the disease. One potent","2020","12","08","Curr Drug Targets","Current drug targets","COVID-19; GS-5734; SARS-CoV-2; coronavirus.; pandemic; remdesivir","Moirangthem","Dinesh Singh","Food Safety Administration, Office of the Chief Medical Officer, Thoubal Wangma Taba, Thoubal District -795138, Manipur. India",NA
"217","33149899","10.12688/f1000research.26253.2","Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings.","Global health pandemics, such as coronavirus disease 2019 (COVID-19), require efficient and well-conducted trials to determine effective interventions, such as treatments and vaccinations. Early work focused on rapid sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequent in-vitro and in-silico work, along with greater understanding of the different clinical phases of the infection, have helped identify a catalogue of potential therapeutic agents requ","2020","12","10","F1000Res","F1000Research","COVID-19; FAME; IPD; MAMS; SARS-CoV-2; adaptive; conduct; efficient; epidemic; meta-analysis; multi-arm; multi-stage; pandemic; platform; trials; Adaptive Clinical Trials as Topic; COVID-19; Humans; Pandemics; Prospective Studies; Research Design","Noor","Nurulamin M","Medical Research Council Clinical Trials Unit, University College London, London, WC1V6LJ, UK",NA
"218","33264543","10.1056/NEJMp2033538","Placebo-Controlled Trials of Covid-19 Vaccines - Why We Still Need Them.",NA,"2021","02","01","N Engl J Med","The New England journal of medicine","COVID-19 Vaccines; Humans; Placebos; Randomized Controlled Trials as Topic","Krause","Philip R","The affiliations of the members of the WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation are the Office of Vaccines Research and Review, Food and Drug Administration, Silver Spring (P.R.K.), the School of Medicine, University of Maryland (M.M.L.), and Johns Hopkins University (S.P.), Baltimore, and the National Institute of Allergy and Infectious Diseases, Bethesda (M.N.) - all in Maryland",NA
"219","33264530","","Ethics and Professionalism on the Frontline: Controlled Human Infection Trials in COVID-19 Vaccine Development: Ethical Considerations.",NA,"2020","12","09","S D Med","South Dakota medicine : the journal of the South Dakota State Medical Association","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Human Experimentation; Humans; Pandemics; Professionalism","Lucido","Christopher","University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota",NA
"220","33264067","10.1139/cjm-2020-0465","Frontrunners in the race to develop a SARS-CoV-2 vaccine.","Numerous studies continue to be published on the COVID-19 pandemic that is being caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Given the rapidly evolving global response to SARS-CoV-2, here we primarily review the leading COVID-19 vaccine strategies that are currently in Phase..III clinical trials. Nonreplicating viral vector strategies, inactivated virus, recombinant protein subunit vaccines, and nucleic acid vaccine platforms are all being pursued in an effort to ","2021","03","01","Can J Microbiol","Canadian journal of microbiology","COVID-19; SARS-CoV-2; SRAS-CoV-2; Severe Acute Respiratory Syndrome Coronavirus 2; coronavirus..2 du syndrome respiratoire aigu s..v..re; d..veloppement de vaccins; vaccine development; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Drug Design; Drug Industry; Humans; Pandemics; SARS-CoV-2","Russell","Raquel L","Department of Microbiology, University of Manitoba, Winnipeg, MB R3T 2N2, Canada",NA
"221","33260775","10.3390/microorganisms8121885","Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study.","We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-CoV-2 antigens (S1, basic nucleocapsid (N) protein and receptor-binding domain (RBD)); and an in-house ELISA detecting antibodies to complete spike, RBD and N in 60 of these donors. Neutralizing antibo","2020","12","26","Microorganisms","Microorganisms","Covid-19; SARS-CoV-2; antibodies; convalescent plasma; novel coronavirus","Terpos","Evangelos","Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece",NA
"222","33259596","10.1182/blood.2020008758","Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.","Vaccinations are effective in preventing infections; however, it is unknown if patients with chronic lymphocytic leukemia (CLL) who are treatment na..ve (TN) or receiving Bruton tyrosine kinase inhibitors (BTKi's) respond to novel adjuvanted vaccines. Understanding the effect of BTKi's on humoral immunity is timely because BTKi's are widely used and vaccination against coronavirus disease 2019 is urgently needed. In 2 open-label, single-arm clinical trials, we measured the effect of BTKi's on de","2021","02","04","Blood","Blood","Adjuvants, Immunologic; Agammaglobulinaemia Tyrosine Kinase; Aged; Female; Hepatitis B Vaccines; Herpes Zoster Vaccine; Humans; Immunity; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Outcome Assessment; Protein Kinase Inhibitors; Vaccination; Vaccines, Synthetic","Pleyer","Christopher","Hematology Branch, National Heart, Lung, and Blood Institute",NA
"223","33259325","10.2196/23624","An Epidemiological Model Considering Isolation to Predict COVID-19 Trends in Tokyo, Japan: Numerical Analysis.","COVID-19 currently poses a global public health threat. Although Tokyo, Japan, is no exception to this, it was initially affected by only a small-level epidemic. Nevertheless, medical collapse nearly happened since no predictive methods were available to assess infection counts. A standard susceptible-infectious-removed (SIR) epidemiological model has been widely used, but its applicability is limited often to the early phase of an epidemic in the case of a large collective population. A full nu","2021","01","04","JMIR Public Health Surveill","JMIR public health and surveillance","COVID-19; SIR model; Tokyo; coronavirus; delay differential equation; epidemiological model; epidemiology; isolation; model; prediction; trend; Basic Reproduction Number; COVID-19; Computer Simulation; Humans; Models, Theoretical; Quarantine; Tokyo","Utamura","Motoaki","Research Laboratory for Nuclear Reactors, Tokyo Institute of Technology, Tokyo, Japan",NA
"224","33257213","10.1016/j.jcyt.2020.11.001","Stem cell therapy in coronavirus disease 2019: current evidence and future potential.","The end of 2019 saw the beginning of the coronavirus disease 2019 (COVID-19) pandemic that soared in 2020, affecting 215 countries worldwide, with no signs of abating. In an effort to contain the spread of the disease and treat the infected, researchers are racing against several odds to find an effective solution. The unavailability of timely and affordable or definitive treatment has caused significant morbidity and mortality. Acute respiratory distress syndrome (ARDS) caused by an unregulated","2021","05","26","Cytotherapy","Cytotherapy","Animals; COVID-19; Clinical Trials as Topic; Comorbidity; Humans; Immunomodulation; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pandemics; Respiratory Distress Syndrome; SARS-CoV-2; Treatment Outcome","Shetty","Rohit","Department of Cornea and Refractive Surgery, Narayana Nethralaya Eye Institute, Bangalore, India",NA
"225","33256750","10.1186/s12941-020-00402-x","COVID-19 vaccine development: What lessons can we learn from TB?","At the time of writing, the SARS-CoV-2 virus has infected more than 49 million people causing more than 1.2 million deaths worldwide since its emergence from Wuhan, China in December 2019. Vaccine development against SARS-CoV-2 has drawn the global attention in order to stop the spread of the virus, with more than 10 vaccines being tested in phase III clinical trials, as of November 2020. However, critical to vaccine development is consideration of the immunological response elicited as well as ","2020","12","07","Ann Clin Microbiol Antimicrob","Annals of clinical microbiology and antimicrobials","COVID-19; SARS-CoV-2; Tuberculosis; Vaccine; COVID-19; COVID-19 Vaccines; Humans; SARS-CoV-2; Tuberculosis Vaccines","Safar","Hussain A","Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, London, UK. h.safar@ucl.ac","h.safar@ucl.ac.uk"
"226","33253656","10.1016/j.actatropica.2020.105778","One year update on the COVID-19 pandemic: Where are we now?","We are living through an unprecedented crisis with the rapid spread of the new coronavirus disease (COVID-19) worldwide within a short time. The timely availability of thousands of SARS-CoV-2 genomes has enabled the scientific community to study the origin, structures, and pathogenesis of the virus. The pandemic has spurred research publication and resulted in an unprecedented number of therapeutic proposals. Because the development of new drugs is time consuming, several strategies, including d","2021","02","16","Acta Trop","Acta tropica","COVID-19; Coronavirus; Drug repurposing; Outbreak; Pandemic; Pathogenesis; SARS-CoV-2; Therapeutics; Vaccines; Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; COVID-19; COVID-19 Vaccines; Chloroquine; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; Drug Combinations; Drug Repositioning; Glucocorticoids; Humans; Hydroxychloroquine; Indoles; Ivermectin; Lopinavir; Mutation; Pandemics; Phytotherapy; Plant Extracts; Pyrazines; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tinospora; Viral Zoonoses","Mishra","Sanjay Kumar","Department of Botany, Ewing Christian College, Prayagraj- 211003, Uttar Pradesh, India",NA
"227","33252246","10.1089/acm.2020.0310","The Effects of Traditional Chinese Medicine as an Auxiliary Treatment for COVID-19: A Systematic Review and Meta-Analysis."," Background:  Coronavirus disease 2019 (COVID-19) has become a pandemic with no specific and widely accepted effective drug or vaccine. However, studies have shown that Traditional Chinese Medicine (TCM) may play a significant role as an auxiliary treatment for COVID-19.  Objective:  This study aimed to assess the effects of TCM as an auxiliary treatment for COVID-19 through a systematic review of randomized-controlled trials (RCTs).  Methods:  Four Engl","2021","03","24","J Altern Complement Med","Journal of alternative and complementary medicine (New York, N.Y.)","COVID-19; SARS-CoV-2; Traditional Chinese Medicine (TCM); Western medicine (WM); auxiliary treatment; Adult; Aged; COVID-19; Drugs, Chinese Herbal; Female; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Pandemics; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome","Zhou","Le-Peng","Department of Nursing, Nanhai Hospital of Southern Medical University, Foshan, Guangdong, China",NA
"228","33251385","10.1016/j.jacbts.2020.11.006","RNA Vaccines for COVID-19: 5 Things Every Cardiologist Should Know.",NA,"2020","12","30","JACC Basic Transl Sci","JACC. Basic to translational science","COVID-19; COVID-19, coronavirus disease 2019; DNA, deoxyribonucleic acid; RNA vaccine; RNA, ribonucleic acid; SARS-COV-2 phase 3 trial; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; mRNA, messenger ribonucleic acid","Lin","Chien-Jung","Center for Cardiovascular Research, Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA",NA
"229","33251093","10.1016/j.scs.2020.102619","Impact of the COVID-19 pandemic on travel behavior in Istanbul: A panel data analysis.","The COVID-19 pandemic, which was reported in early January 2020 in China and spread rapidly around the globe, will certainly remain as one of the most impactful disruptive events of the 21<sup>st</sup> century. To contain the spread of the virus while awaiting a vaccine, countries applied different approaches from simply giving advice on personal hygiene and applying progressive measures to total lockdown. This paper aims to investigate the impacts of the pandemic on travel behavior in Istanbul,","2021","01","06","Sustain Cities Soc","Sustainable cities and society","COVID-19 pandemic; Istanbul; Public transportation; Teleworking; Travel behavior","Shakibaei","Shahin","Transportation Engineering Department, Civil Engineering Faculty, Istanbul Technical University, Istanbul, Turkey",NA
"230","33250897","10.3389/fimmu.2020.592370","Rapid Response Subunit Vaccine Design in the Absence of Structural Information.","Prior to 2020, the threat of a novel viral pandemic was omnipresent but largely ignored. Just 12 months prior to the Coronavirus disease 2019 (COVID-19) pandemic our team received funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to establish and validate a rapid response pipeline for subunit vaccine development based on our proprietary Molecular Clamp platform. Throughout the course of 2019 we conducted two mock tests of our system for rapid antigen production against two ","2020","12","24","Front Immunol","Frontiers in immunology","Arenaviridae; Coalition for Epidemic Preparedness Innovations ; Disease X; Paramyxoviridae; membrane fusion protein; molecular clamp; pre-fusion conformation; subunit vaccine; Animals; Arenaviridae; COVID-19 Vaccines; Civil Defense; Clinical Trials as Topic; Drug Design; Humans; Molecular Structure; Paramyxovirinae; Time Factors; Vaccines, Subunit; Viral Vaccines","Wijesundara","Danushka K","School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia",NA
"231","33250809","10.3389/fpsyg.2020.563426","Risk Perception and Media in Shaping Protective Behaviors: Insights From the Early Phase of COVID-19 Italian Outbreak.","In the absence of target treatments or vaccination, the SARS-CoV-2 pandemic can be impeded by effectively implementing containment measures and behaviors. This relies on individuals' adoption of protective behaviors, their perceived risk, and the use and trust of information sources. During a health emergency, receiving timely and accurate information enables individuals to take appropriate actions to protect themselves, shaping their risk perception. Italy was the first western country plagued ","2020","12","01","Front Psychol","Frontiers in psychology","COVID-19; containment measures; efficacy; media; protective behaviors; risk perception; social media; vaccine","Vai","Benedetta","Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy",NA
"232","33247210","10.1038/s41565-020-00820-0","Nanomedicine and the COVID-19 vaccines.",NA,"2020","12","17","Nat Nanotechnol","Nature nanotechnology","COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Humans; Lipids; Nanomedicine; Nanoparticles; RNA, Messenger; Spike Glycoprotein, Coronavirus; United States; United States Food and Drug Administration",NA,NA,NA,NA
"233","33247138","10.1038/s41467-020-19967-4","Cellular events of acute, resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates.","Understanding SARS-CoV-2 associated immune pathology is crucial to develop pan-effective vaccines and treatments. Here we investigate the immune events from the acute state up to four weeks post SARS-CoV-2 infection, in non-human primates (NHP) with heterogeneous pulmonary pathology. We show a robust migration of CD16 expressing monocytes to the lungs occurring during the acute phase, and we describe two subsets of interstitial macrophages (HLA-DR<sup>+</sup>CD206<sup>-</sup>): a transitional CD","2020","12","08","Nat Commun","Nature communications","Acute Disease; Animals; COVID-19; Cytokines; Disease Models, Animal; Disease Progression; Female; Humans; Lung; Macaca mulatta; Macrophages; Male; Monocytes; Neutrophils; SARS-CoV-2; Severity of Illness Index; Viral Load; Virus Replication","Fahlberg","M D","Tulane National Primate Research Center, Covington, LA, USA",NA
"234","33245898","10.1016/j.ejphar.2020.173751","COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies.","Coronavirus Disease 2019 named as COVID-19 imposing a huge burden on public health as well as global economies, is caused by a new strain of betacoronavirus named as SARS-CoV-2. The high transmission rate of the virus has resulted in current havoc which highlights the need for a fast and effective approach either to prevent or treat the deadly infection. Development of vaccines can be the most prominent approach to prevent the virus to cause COVID-19 and hence will play a vital role in controlli","2021","01","22","Eur J Pharmacol","European journal of pharmacology","COVID-19; Platforms; SARS-CoV-2; Targets; Vaccine designing; Animals; Biological Products; COVID-19; COVID-19 Vaccines; Coronavirus; Drug Design; Drug Development; Humans; Immunologic Factors; Viral Structures","Rawat","Kajal","Department of Pharmacology, Post Graduate Institute of Medical Education &amp",NA
"235","33241838","10.1039/d0nr06816k","Spontaneous, solvent-free entrapment of siRNA within lipid nanoparticles.","Lipid nanoparticle (LNP) formulations of nucleic acid are leading vaccine candidates for COVID-19, and enabled the first approved RNAi therapeutic, Onpattro. LNPs are composed of ionizable cationic lipids, phosphatidylcholine, cholesterol, and polyethylene glycol (PEG)-lipids, and are produced using rapid-mixing techniques. These procedures involve dissolution of the lipid components in an organic phase and the nucleic acid in an acidic aqueous buffer (pH 4). These solutions are then combined us","2020","12","28","Nanoscale","Nanoscale","Animals; COVID-19; Cell Line; Hydrogen-Ion Concentration; Lab-On-A-Chip Devices; Lipids; Mice; Nanoparticles; RNA, Small Interfering; SARS-CoV-2","Kulkarni","Jayesh A","NanoMedicines Innovation Network, Vancouver, British Columbia, Canada. pieterc@mail.ubc.ca j.kulkarni@alumni.ubc","pieterc@mail.ubc.ca"
"236","33241728","10.1080/22221751.2020.1852059","Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models.","The ongoing COVID-19 pandemic is causing huge impact on health, life, and global economy, which is characterized by rapid spreading of SARS-CoV-2, high number of confirmed cases and a fatality/case rate worldwide reported by WHO. The most effective intervention measure will be to develop safe and effective vaccines to protect the population from the disease and limit the spread of the virus. An inactivated, whole virus vaccine candidate of SARS-CoV-2 has been developed by Wuhan Institute of Biol","2021","01","04","Emerg Microbes Infect","Emerging microbes &amp; infections","SARS-CoV-2; animal models; immunogenicity; inactivated vaccine; toxicity; Animals; Antibodies, Viral; COVID-19 Vaccines; Female; Immunity, Humoral; Male; SARS-CoV-2; Vaccines, Inactivated","Wang","Ze-Jun","Wuhan Institute of Biological Products Co. Ltd., Wuhan, People's Republic of China",NA
"237","33240370","","The race for a COVID-19 vaccine.",NA,"2020","12","10","Can J Dent Hyg","Canadian journal of dental hygiene : CJDH = Journal canadien de l'hygiene dentaire : JCHD","COVID-19; COVID-19 Vaccines; Canada; Chromosome Mapping; Clinical Trials as Topic; Delivery of Health Care; Humans; SARS-CoV-2; Safety; Treatment Outcome","Lavigne","Salme E","Scientific editor, Canadian Journal of Dental Hygiene",NA
"238","33239864","10.2147/DDDT.S282252","Repurposing Anti-Cancer Drugs for COVID-19 Treatment.","The novel coronavirus disease 2019 (COVID-19) pandemic has caused catastrophic damage to human life across the globe along with social and financial hardships. According to the Johns Hopkins University Coronavirus Resource Center, more than 41.3 million people worldwide have been infected, and more than 1,133,000 people have died as of October 22, 2020. At present, there is no available vaccine and a scarcity of efficacious therapies. However, there is tremendous ongoing effort towards identifyi","2020","12","04","Drug Des Devel Ther","Drug design, development and therapy","COVID-19; anti-cancer drugs; drug-repurposing; Antineoplastic Agents; Antiviral Agents; COVID-19; Clinical Trials as Topic; Drug Repositioning; Humans","Borcherding","Nicholas","Holden Comprehensive Cancer Center, University of Iowa, College of Medicine, Iowa City, IA, USA",NA
"239","33236048","10.1093/jmp/jhaa028","Challenge Trials: What Are the Ethical Problems?","If, as is alleged, challenge trials of vaccines against COVID-19 are likely to save thousands of lives and vastly diminish the economic and social harms of the pandemic while subjecting volunteers to risks that are comparable to kidney donation, then it would seem that the only sensible objection to such trials would be to deny that they have low risks or can be expected to have immense benefits. This essay searches for a philosophical rationale for rejecting challenge trials while supposing tha","2021","02","05","J Med Philos","The Journal of medicine and philosophy","COVID-19; SARS-CoV-2; challenge trials; human subjects; vaccine trials; Biomedical Research; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Pandemics; Philosophy, Medical; SARS-CoV-2","Hausman","Daniel M","Rutgers University, New Brunswick, New Jersey, USA",NA
"240","33234420","10.1016/j.biologicals.2020.11.003","Virology, epidemiology, immunology and vaccine development of SARS-CoV-2, update after nine months of pandemic.","This International Alliance for Biological Standardization COVID-19 webinar was organized to provide an update on the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2, none months after COVID-19 was declared a public health emergency of international concern. It brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable delegation from low- and middle-income countries.","2021","02","11","Biologicals","Biologicals : journal of the International Association of Biological Standardization","Epidemiology; Immunology; SARS-CoV-2; Vaccine; Virology; Antibodies, Neutralizing; Antibodies, Viral; Biological Products; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Development; Europe; Humans; Immunity, Cellular; Pandemics; SARS-CoV-2; Safety; World Health Organization","Baay","Marc","P95 Epidemiology &amp",NA
"241","33232871","10.1016/j.ebiom.2020.103125","Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza.","The pharmacokinetics and appropriate dose regimens of favipiravir are unknown in hospitalized influenza patients; such data are also needed to determine dosage selection for favipiravir trials in COVID-19. In this dose-escalating study, favipiravir pharmacokinetics and tolerability were assessed in critically ill influenza patients. Participants received one of two dosing regimens; Japan licensed dose (1600..mg BID on day 1 and 600..mg BID on the following days) and the higher dose (1800..mg/800","2020","12","22","EBioMedicine","EBioMedicine","COVID-19; Concentration; Critical illness; Favipiravir; Influenza; Intensive care; Pharmacokinetics; Aged; Amides; Drug Therapy, Combination; Female; Humans; Influenza, Human; Male; Middle Aged; Oseltamivir; Pyrazines; Severity of Illness Index","Wang","Yeming","Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China",NA
"242","33232690","10.1016/j.lfs.2020.118801","Thermal inactivation of SARS COVID-2 virus: Are steam inhalations a potential treatment?","The emergence of SARS-CoV-2 pandemic has upset health systems around the world and caused immeasurable losses and costs. Until a vaccine will become available, the recommended prevention measures remain physical distancing and enhanced hygiene. The proteic structure external to the virus is the main target that may eventually lead to reduce or block its replication in the upper airways. We developed a protocol based of repeated steam inhalation cycles aimed at reducing the risk of progression to","2021","01","07","Life Sci","Life sciences","COVID-19; Healthcare professionals; Prevention; Steam inhalation; Treatment; Administration, Inhalation; Adult; COVID-19; Disease Progression; Female; Hot Temperature; Humans; Male; Middle Aged; Polymerase Chain Reaction; Respiratory Mucosa; SARS-CoV-2; Steam; Virus Shedding","la Marca","Giancarlo","Newborn Screening, Biochemistry and Pharmacology Laboratory, Meyer Children's University Hospital, Florence, Italy","giancarlo.lamarca@meyer.it"
"243","33232205","10.1080/22221751.2020.1855945","Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate.","In the face of COVID-19 pandemic caused by the newly emerged SARS-CoV-2, an inactivated, Vero cell-based, whole virion vaccine candidate has been developed and entered into phase III clinical trials within six months. Biochemical and immunogenic characterization of structural proteins and their post-translational modifications in virions, the end-products of the vaccine candidate, would be essential for the quality control and process development of vaccine products and for studying the immunoge","2020","12","22","Emerg Microbes Infect","Emerging microbes &amp; infections","Inactivated vaccine; SARS-CoV-2; antigenicity; modifications; structural proteins; Animals; Antigens, Viral; COVID-19 Vaccines; Cattle; Chlorocebus aethiops; Humans; Protein Processing, Post-Translational; Rabbits; SARS-CoV-2; Vaccines, Inactivated; Vero Cells; Viral Structural Proteins; Virion","Zhang","Xiao-Yu","Wuhan Institute of Biological Products, Co. Ltd, Wuhan, People's Republic of China",NA
"244","33230423","10.2144/fsoa-2020-0132","Important updates from the AACR..virtual meeting: COVID-19 and cancer.","In this article, we present the pivotal abstracts presented at the 'AACR Virtual Meeting: COVID-19 and Cancer' held in July 2020. Much is unknown regarding the effect of COVID-19 on cancer patients, and this conference presented important updates in therapeutics and epidemiology. Specifically, cancer therapeutics have been hypothesized to treat cytokine release syndrome in patients with COVID-19, and the JAK1/2 inhibitor, ruxolitinib, is currently being used in a Phase III trial to assess its ef","2021","04","28","Future Sci OA","Future science OA","COVID-19; cancer; cytokine release syndrome; oncology; vaccine","Ripp","Jacob","Department of Internal Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA",NA
"245","33230278","10.1038/d41586-020-03326-w","Why Oxford's positive COVID vaccine results are puzzling scientists.",NA,"2020","12","07","Nature","Nature","SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Drug Industry; Humans; Immunization Schedule; Models, Immunological; SARS-CoV-2; Spike Glycoprotein, Coronavirus; United Kingdom; Vaccination","Callaway","Ewen",NA,NA
"246","33230275","10.1038/d41586-020-03219-y","Why emergency COVID-vaccine approvals pose a dilemma for scientists.",NA,"2020","12","08","Nature","Nature","COVID-19; COVID-19 Vaccines; Compassionate Use Trials; Controlled Clinical Trials as Topic; Drug Approval; Emergencies; Humans; Vaccination","Cyranoski","David",NA,NA
"247","33228458","10.1080/21645515.2020.1834325","Factors associated with parents' willingness to enroll their children in trials for COVID-19 vaccination.","The coronavirus disease 2019 (COVID-19) pandemic has taken an unprecedented global toll and vaccination is needed to restore healthy living. Timely inclusion of children in vaccination trials is critical. We surveyed caregivers of children seeking care in 17 Emergency Departments (ED) across 6 countries during the peak of the pandemic to identify factors associated with intent to participate in COVID-19 vaccine trials. Questions about child and parent characteristics, COVID-19 expressed concerns","2021","05","13","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","Coronavirus; decision-making; global survey; parental attitudes; vaccine trials; Adolescent; COVID-19; COVID-19 Vaccines; Child; Health Knowledge, Attitudes, Practice; Humans; Parents; Patient Participation; Randomized Controlled Trials as Topic; Vaccination","Goldman","Ran D","The Pediatric Research in Emergency Therapeutics (Pretx) Program, Division of Emergency Medicine, Department of Pediatrics, University of British Columbia, and BC Children's Hospital Research Institute, Vancouver, BC, Canada",NA
"248","33227451","10.1016/j.cct.2020.106225","Innovative trial designs and analyses for vaccine clinical development.","In the past decades, the world has experienced several major virus outbreaks, e.g. West African Ebola outbreak, Zika virus in South America and most recently global coronavirus (COVID-19) pandemic. Many vaccines have been developed to prevent a variety of infectious diseases successfully. However, several infections have not been preventable so far, like COVID-19, which induces an immediate urgent need for effective vaccines. These emerging infectious diseases often pose unprecedent challenges f","2021","03","03","Contemp Clin Trials","Contemporary clinical trials","Adaptive design; Bayesian design; COVID-19; Correlate of protection; Master protocol; RWD; Vaccine trials; Bayes Theorem; Biomedical Research; Clinical Trials as Topic; Drug Development; Humans; Time Factors; Viral Vaccines","Liu","Mengya","Takeda Pharmaceuticals, 300 Massachusetts Ave, Cambridge, MA 02139, United States. Electronic address: Mona.Liu@takeda","Mona.Liu@takeda.com"
"249","33227285","10.1016/j.ejphar.2020.173748","A review on possible mechanistic insights of Nitazoxanide for repurposing in COVID-19.","The global pandemic of Coronavirus Disease 2019 (COVID-19) has brought the world to a grinding halt. A major cause of concern is the respiratory distress associated mortality attributed to the cytokine storm. Despite myriad rapidly approved clinical trials with repurposed drugs, and time needed to develop a vaccine, accelerated search for repurposed therapeutics is still ongoing. In this review, we present Nitazoxanide a US-FDA approved antiprotozoal drug, as one such promising candidate. Nitazo","2021","01","05","Eur J Pharmacol","European journal of pharmacology","Antiviral; COVID-19; Clinical trials; Immunomodulation; Nitazoxanide; SARS-CoV-2; Antiprotozoal Agents; COVID-19; Clinical Trials as Topic; Drug Repositioning; Humans; Immunity, Innate; SARS-CoV-2; Thiazoles","Lokhande","Amit S","Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N. P. Marg, Matunga, Mumbai, 400019, Maharashtra, India",NA
"250","33227061","10.4103/psychiatry.IndianJPsychiatry_840_20","Solutions to prevent and address physician burnout during the pandemic in Mexico.","The COVID-19 pandemic has tested the level of preparedness and readiness of governments globally. The demand for services exceeding the capacity of the health systems in both developed and developing countries has been the rule rather than the exception. Physicians and the rest of the health-care personnel have been put through unprecedented levels of demand, within a field of uncertainty, from an evolving and insufficient understanding of the pathophysiology of the viral process, the unclear be","2020","11","25","Indian J Psychiatry","Indian journal of psychiatry","Burn out; Mexican healthcare personnel; Mexico; pandemic; stress","Ng","Bernardo","Mexican Psychiatric Association, Mexico City, Mexico",NA
"251","33226855","10.7326/M20-5350","Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.","Anticipated success rates and timelines for COVID-19 vaccine development vary. Recent experience with developing and testing viral vaccine candidates can inform expectations regarding the development of safe and effective vaccines. To estimate timelines and probabilities of success for recent vaccine candidates. ClinicalTrials.gov was searched to identify trials testing viral vaccines that had not advanced to phase 2 before 2005, and the progress of each vaccine from phase 1 through to U.S. Food","2021","03","23","Ann Intern Med","Annals of internal medicine","COVID-19; COVID-19 Vaccines; Communicable Diseases, Emerging; Drug Approval; Drug Development; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza, Human; Pandemics; Retrospective Studies; SARS-CoV-2; Time Factors; United States; United States Food and Drug Administration; Virus Diseases","MacPherson","Amanda","Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada (A.M., N.H., O.S., E.O., E.F., C.O., J.S., F.A., C.W., J",NA
"252","33226581","10.1007/s12602-020-09727-7","Probiotics-Derived Peptides and Their Immunomodulatory Molecules Can Play a Preventive Role Against Viral Diseases Including COVID-19.","As of recent, the pandemic episode of COVID-19, a severe acute respiratory syndrome brought about by a novel coronavirus (SARS-CoV-2) expanding the pace of mortality, has affected the disease rate profoundly. Invulnerability is the fundamental choice to prevent the ruining event of COVID-19, as the drugs and antibodies are in the phase of preliminary clinical trials. Within this brief period, a few strains of SARS-CoV-2 have been recognized by the vaccine manufacturers, which could be an incorre","2020","11","26","Probiotics Antimicrob Proteins","Probiotics and antimicrobial proteins","COVID-19; Immunomodulatory; Peptides; Probiotics; SARS-CoV-2","Manna","Sounik","Department of Microbiology, Midnapore College (Autonomous), Paschim Medinipur, India",NA
"253","33224928","10.3389/fbioe.2020.557652","Transplantation of Mesenchymal Stem Cells: A Potential Adjuvant Therapy for COVID-19.","Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative pathogen for coronavirus disease-2019 (COVID-19), which has posed an increasing serious public health threat. However, still there are no approved antiviral agents or vaccines available yet. Mesenchymal stem cells (MSCs) are emerging as a novel promising adjuvant therapy for the attenuation of COVID-19 based on its putative pathogenesis. MSCs may exert anti-inflammatory, immunomodulatory, anti-apoptotic, as well as reg","2020","11","24","Front Bioeng Biotechnol","Frontiers in bioengineering and biotechnology","ALI/ARDS; COVID-19; SARS-CoV-2; anti-inflammation; clinical trial; cytokine storm; immunomodulation; mesenchymal stem cells","Zhu","Yingqian","Department of Geriatrics, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China",NA
"254","33224275","10.1177/1758835920968463","Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.","This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively rec","2020","11","24","Ther Adv Med Oncol","Therapeutic advances in medical oncology","COVID-19; SARS-CoV-2; cancer patients; immune-checkpoint inhibitors; influenza-like illness","Bersanelli","Melissa","Medicine and Surgery Department, University of Parma, and Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, Parma 43126, Italy",NA
"255","33221134","10.1016/j.mehy.2020.110365","Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis.","Immunotherapy is the newest approach to combat cancer. It can be achieved using several strategies, among which is the dendritic cell (DC) vaccine therapy. Several clinical trials are ongoing using DC vaccine therapy either as a sole agent or in combination with other interventions to tackle different types of cancer. Immunotherapy can offer a potential treatment to coronavirus disease 2019 (COVID-19) the worst pandemic facing this generation, a disease with deleterious effects on the health and","2021","02","01","Med Hypotheses","Medical hypotheses","Advantages; COVID-19; Cancer; Combination therapy; Dendritic cell vaccine; Disadvantages; Immunotherapy; COVID-19; COVID-19 Vaccines; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dendritic Cells; Drug Development; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Models, Immunological; Neoplasms; SARS-CoV-2","Saadeldin","Mona Kamal","Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan 20139, Italy. Electronic address: m.kamal@aucegypt","m.kamal@aucegypt.edu"
"256","33220855","10.1016/S0140-6736(20)32466-1","Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.","Older adults (aged ...70 years) are at increased risk of severe disease and death if they develop COVID-19 and are therefore a priority for immunisation should an efficacious vaccine be developed. Immunogenicity of vaccines is often worse in older adults as a result of immunosenescence. We have reported the immunogenicity of a novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19 (AZD1222), in young adults, and now describe the safety and immunogenicity of this vaccine in a wider range o","2020","12","31","Lancet","Lancet (London, England)","Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; COVID-19; COVID-19 Vaccines; Female; Humans; Immunization, Secondary; Immunogenicity, Vaccine; Immunoglobulin G; Male; Middle Aged; SARS-CoV-2; Single-Blind Method; Young Adult","Ramasamy","Maheshi N","Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Electronic address: maheshi.ramasamy@paediatrics.ox.ac","maheshi.ramasamy@paediatrics.ox.ac.uk"
"257","33219926","10.1007/s40264-020-01018-y","How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.",NA,"2021","01","27","Drug Saf","Drug safety","Adverse Drug Reaction Reporting Systems; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans","Shakir","Saad","Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, Hampshire, SO31 1AA, UK",NA
"258","33218366","10.1186/s13643-020-01516-1","Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project).","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) which has rapidly spread worldwide. Several human randomized clinical trials assessing potential vaccines are currently underway. There is an urgent need for a living systematic review that continuously assesses the beneficial and harmful effects of all available vaccines for COVID-19. We will conduct a living systematic review based on searches of major medical databases (e.g., MEDLINE, EMBAS","2020","12","14","Syst Rev","Systematic reviews","COVID-19; COVID-19 Vaccines; Humans; Meta-Analysis as Topic; Network Meta-Analysis; Pandemics; Quality of Life; Research Design; SARS-CoV-2; Systematic Reviews as Topic; Treatment Outcome","Korang","Steven Kwasi","Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100, Copenhagen, Denmark. steven.korang@ctu","steven.korang@ctu.dk"
"259","33218001","10.3390/v12111324","Application of Viral Vectors for Vaccine Development with a Special Emphasis on COVID-19.","Viral vectors can generate high levels of recombinant protein expression providing the basis for modern vaccine development. A large number of different viral vector expression systems have been utilized for targeting viral surface proteins and tumor-associated antigens. Immunization studies in preclinical animal models have evaluated the elicited humoral and cellular responses and the possible protection against challenges with lethal doses of infectious pathogens or tumor cells. Several vaccin","2020","12","09","Viruses","Viruses","COVID-19 vaccines; DNA-based vaccines; RNA-based vaccines; cancers; infectious diseases; self-replicating RNA vectors; viral vaccines; Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Disease Models, Animal; Drug Development; Genetic Vectors; Humans; Mice; Pandemics; Recombinant Proteins; SARS-CoV-2; Vaccination; Vaccines, DNA","Lundstrom","Kenneth","PanTherapeutics, CH1095 Lutry, Switzerland",NA
"260","33217362","10.1016/S1473-3099(20)30843-4","Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.","With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac (Sinovac Life Sciences, Beijing, China), an inactivated vaccine candidate against COVID-19, containing inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), for its safety, tolerability and immunogenicity. In this randomised, double-blind, placebo-controlled, phase 1/2 clinical trial, healthy adults aged 18-59 years wer","2021","02","15","Lancet Infect Dis","The Lancet. Infectious diseases","Adolescent; Adult; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; China; Female; Healthy Volunteers; Humans; Immunization Schedule; Immunogenicity, Vaccine; Immunoglobulin G; Immunoglobulin M; Male; Middle Aged; SARS-CoV-2; Seroconversion; Vaccination; Vaccines, Inactivated; Young Adult","Zhang","Yanjun","Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China",NA
"261","33216636","10.7326/M20-7357","Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine.",NA,"2021","02","25","Ann Intern Med","Annals of internal medicine","COVID-19; COVID-19 Vaccines; Drug Industry; Ethics, Research; Humans; Pandemics; Randomized Controlled Trials as Topic; Research Design; SARS-CoV-2; United States; United States Food and Drug Administration","Dal-R..","Rafael","Epidemiology Unit, Health Research Institute-Fundaci..n Jim..nez D..az University Hospital, Universidad Aut..noma de Madrid, Madrid, Spain (R",NA
"262","33215698","10.1002/14651858.CD006207.pub5","Physical interventions to interrupt or reduce the spread of respiratory viruses.","Viral epidemics or pandemics of acute respiratory infections (ARIs) pose a global threat. Examples are influenza (H1N1) caused by the H1N1pdm09 virus in 2009, severe acute respiratory syndrome (SARS) in 2003, and coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in 2019. Antiviral drugs and vaccines may be insufficient to prevent their spread. This is an update of a Cochrane Review published in 2007, 2009, 2010, and 2011. The evidence summarised in this review does not include results fro","2020","12","04","Cochrane Database Syst Rev","The Cochrane database of systematic reviews","Bias; COVID-19; Case-Control Studies; Epidemics; Hand Hygiene; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Masks; Randomized Controlled Trials as Topic; Respiratory Tract Infections; SARS-CoV-2; Severe Acute Respiratory Syndrome; Virus Diseases; Virus Shedding","Jefferson","Tom","Centre for Evidence Based Medicine, University of Oxford, Oxford, UK",NA
"263","33215168","10.1101/2020.11.08.20227876","Design and implementation of the multi-arm, multi-stage Therapeutics for Inpatients with COVID-19 (TICO) platform master protocol: An Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative.","The SARS-CoV-2 pandemic is a public health emergency. Safe and effective therapies are urgently needed. Therapeutics for Inpatients with COVID-19 (TICO), is a global multi-arm, multi-stage (MAMS) platform master protocol, which facilitates the rapid evaluation of the safety and efficacy of candidate anti-viral therapeutic agents for adults hospitalized with COVID-19. The protocol design allows multiple therapeutic agents to be evaluated in an efficient and scientifically rigorous manner, with ef","2021","04","17","medRxiv","medRxiv : the preprint server for health sciences","COVID-19; Multi-arm Multi-stage; SARS-CoV-2; neutralizing monoclonal antibody; platform trials","Murray","Daniel D","CHIP Centre of Excellence for Health, Immunity, and Infections, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark",NA
"264","33214255","10.1126/science.370.6519.894","Vaccine wagers on coronavirus surface protein pay off.",NA,"2020","12","01","Science","Science (New York, N.Y.)","Biotechnology; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunogenicity, Vaccine; Pandemics; Pneumonia, Viral; RNA, Messenger; RNA, Viral; Spike Glycoprotein, Coronavirus; Viral Vaccines","Cohen","Jon",NA,NA
"265","33213829","10.1016/j.ijantimicag.2020.106208","Therapeutic modalities and novel approaches in regenerative medicine for COVID-19.","The recent coronavirus disease 2019 outbreak around the world has had an enormous impact on the global health burden, threatening the lives of many individuals, and has had severe socio-economic consequences. Many pharmaceutical and biotechnology companies have commenced intensive research on different therapeutic strategies, from repurposed antiviral drugs to vaccines and monoclonal antibodies to prevent the spread of the disease and treat infected patients. Among the various strategies, advanc","2020","12","08","Int J Antimicrob Agents","International journal of antimicrobial agents","ATMP; Advanced therapeutic approaches; COVID-19; SARS-CoV-2; Antibodies, Monoclonal; Anticoagulants; Antiviral Agents; COVID-19; COVID-19 Vaccines; Cytokine Release Syndrome; Humans; Regenerative Medicine; SARS-CoV-2","Ramezankhani","Roya","Department of Applied Cell Sciences, Faculty of Basic Science and Advanced Medical Technologies, Royan Institute, Academic Centre for Education, Culture and Research, Tehran, Iran",NA
"266","33211647","10.1051/medsci/2020231","[Fight against COVID-19: market overview and pipeline of ongoing trials].",NA,"2020","12","30","Med Sci (Paris)","Medecine sciences : M/S","Antibodies; Antiviral Agents; Biomedical Research; COVID-19; Clinical Trials as Topic; Commerce; Drug Development; Drug Industry; France; Health Care Sector; Humans; International Cooperation; Investments; Pandemics; SARS-CoV-2; Viral Vaccines","Pontremoli","Richard","MabDesign, 17 rue Crepet, 69007 Lyon, France",NA
"267","33211246","10.17269/s41997-020-00439-7","Can BCG be useful to mitigate the COVID-19 pandemic? A Canadian perspective.","There is ample evidence from in vitro, animal and human studies that the Bacillus Calmette-Guerin (BCG) vaccine epigenetically reprograms innate immunity to provide &quot;off target&quot; protection against pathogens other than mycobacteria. This process has been termed &quot;trained immunity&quot;. Although recent ecological studies suggested an association between BCG policies and the frequency or severity of COVID-19 in different countries, the interpretation of these results is challenging. ","2020","12","22","Can J Public Health","Canadian journal of public health = Revue canadienne de sante publique","BCG; COVID-19; Coronavirus; Innate immunity; SARS-CoV-2; Trained immunity; BCG Vaccine; COVID-19; Canada; Case-Control Studies; Clinical Trials, Phase III as Topic; Humans; Immunity, Innate; Pandemics","De Wals","Philippe","D..partement de M..decine sociale et pr..ventive, Universit.. Laval, CRIUCPQ, 2725, Chemin Sainte-Foy, Qu..bec, QC, G1G 4G5, Canada. philippe.dewals@criucpq.ulaval","philippe.dewals@criucpq.ulaval.ca"
"268","33210600","","[Progress in possible effects of BCG vaccine on the prevention of SARS-CoV-2 infection: An update].","The research and development of the coronavirus disease 2019 (COVID-19) vaccine is being carried out globally. Although vaccine research and development technology has made great progress, the possibility of obtaining a safe and effective vaccine that can control the global epidemic in a short period of time is still low due to the antibody-dependent enhancement effect (ADE) of the vaccine and the mutation of the virus. In the absence of specific treatment for COVID-19, finding other alternative","2020","11","23","Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi","Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","BCG Vaccine; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2","Huang","Wenmian","Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China",NA
"269","33204211","10.1007/s11042-020-10134-x","Chaotic-map based authenticated security framework with privacy preservation for remote point-of-care.","The challenge of COVID-19 has become more prevalent across the world. It is highly demanding an intelligent strategy to outline the precaution measures until the clinical trials find a successful vaccine. With technological advancement, Wireless Multimedia Sensor Networks (WMSNs) has extended its significant role in the development of remote medical point-of-care (RM-PoC). WMSN is generally located on a communication device to sense the vital signaling information that may periodically be transm","2020","11","19","Multimed Tools Appl","Multimedia tools and applications","And key agreement; Authentication; Chaotic-map; Real-or-random; Remote point-of-care; Security and privacy","Deebak","B D","School of Computer Science and Engineering, Vellore Institute of Technology, Vellore, 632014 India",NA
"270","33200726","10.4269/ajtmh.20-1294","Inadequate Minority Representation within SARS-CoV-2 Vaccine Trials.","Minority communities have borne the brunt of COVID-19 disease in the United States. Nonwhites have contracted most of the SARS-CoV-2 infections; COVID-19 mortality rates for Black Americans are more than twice those for whites. Given this, studying the most effective ways to prevent and treat SARS-CoV-2 in these populations should be a research priority, particularly with respect to vaccine trials. Federal guidelines from the National Institutes of Health and Food and Drug Administration emphasi","2021","01","25","Am J Trop Med Hyg","The American journal of tropical medicine and hygiene","African Americans; American Natives; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Ethnic Groups; Healthcare Disparities; Hispanic Americans; Humans; Minority Groups; Research Design; SARS-CoV-2; United States","Craft","Joshua F","Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland",NA
"271","33200085","10.1007/s13337-020-00631-w","Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters.","SARS-CoV-2, or novel coronavirus, is causing the fatal and contagious coronavirus disease-2019 (COVID-19) affecting thousands of people every single day. Researchers are continuously searching for any possible cure and/or vaccine, but no conclusive report is available till date. Like many others, we realize that a rapid, immediate, and elaborate strategy must be adopted to protect mankind. To avoid the time-loss due to clinical trials, we have performed in silico analyses on some FDA-approved dr","2020","11","18","Virusdisease","Virusdisease","COVID-19; FDA-approved drugs; Immune-boosters; Pandemic; SARS-CoV-2; Supplements","Roy Chattopadhyay","Nabanita","Department of Biotechnology, Visva Bharati, Santiniketan, Bolpur, 731235 India",NA
"272","33199968","10.1016/j.jsps.2020.10.019","Current COVID-19 vaccine candidates: Implications in the Saudi population.","The purpose of this review is to discuss the current status of local and international efforts undergoing clinical trials aiming at developing a Coronavirus Disease-2019 (COVID-19) vaccine, and to highlight the anticipated challenges of this vaccine globally and in Saudi Arabia. COVID-19 vaccine development efforts started in early January 2020 when Chinese scientists shared the Coronavirus genomic sequence in public domain. Approximately 321 research groups initiated the search for a vaccine, o","2020","12","30","Saudi Pharm J","Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society","COVID-19; Effectiveness; SARS-CoV-2; Safety; Saudi Arabia; Vaccines","Raja","AlAnoud TofailAhmed","College of Pharmacy, Alfaisal University, Riyadh, Saudi Arabia",NA
"273","33199901","10.1038/d41586-020-03248-7","COVID vaccine excitement builds as Moderna reports third positive result.",NA,"2020","11","26","Nature","Nature","SARS-CoV-2; Vaccines; Adult; Age Factors; Aged; Aging; Biotechnology; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Time Factors; Vaccination; Viral Vaccines","Callaway","Ewen",NA,NA
"274","33199863","10.1038/s41564-020-00824-5","Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals.","Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)<sup>1-3</sup> and individuals with COVID-19 have symptoms that can be asymptomatic, mild, moderate or severe<sup>4,5</sup>. In the early phase of infection, T- and B-cell counts are substantially decreased<sup>6,7</sup>; however, IgM<sup>8-11</sup> and IgG<sup>12-14</sup> are detectable within 14...d after symptom onset. In COVID-19-convalescent individuals, spike-specific","2021","01","13","Nat Microbiol","Nature microbiology","Antibodies, Neutralizing; Antibodies, Viral; Broadly Neutralizing Antibodies; COVID-19; Cross Reactions; Humans; Receptors, CXCR3; SARS-CoV-2; T Follicular Helper Cells","Zhang","Jian","Translational Medicine Institute, The First People's Hospital of Chenzhou, University of South China, Chenzhou, China",NA
"275","33197879","10.2196/22521","Associations of Medications With Lower Odds of Typical COVID-19 Symptoms: Cross-Sectional Symptom Surveillance Study.","As the COVID-19 pandemic continues to spread across the globe, the search for an effective medication to treat the symptoms of COVID-19 continues as well. It would be desirable to identify a medication that is already in use for another condition and whose side effect profile and safety data are already known and approved. The objective of this study was to evaluate the effect of different medications on typical COVID-19 symptoms by using data from an online surveillance survey. Between early Ap","2021","01","11","JMIR Public Health Surveill","JMIR public health and surveillance","COVID-19; SARS-CoV-2; antihypertensives; hydroxymethyl-glutaryl-coenzyme A reductase inhibitors; online survey; statins; surveillance; Aged; Antihypertensive Agents; COVID-19; Cross-Sectional Studies; Epidemiological Monitoring; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mobile Applications; Prospective Studies; SARS-CoV-2; Self Report; Surveys and Questionnaires","Urbach","Dietmar","Helios-Klinikum Gifhorn, Gifhorn, Germany",NA
"276","33196555","10.1097/QAI.0000000000002570","COVID-19 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy Among Black Americans Living With HIV.","Medical mistrust, a result of systemic racism, is prevalent among Black Americans and may play a role in COVID-19 inequities. In a convenience sample of HIV-positive Black Americans, we examined associations of COVID-19-related medical mistrust with COVID-19 vaccine and COVID-19 treatment hesitancy and negative impacts of COVID-19 on antiretroviral therapy (ART) adherence. Participants were 101 HIV-positive Black Americans (age: M = 50.3 years; SD = 11.5; 86% cisgender men; 77% sexual minority) ","2021","01","19","J Acquir Immune Defic Syndr","Journal of acquired immune deficiency syndromes (1999)","Adult; African Americans; Anti-Retroviral Agents; COVID-19; COVID-19 Vaccines; Female; HIV Infections; Health Knowledge, Attitudes, Practice; Humans; Los Angeles; Male; Medication Adherence; Middle Aged; SARS-CoV-2; Sexual and Gender Minorities; Trust","Bogart","Laura M","RAND Corporation",NA
"277","33196005","10.31138/mjr.31.3.275","COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment.","The magnitude of the SARS-CoV-2 pandemic found health systems unprepared, not allowing for prompt evaluation, collaboration among specialities and treatment of severely ill patients admitted to intensive care units, with many of them having an unfortunate outcome. Current data demonstrate an acute immune dysregulation in severe forms of the disease. The above is concluded by clinical evolution and laboratory findings, indicating a severe inflammatory response of the innate immune system, initiat","2020","11","17","Mediterr J Rheumatol","Mediterranean journal of rheumatology","SARS-CoV-2; corticosteroids; disease-modifying anti-rheumatic drugs; hyperferritinaemia; immunotherapy; rheumatology","Vounotrypidis","Periklis","Rheumatology Department, 424 General Military Hospital, Thessaloniki, Greece",NA
"278","33194697","10.3389/fonc.2020.577696","Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis.","Immune checkpoint inhibitors (ICI) have become the standard of care treatment for several tumor types. ICI-induced pneumonitis is a serious complication seen with treatment with these agents. Cancer has been reported to be one of the risk factors for severe coronavirus disease 2019 (COVID-19) caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that has engulfed the world in the last couple of months. In patients with cancer treated with ICI who present at the e","2020","11","17","Front Oncol","Frontiers in oncology","COVID-19; SARS-CoV-2; co-rads; immune check inhibitor (ICI); pneumonitis","Dumoulin","Daphne W","Department of Pulmonary Medicine, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands",NA
"279","33189639","10.1016/j.chemphyslip.2020.105009","Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises.","There are no commercially available effective antiviral medications or vaccines to deal with novel coronavirus disease (COVID-19). Hence there is a substantial unmet medical need for new and efficacious treatment options for COVID-19. Most COVID-19 deaths result from acute respiratory distress syndrome (ARDS). This virus induces excessive and aberrant inflammation so it is important to control the inflammation as soon as possible. To date, results of numerous studies have been shown that mesench","2021","01","11","Chem Phys Lipids","Chemistry and physics of lipids","Exosome based therapy; MSC exsosomes; covid-19; Antiviral Agents; COVID-19; Clinical Trials as Topic; Drug Delivery Systems; Exosomes; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; SARS-CoV-2; Treatment Outcome","Rezakhani","Leila","Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran",NA
"280","33188930","10.1016/j.cct.2020.106213","Causal inference methods for small non-randomized studies: Methods and an application in COVID-19.","The usual development cycles are too slow for the development of vaccines, diagnostics and treatments in pandemics such as the ongoing SARS-CoV-2 pandemic. Given the pressure in such a situation, there is a risk that findings of early clinical trials are overinterpreted despite their limitations in terms of size and design. Motivated by a non-randomized open-label study investigating the efficacy of hydroxychloroquine in patients with COVID-19, we describe in a unified fashion various alternativ","2021","01","08","Contemp Clin Trials","Contemporary clinical trials","COVID-19; Causal inference; Propensity score; Small samples; Antiviral Agents; COVID-19; Causality; Clinical Trials as Topic; Humans; Hydroxychloroquine; Pandemics; Propensity Score; SARS-CoV-2; Sample Size","Friedrich","Sarah","Department of Medical Statistics, University Medical Center G..ttingen, Humboldtallee 32, 37073 G..ttingen, Germany. Electronic address: sarah.friedrich@med.uni-goettingen","sarah.friedrich@med.uni"
"281","33188794","10.1016/j.pharmthera.2020.107745","Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19.","While COVID-19, the disease driven by SARS-CoV-2 has ignited interest in the host immune response to this infection, it has also highlighted the lack of treatment options for the damaging inflammatory responses driven by pathogens that precipitate the acute respiratory distress syndrome (ARDS). With the global prevalence of SARS-CoV-2 and the likelihood of a second winter spike alongside seasonal flu, the need for effective and targeted anti-inflammatory agents is even more pressing. Here we dis","2021","05","03","Pharmacol Ther","Pharmacology &amp; therapeutics","ARDS; COVID-19; Inflammation; SARS-CoV-2; p38 MAP kinase; Anti-Inflammatory Agents; COVID-19; Clinical Trials as Topic; Humans; Immunity, Innate; MAP Kinase Signaling System; Pneumonia; Protein Kinase Inhibitors; Respiratory Distress Syndrome","Gilroy","Derek W","Division of Medicine, University College London, London, UK. Electronic address: D.gilroy@ucl.ac","D.gilroy@ucl.ac.uk"
"282","33185828","10.1007/s11033-020-05988-1","Potential approaches to combat COVID-19: a mini-review.","The outbreak of a novel coronavirus namely SARS-CoV-2, which first emerged from Wuhan, China, has wreaked havoc not only in China but the whole world that now has been engulfed in its wrath. In a short lapse of time, this virus was successful in spreading at a blistering pace throughout the globe, hence raising the flag of pandemic status. The mounting number of deaths with each elapsing day has summoned researchers from all around the world to play their part in driving this SARS-CoV-2 pandemic","2020","12","17","Mol Biol Rep","Molecular biology reports","Approaches; COVID-19; Combat strategies; Epidemiology; SARS-CoV-2; Vaccines; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal; Antiviral Agents; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Repositioning; Humans; Infectious bronchitis virus; Mesenchymal Stem Cell Transplantation; RNA, Messenger; Recombinant Proteins; Single-Domain Antibodies; Vaccines, Attenuated; Vaccines, Subunit; Vaccines, Synthetic","Sarwar","Zainab","Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), Islamabad, Pakistan",NA
"283","33185497","10.1080/21645515.2020.1833577","Harnessing the non-specific immunogenic effects of available vaccines to combat COVID-19.","No proven remedy is identified for COVID-19 yet. SARS-CoV-2, the viral agent, is recognized by some endosomal and cytosolic receptors following cell entry, entailing innate and adaptive immunity stimulation, notably through interferon induction. Impairment in immunity activation in some patients, mostly elderlies, leads to high mortalities; thus, promoting immune responses may help. BCG vaccine is under investigation to prevent COVID-19 due to its non-specific effects on the immune system. Howev","2021","05","13","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","BCG vaccine; COVID-19; immunity; influenza vaccine; pandemic; severe acute respiratory syndrome coronavirus 2; trained immunity; BCG Vaccine; COVID-19; Clinical Trials as Topic; Humans; Immunity, Innate; Influenza Vaccines; Interferons; Pandemics; Prospective Studies","Mosaddeghi","Pouria","Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran",NA
"284","33184184","10.1126/science.370.6518.748","Effective vaccine offers shot of hope for pandemic.",NA,"2020","12","09","Science","Science (New York, N.Y.)","COVID-19; COVID-19 Vaccines; Humans; Pandemics; Placebos; Randomized Controlled Trials as Topic; Vaccines, Synthetic","Cohen","Jon",NA,NA
"285","33180929","10.1084/jem.20201116","Vi-specific serological correlates of protection for typhoid fever.","Typhoid Vi vaccines have been shown to be efficacious in children living in endemic regions; however, a widely accepted correlate of protection remains to be established. We applied a systems serology approach to identify Vi-specific serological correlates of protection using samples obtained from participants enrolled in an experimental controlled human infection study. Participants were vaccinated with Vi-tetanus toxoid conjugate (Vi-TT) or unconjugated Vi-polysaccharide (Vi-PS) vaccines and w","2020","11","23","J Exp Med","The Journal of experimental medicine","Adult; Bacterial Load; Humans; Immunity, Humoral; Immunogenicity, Vaccine; Immunoglobulin G; Time Factors; Typhoid Fever; Typhoid-Paratyphoid Vaccines; Vaccines, Conjugate","Jin","Celina","Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, UK",NA
"286","33178779","10.21037/atm-20-4071","Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option.","The recent seemingly uncontrollable pandemic caused by the novel severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has been able to spread quickly due to the non-availability of effective antivirals or vaccines. The virus has structural and non-structural proteins that are considered as possible targets. Receptor recognition is the critical determinant and preliminary phase of viral infection to enter the host cell and causes tissue tropism. We have conducted a comprehensive r","2020","11","13","Ann Transl Med","Annals of translational medicine","COVID-19; SARS-CoV-1; Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2); antivirals; repurposing","Sabarimurugan","Shanthi","School of Biomedical Sciences, The University of Western Australia, Perth, Australia",NA
"287","33178207","10.3389/fimmu.2020.580250","A Longitudinal Study of Immune Cells in Severe COVID-19 Patients.","Little is known about the time-dependent immune responses in severe COVID-19. Data of 15 consecutive patients were sequentially recorded from intensive care unit admission. Lymphocyte subsets and total monocyte and subsets counts were monitored as well as the expression of HLA-DR. For 5 patients, SARS-CoV-2-specific T-cell polyfunctionality was assessed against Spike and Nucleoprotein SARS-CoV-2 peptides. Non-specific inflammation markers were increased in all patients. Median monocyte HLA-DR ex","2020","12","07","Front Immunol","Frontiers in immunology","SARS-CoV-2; antigen-specific polyfunctional T-cells; immunity; intensive care unit; monocyte HLA-DR; Aged; Biomarkers; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; COVID-19; Female; GPI-Linked Proteins; HLA-DR Antigens; Humans; Immunity, Cellular; Lipopolysaccharide Receptors; Longitudinal Studies; Male; Middle Aged; Monocytes; Prospective Studies; Receptors, IgG; SARS-CoV-2; Severity of Illness Index","Payen","Didier","Universit.. Paris 7 Denis Diderot, UMR 1160 INSERM, Paris, France",NA
"288","33177689","10.1038/d41586-020-03209-0","Russia announces positive COVID-vaccine results from controversial trial.",NA,"2020","11","13","Nature","Nature","SARS-CoV-2; Vaccines","Callaway","Ewen",NA,NA
"289","33177214","10.1128/mSphere.00827-20","Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.","Viral shedding patterns and their correlations with immune responses are still poorly characterized in mild coronavirus (CoV) disease 2019 (COVID-19). We monitored shedding of viral RNA and infectious virus and characterized the immune response kinetics of the first five patients quarantined in Geneva, Switzerland. High viral loads and infectious virus shedding were observed from the respiratory tract despite mild symptoms, with isolation of infectious virus and prolonged positivity by reverse t","2020","11","23","mSphere","mSphere","COVID-19; SARS-CoV-2; antibody response; cytokines; immunity; viral load; Adaptive Immunity; Adult; Aged; Antibodies, Viral; Betacoronavirus; Biomarkers; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Coronavirus Infections; Cytokines; Humans; Immunity, Innate; Kinetics; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index; Viral Load; Virus Shedding","Vetter","Pauline","Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland Pauline.vetter@hcuge","Pauline.vetter@hcuge.ch"
"290","33176585","10.1177/1403494820969539","Is fighting against COVID-19 enough?","Tools of empirical epidemiology have been and are indispensable to focus political power on blocking the spreading of coronavirus disease 2019 (COVID-19) by stopping transmission. The present paper is a comment on E. Gibney's article 'Whose coronavirus strategy worked best?' (Nature 2020;581:15-6). The strategy for phase 2 should be more complex and interdisciplinary than described in the paper in Nature, especially in the period before a vaccine and specific treatments are availab","2021","02","05","Scand J Public Health","Scandinavian journal of public health","COVID-19; NaCuHeal; Nature-Culture-Health; community medicine; health promotion and prevention; infectious diseases; public health; Aged; COVID-19; Coronavirus Infections; Global Health; Humans; Pandemics; SARS-CoV-2","Kofler","Walter","Medical University of Innsbruck, Austria",NA
"291","33176090","10.1056/NEJMe2033111","Audio Interview: An Update from Operation Warp Speed.",NA,"2020","11","24","N Engl J Med","The New England journal of medicine","Antibodies, Monoclonal; Anticoagulants; Antiviral Agents; Biomarkers; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Community Participation; Coronavirus Infections; Drug Approval; Drug Evaluation; Drug Industry; Humans; Immunomodulation; International Cooperation; Pandemics; Plasma; Pneumonia, Viral; Time Factors; United States; United States Food and Drug Administration; Viral Load; Viral Vaccines","Rubin","Eric J",NA,NA
"292","33175700","10.3855/jidc.13436","COVID-19, indications for professional football teams and referees training resumption.","These indications were drawn up by the Federal Medical-Scientific Commission (FIGC Commission), supplemented for the necessary time by some experts on the subject; currently they are intended to grant the highest achievable guarantee level to protect the health of players, referees and all professionals involved in case of resumption of collective training (Document dated 18 April 2020). They were designed to minimize the risk of contagion were thus based on the fact that during that phase of SA","2020","11","18","J Infect Dev Ctries","Journal of infection in developing countries","COVID-19; football; infection; prevention; protocol; referees; Betacoronavirus; COVID-19; Coronavirus Infections; Decontamination; Humans; Italy; Pandemics; Pneumonia, Viral; Return to Sport; SARS-CoV-2; Soccer; Sports and Recreational Facilities","Donadu","Matthew Gavino","Biomedical Commission Referees Technical Sector, Italian Referees Association, Italian Football Federation, Rome, Italy. mdonadu@jidc","mdonadu@jidc.org"
"293","33175649","10.1177/0141076820972668","COVID-19, seasonal influenza and measles: potential triple burden and the role of flu and MMR vaccines.",NA,"2020","12","29","J R Soc Med","Journal of the Royal Society of Medicine","COVID-19; Hospitalization; Humans; Influenza Vaccines; Influenza, Human; Measles; Measles-Mumps-Rubella Vaccine; Pandemics; SARS-CoV-2","Islam","Nazrul","Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK",NA
"294","33171100","10.1016/j.cell.2020.10.037","Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19.","We present an integrated analysis of the clinical measurements, immune cells, and plasma multi-omics of 139 COVID-19 patients representing all levels of disease severity, from serial blood draws collected during the first week of infection following diagnosis. We identify a major shift between mild and moderate disease, at which point elevated inflammatory signaling is accompanied by the loss of specific classes of metabolites and metabolic processes. Within this stressed plasma environment at m","2020","12","21","Cell","Cell","CITE-seq; COVID-19; immune response; infection; metabolomics; multi-omics; proteomics; single-cell RNA-seq; single-cell TCR-seq; single-cell secretome; Adolescent; Adult; Aged; Aged, 80 and over; COVID-19; Female; Genomics; Humans; Male; Middle Aged; RNA-Seq; SARS-CoV-2; Severity of Illness Index; Single-Cell Analysis","Su","Yapeng","Institute for Systems Biology, Seattle, WA 98109, USA",NA
"295","33168971","10.1038/d41586-020-03139-x","'I've never worked harder': the race to develop a COVID-19 vaccine.",NA,"2020","11","13","Nature","Nature","Careers; SARS-CoV-2; Vaccines; Virology; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase III as Topic; Coronavirus Infections; Female; Humans; Pandemics; Pneumonia, Viral; Research Personnel; SARS-CoV-2; T-Lymphocytes; Viral Vaccines; Workload","Woolston","Chris",NA,NA
"296","33167900","10.1186/s12879-020-05549-8","Kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19: a descriptive study.","To explore the kinetic changes in virology, specific antibody response and imaging during the clinical course of COVID-19. This observational study enrolled 20 patients with COVID-19, who were hospitalized between January 20-April 6, 2020, in the two COVID-19 designated hospitals of Zhoushan, Zhejiang and Rushan, Shandong, China, The laboratory findings, imaging, serum response to viral infection, and viral RNA level in the throat and stool samples were assessed from onset to recovery phase in p","2020","11","18","BMC Infect Dis","BMC infectious diseases","Antibody response and qRT-PCR; COVID-19; Lung image; SARS-CoV-2; Adolescent; Adult; Aged; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Child; China; Clinical Laboratory Techniques; Coronavirus Infections; Coronavirus Nucleocapsid Proteins; Female; Humans; Immunoglobulin G; Immunoglobulin M; Lung; Male; Middle Aged; Nucleocapsid Proteins; Pandemics; Phosphoproteins; Pneumonia, Viral; RNA, Viral; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Sputum; Tomography, X-Ray Computed; Young Adult","Wang","Qiu-Jing","Department of Infectious Diseases, Zhoushan Hospital, Wenzhou Medical University, NO.739 Dingshen Road, Zhoushan City, 316021, Zhejiang, China",NA
"297","33167401","10.3390/pathogens9110917","Antibody-Based Immunotherapeutic Strategies for COVID-19.","Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development of novel preventive vaccines and effective therapeutics. Passive antibody therapies using convalescent plasma, SARS-CoV-2 (Severe-Acute-Respiratory-Syndrome-Corona-Virus-2)-specific neutralizing antibodies (NAbs), and the development of monoclonal antibodies (MAbs) are among the most promising strategies for prophylaxis and treatment of SARS-CoV-2 infections. In addition, several immunomodulatory antibodies","2020","11","28","Pathogens","Pathogens (Basel, Switzerland)","COVID-19; SARS CoV-2; antibodies; clinical trials; immunotherapy","Hussen","Jamal","Department of Microbiology, College of Veterinary Medicine, King Faisal University, Al-Ahsa 31982, Saudi Arabia",NA
"298","33166303","10.1371/journal.pbio.3001000","Monitor for COVID-19 vaccine resistance evolution during clinical trials.","Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-term impact of COVID-19 vaccines.","2020","12","01","PLoS Biol","PLoS biology","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Resistance, Viral; Humans; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2; Viral Vaccines","Kennedy","David A","Center for Infectious Disease Dynamics, Department of Biology, The Pennsylvania State University, Pennsylvania, United States of America",NA
"299","33165503","10.1093/cid/ciaa1703","Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults.","We evaluated an inactivated SARS-CoV-2 vaccine for immunogenicity and safety in adults aged 18-59 years. In this randomized, double-blinded and controlled trial, healthy adults received a medium (MD) or a high dose (HD) of the vaccine at an interval of either 14 days or 28 days. Neutralizing antibody (NAb) and anti-S and anti-N antibodies were detected at different times, and adverse reactions were monitored for 28 days after full immunization. A total of 742 adults were enrolled in the immunoge","2020","12","10","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","Inactivated SARS-CoV-2 vaccine; immunogenicity; phase II trial; safety","Che","Yanchun","Institute of Medical Biology, Chinese Academy of Medicine Science &amp",NA
"300","33163683","10.1016/j.heliyon.2020.e05421","Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins.","Corona virus disease 2019 (COVID-19) is a respiratory disease caused by a new coronavirus (SARS-CoV-2) which causes significant morbidity and mortality. The emergence of this novel and highly pathogenic SARS-CoV-2 and its rapid international spread poses a serious global public health emergency. To date 32,174,627 cases, of which 962,613 (2.99%) have died, have been reported (https://www.who.int/westernpacific/health-topics/coronavirus, accessed 23 Sep 2020). The outbreak was declared a Public H","2021","03","30","Heliyon","Heliyon","Antiviral; Aptamer; BC 007; COVID-19; Clinical research; Health sciences; Infectious disease; Pharmaceutical science; Pharmacology; Re-purposing; SARS-CoV-2","Weisshoff","Hardy","Department of Chemistry, NMR Facility, Humboldt University of Berlin, Brook-Taylor-Stra..e 2, 12489 Berlin, Germany",NA
"301","33163467","10.3389/fped.2020.582798","A Pediatric Strategy for the Next Phase of the SARS-CoV-2 Pandemic.","Although the first wave of the SARS-CoV-2 pandemic relatively spared children, the next winter season will put a strain on health systems including pediatric services. Clinical staff managing children will need to deal not only with suspected cases of COVID-19, but also with the classic infectious agents that involve children during cold seasons. It will be necessary for physicians, institutions, policy makers, and families to prepare themselves for difficulties of this phase of the pandemic. Ot","2020","11","12","Front Pediatr","Frontiers in pediatrics","COVID-19; SARS-CoV-2; children; policy; vaccination","Buonsenso","Danilo","Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy",NA
"302","33163330","10.1016/j.scs.2020.102571","A deep learning-based social distance monitoring framework for COVID-19.","The ongoing COVID-19 corona virus outbreak has caused a global disaster with its deadly spreading. Due to the absence of effective remedial agents and the shortage of immunizations against the virus, population vulnerability increases. In the current situation, as there are no vaccines available; therefore, social distancing is thought to be an adequate precaution (norm) against the spread of the pandemic virus. The risks of virus spread can be minimized by avoiding physical contact among people","2021","01","06","Sustain Cities Soc","Sustainable cities and society","COVID-19; Deep learning; Overhead view; Person detection; Social distancing; Transfer learning; YOLOv3","Ahmed","Imran","Center of Excellence in Information Technology, Institute of Management Sciences, 1-A, Sector E-5, Phase VII, Hayatabad, Peshawar, Pakistan",NA
"303","33163000","10.3389/fimmu.2020.585354","A Review of the Progress and Challenges of Developing a Vaccine for COVID-19.","A novel coronavirus, which has been designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in December 2019 in Wuhan China and causes the highly infectious disease referred to as COVID-19. COVID-19 has now spread worldwide to become a global pandemic affecting over 24 million people as of August 26th, 2020 and claimed the life of more than 800,000 people worldwide. COVID-19 is asymptomatic for some individuals and for others it can cause symptoms ranging f","2020","12","07","Front Immunol","Frontiers in immunology","COVID-19 pandemic; DNA vaccine; RNA vaccine; SARS-CoV-2; inactivated virus particle vaccine; neutralizing antibodies; non-replication viral vector vaccine; vaccine development; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Drug Development; Female; Host-Pathogen Interactions; Humans; Immunogenicity, Vaccine; Male; Middle Aged; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, DNA; Vaccines, Inactivated","Sharma","Omna","Weill Cornell Medicine-Qatar, Doha, Qatar",NA
"304","33161277","10.1016/j.drup.2020.100733","COVID-19 update: The race to therapeutic development.","The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented challenge to global public health. At the time of this review, COVID-19 has been diagnosed in over 40 million cases and associated with 1.1 million deaths worldwide. Current management strategies for COVID-19 are largely supportive, and while there are more than 2000 interventional clinical trials registered with the U.S. National Library of Medicine (clinicaltrials.gov), re","2020","12","23","Drug Resist Updat","Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","ACE2; Antivirals; COVID-19; Drug development; Existing drugs; Immunomodulators; Monoclonal antibodies; Repurposed use; SARS-CoV-2; Spike protein; Therapeutic targets; Virus life cycle; Animals; Antibodies, Monoclonal; Antiviral Agents; COVID-19; Drug Development; Humans; Immunologic Factors; Time Factors; Virus Internalization","Twomey","Julianne D","Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, United States",NA
"305","33160429","10.20344/amp.14606","Reminder: Cardiovascular Patients Also Benefit from Influenza Vaccine.",NA,"2020","11","25","Acta Med Port","Acta medica portuguesa","COVID-19; Cardiovascular Diseases; Common Cold; Influenza Vaccines; Influenza, Human; Age Factors; Betacoronavirus; COVID-19; Cardiovascular Diseases; Cause of Death; Coinfection; Coronary Artery Disease; Coronavirus Infections; Heart Failure; Humans; Influenza Vaccines; Influenza, Human; Pandemics; Pneumonia, Viral; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; SARS-CoV-2; Vaccination","Alves","Mariana","Servi..o de Medicina III. Hospital Pulido Valente. Centro Hospitalar Universit..rio Lisboa Norte. Lisbon",NA
"306","33160207","10.1016/j.ebiom.2020.103101","Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity.","Reliable high-throughput serological assays for SARS-CoV-2 antibodies are urgently needed for the effective containment of the COVID-19 pandemic, as it is of crucial importance to understand the strength and duration of immunity after infection, and to make informed decisions concerning the activation or discontinuation of physical distancing restrictions. In 184 serum samples from 130 COVID-19 patients and 54 SARS-CoV-2 negative subjects, the analytical and clinical performances of four commerc","2020","12","22","EBioMedicine","EBioMedicine","Antibodies; Clinical performances; Immunoassays; SARS-CoV-2; Serology; Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Serological Testing; Female; Humans; Male; Middle Aged; SARS-CoV-2","Padoan","Andrea","Department of Medicine-DIMED, Medical School, University of Padova, Italy",NA
"307","33156564","10.1111/ijcp.13825","An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.","At present, neither specific antiviral drugs, nor vaccine is recommended for coronavirus disease 2019 (COVID-19) treatment. In this review we discuss the drugs suggested as therapy for COVID-19 infection, with a focus on chloroquine and hydroxychloroquine. The list of drugs used for COVID-19 treatment includes a combination of lopinavir and ritonavir, remdesivir, favipiravir, alpha-interferon, ribavirin, atazanavir, umifenovir, and tocilizumab. As their efficacy and safety are under investigatio","2021","05","11","Int J Clin Pract","International journal of clinical practice","Antimalarials; Antiviral Agents; COVID-19; Chloroquine; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic; SARS-CoV-2","Dragojevic Simic","Viktorija","Center for Clinical Pharmacology, Military Medical Academy, Belgrade, Serbia",NA
"308","33154276","10.4103/npmj.npmj_208_20","COVID-19: A review of the effectiveness of non-pharmacological interventions.","COVID-19, a highly infectious disease, caused by a novel virus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought about an unprecedented threat to global health. First reported in Wuhan, China, in December 2019, it has now spread to all continents of the world becoming a pandemic. There is no known treatment or vaccine for it although many candidate drugs and vaccines are in various clinical trial phases. For now, non-pharmacological interventions (NPIs) have become t","2020","11","11","Niger Postgrad Med J","The Nigerian postgraduate medical journal","Coronavirus disease 2019; epidemic; non-pharmacological interventions; pandemic; severe acute respiratory syndrome coronavirus-2; Betacoronavirus; COVID-19; Coronavirus Infections; Hand Hygiene; Humans; Masks; Nigeria; Pandemics; Pneumonia, Viral; Quarantine; SARS-CoV-2; Social Isolation","Odusanya","Olumuyiwa O","Department of Community Health and Primary Health Care, Lagos State University College of Medicine, Ikeja, Nigeria",NA
"309","33151142","10.1099/jgv.0.001513","Lysine 164 is critical for SARS-CoV-2 Nsp1 inhibition of host gene expression.","The emerging pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused social and economic disruption worldwide, infecting over 9.0...million people and killing over 469...000 by 24 June 2020. Unfortunately, no vaccine or antiviral drug that completely eliminates the transmissible disease coronavirus disease 2019 (COVID-19) has been developed to date. Given that coronavirus nonstructural protein 1 (nsp1) is a good target for attenuated vaccines, it is of great significance","2021","02","10","J Gen Virol","The Journal of general virology","40S ribosomal subunit; Host gene expression inhibition; K164; Nonstructural protein 1; Severe acute respiratory syndrome coronavirus 2; Amino Acid Sequence; Amino Acid Substitution; Computational Biology; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation; Genes, Reporter; HEK293 Cells; Host-Pathogen Interactions; Humans; Luciferases; Lysine; Mutation; Ribosomal Proteins; Ribosome Subunits, Small, Eukaryotic; SARS Virus; SARS-CoV-2; Sequence Alignment; Sequence Homology, Amino Acid; Signal Transduction; Viral Nonstructural Proteins","Shen","Zhou","Key Laboratory of Preventive Veterinary Medicine in Hubei Province, The Cooperative Innovation Center for Sustainable Pig Production, PR China",NA
"310","33150094","10.7717/peerj.10261","Computerized monitoring of COVID-19 trials, studies and registries in ClinicalTrials.gov registry.","Clinical trial registries can provide important information about relevant studies for a given condition to other researchers and the public. We developed a computerized informatics based approach to provide an overview and analysis of COVID-19 studies registered on ClinicalTrials.gov registry. Using the perspective of analyzing active or completed COVID-19 studies, we identified 401 interventional clinical trials, 287 observational studies and 64 registries. We analyzed features of each study t","2020","11","06","PeerJ","PeerJ","COVID-19; Clinical trials; Data science","Mayer","Craig S","Lister Hill National Center for Biomedical Communication, National Library of Medicine, NIH, Bethesda, MD, USA",NA
"311","33144321","10.1128/JVI.01828-20","Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses to the spike (S) protein monomer, S protein native trimeric form, or the nucleocapsid (N) proteins were evaluated in cohorts of individuals with acute infection (n...=...93) and in individuals enrolled in a postinfection seroprevalence population study (n...=...578) in Switzerland. Commercial assays specific for the S1 monomer, for the N protein, or within a newly developed Luminex assay using ","2021","01","22","J Virol","Journal of virology","S protein trimer; SARS-CoV-2; serology; Antibodies, Viral; COVID-19; Coronavirus Nucleocapsid Proteins; Female; Humans; Immunoassay; Immunoglobulin A; Immunoglobulin G; Male; Phosphoproteins; Protein Multimerization; SARS-CoV-2; Sensitivity and Specificity; Seroepidemiologic Studies; Spike Glycoprotein, Coronavirus; Switzerland; Time Factors","Fenwick","Craig","Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland",NA
"312","33139139","10.1016/j.vaccine.2020.10.064","NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.","There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion conformation. Cynomolgus macaques (Macaca fascicularis) immunized with NVX-CoV2373 and the saponin-based Matrix-M... adjuvant induced anti-S antibody that was neutralizing and bloc","2020","12","11","Vaccine","Vaccine","COVID-19; Matrix-M adjuvant; NVX-CoV2373 nanoparticles; Nonhuman primate; SARS-CoV-2; Spike glycoprotein; Adjuvants, Immunologic; Adolescent; Adult; Aged; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; COVID-19; COVID-19 Vaccines; Chlorocebus aethiops; Female; Humans; Immune Sera; Macaca fascicularis; Male; Middle Aged; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, Synthetic; Vero Cells; Viral Load; Young Adult","Guebre-Xabier","Mimi","Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: mguebre-xabier@Novavax","xabier@Novavax.com"
"313","33139059","10.1016/j.jaci.2020.09.026","Eosinophilic pulmonary vasculitis as a manifestation of the hyperinflammatory phase of COVID-19.",NA,"2021","01","15","J Allergy Clin Immunol","The Journal of allergy and clinical immunology","COVID-19; Eosinophils; Humans; SARS-CoV-2; Vaccination; Vasculitis","Luecke","Eva","Department of Pneumology, Health Campus Immunology, Infectiology and Inflammation, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany. Electronic address: eva.luecke@med.ovgu","eva.luecke@med.ovgu.de"
"314","33138946","10.1016/j.sste.2020.100379","Can COVID-19 symptoms as reported in a large-scale online survey be used to optimise spatial predictions of COVID-19 incidence risk in Belgium?","Although COVID-19 has been spreading throughout Belgium since February, 2020, its spatial dynamics in Belgium remain poorly understood, partly due to the limited testing of suspected cases during the epidemic's early phase. We analyse data of COVID-19 symptoms, as self-reported in a weekly online survey, which is open to all Belgian citizens. We predict symptoms' incidence using binomial models for spatially discrete data, and we introduce these as a covariate in the spatial analysis of COVID-19","2020","11","27","Spat Spatiotemporal Epidemiol","Spatial and spatio-temporal epidemiology","COVID-19; Disease mapping; Integrated nested Laplace approximation; Self-reporting; Spatially correlated random effects; Adult; Aged; Belgium; Betacoronavirus; COVID-19; Coronavirus Infections; Female; Health Surveys; Humans; Incidence; Male; Middle Aged; Pandemics; Pneumonia, Viral; Risk Assessment; SARS-CoV-2; Spatial Analysis","Neyens","Thomas","I-BioStat, Data Science Institute, Hasselt University, Martelarenlaan 42, Hasselt B-3500, Belgium","thomas.neyens@uhasselt.be"
"315","33082937","10.12688/f1000research.26707.2","The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days.","Background: Never before have clinical trials drawn as much public attention as those testing interventions for COVID-19. We aimed to describe the worldwide COVID-19 clinical research response and its evolution over the first 100 days of the pandemic. Methods: Descriptive analysis of planned, ongoing or completed trials by April 9, 2020 testing any intervention to treat or prevent COVID-19, systematically identified in trial registries, preprint servers, and literature databases. A","2020","11","06","F1000Res","F1000Research","COVID-19; clinical research agenda; hydroxychloroquine; Betacoronavirus; Biomedical Research; COVID-19; China; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States","Janiaud","Perrine","Meta-Research Innovation Center at Stanford (METRICS), Stanford University,, Stanford, California, USA",NA
"316","33137284","10.1016/S2213-2600(20)30518-X","COVID-19 human challenge studies in the UK.",NA,"2020","12","21","Lancet Respir Med","The Lancet. Respiratory medicine","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Drug Development; Human Experimentation; Humans; Pandemics; SARS-CoV-2; United Kingdom","Kirby","Tony",NA,NA
"317","33137200","10.1093/milmed/usaa261","Gut Microbiota-targeted Interventions for Reducing the Incidence, Duration, and Severity of Respiratory Tract Infections in Healthy Non-elderly Adults.","Respiratory tract infections (RTI), such as those caused by influenza viruses and, more recently, the severe acute respiratory syndrome coronavirus-2, pose a significant burden to military health care systems and force readiness. The gut microbiota influences immune function, is malleable, and may provide a target for interventions aiming to reduce RTI burden. This narrative review summarizes existing evidence regarding the effectiveness of probiotics, prebiotics, and synbiotics, all of which ar","2021","03","04","Mil Med","Military medicine","Adult; COVID-19; Gastrointestinal Microbiome; Humans; Incidence; Meta-Analysis as Topic; Military Personnel; Probiotics; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Systematic Reviews as Topic","Karl","J Philip","Military Nutrition Division, U.S. Army Research Institute of Environmental Medicine, Natick, MA 01760, USA",NA
"318","33134200","10.18683/germs.2020.1208","COVID-19 (SARS-CoV-2) pandemic: fears, facts and preventive measures.","The aim of this review is to give a synopsis on the coronavirus disease 2019 (COVID-19) pandemic, with major focus on the preventive measures. Ever since the influenza pandemic of 1918, and the second world war of (1939-1945), the world has not been faced with a common problem in recent memory like the COVID-19 pandemic. The unprecedented COVID-19 pandemic is caused by infection with a viral pathogen, the nascent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and is characterized ","2021","01","05","Germs","Germs","COVID-19 pandemic; SARS-CoV-2; control measures; mitigation; prevention","Ayenigbara","Israel Oluwasegun","M Ed, Doctoral Candidate, School and Community Health Education Unit, Department of Health Education, University of Ibadan, Ajibode street number 022, postal code 200284, Ibadan, Nigeria",NA
"319","33133071","10.3389/fimmu.2020.561851","Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial.",NA,"2020","11","19","Front Immunol","Frontiers in immunology","COVID-19; SARS-CoV-2; coronavirus; immunoinformatic; vaccine candidates; Animals; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Usmani","Salman Sadullah","Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India",NA
"320","33132155","10.1016/j.cct.2020.106189","Infectious diseases epidemiology, quantitative methodology, and clinical research in the midst of the COVID-19 pandemic: Perspective from a European country.","Starting from historic reflections, the current SARS-CoV-2 induced COVID-19 pandemic is examined from various perspectives, in terms of what it implies for the implementation of non-pharmaceutical interventions, the modeling and monitoring of the epidemic, the development of early-warning systems, the study of mortality, prevalence estimation, diagnostic and serological testing, vaccine development, and ultimately clinical trials. Emphasis is placed on how the pandemic had led to unprecedented s","2021","01","08","Contemp Clin Trials","Contemporary clinical trials","Antiviral therapy; Data sharing; Diagnostic testing; Factorial designs; Infection fatality rate; Mathematical epidemiology; Mathematical modeling; Mortality; Non-pharmaceutical intervention; Nowcasting; Platform trials; Pragmatic trials; Prevalence; SARS-CoV-2; Vaccine development; Age Factors; Biomedical Research; Biostatistics; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Cause of Death; Communicable Disease Control; Drug Development; Drug Industry; Endpoint Determination; Epidemiologic Methods; Europe; Health Communication; Humans; Immunity, Herd; Models, Theoretical; Pandemics; Prevalence; Public Opinion; Randomized Controlled Trials as Topic; SARS-CoV-2; Seasons; Sex Factors; Time Factors","Molenberghs","Geert","Interuniversity Institute for Biostatistics and statistical Bioinformatics, Data Science Institute, Hasselt University, Belgium",NA
